

Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Mutations in Lung Cancers

Journal of the National Cancer Institute

97, 339-346

DOI: 10.1093/jnci/dji055

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Molecular Markers Help Characterize Neuroendocrine Lung Tumors. <i>Annals of Thoracic Surgery</i> , 1996, 62, 798-810. | 1.3 | 118 |
| 2 | Aberrant methylation: common in thymic carcinomas, rare in thymomas. <i>Oncology Reports</i> , 2005, 14, 1621. | 2.6 | 10 |
| 3 | Program for the Assessment of Clinical Cancer Tests (PACCT): assisting the development of tailored cancer therapy. <i>Personalized Medicine</i> , 2005, 2, 363-369. | 1.5 | 1 |
| 4 | Detection of Oncogenic Mutations in the EGFR Gene in Lung Adenocarcinoma with Differential Sensitivity to EGFR Tyrosine Kinase Inhibitors. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2005, 70, 73-81. | 1.1 | 37 |
| 5 | EGFR Tyrosine Kinase Domain Mutations Are Detected in Histologically Normal Respiratory Epithelium in Lung Cancer Patients. <i>Cancer Research</i> , 2005, 65, 7568-7572. | 0.9 | 259 |
| 6 | What is the best way to manage patients treated with gefitinib for non-small-cell lung cancer?. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 290-291. | 4.3 | 0 |
| 7 | Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy. <i>Cell Research</i> , 2005, 15, 212-217. | 12.0 | 58 |
| 8 | Targeted therapies for non-small cell lung cancer. <i>International Journal of Clinical Practice</i> , 2005, 59, 1055-1062. | 1.7 | 14 |
| 9 | Current Management of Advanced Non-Small Cell Lung Cancer: Targeted Therapy. <i>Seminars in Oncology</i> , 2005, 32, 315-328. | 2.2 | 43 |
| 10 | Ongoing First-Line Studies of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Select Patient Populations. <i>Seminars in Oncology</i> , 2005, 32, 9-15. | 2.2 | 72 |
| 11 | Integrative analysis of multiple gene expression profiles with quality-adjusted effect size models. <i>BMC Bioinformatics</i> , 2005, 6, 128. | 2.6 | 45 |
| 12 | Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors. <i>Journal of Molecular Medicine</i> , 2005, 83, 976-983. | 3.9 | 27 |
| 14 | Epidermal Growth Factor Receptor Mutations in Patients with Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2005, 65, 7525-7529. | 0.9 | 143 |
| 15 | Inhibition of EGFR Signaling: All Mutations Are Not Created Equal. <i>PLoS Medicine</i> , 2005, 2, e377. | 8.4 | 38 |
| 16 | Selecting Patients for Epidermal Growth Factor Receptor Inhibitor Treatment: A FISH Story or a Tale of Mutations?. <i>Journal of Clinical Oncology</i> , 2005, 23, 6813-6816. | 1.6 | 56 |
| 17 | Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants. <i>PLoS Medicine</i> , 2005, 2, e313. | 8.4 | 603 |
| 18 | A Curious Link Between Epidermal Growth Factor Receptor Amplification and Survival: Effect of Allele Dilution on Gefitinib Sensitivity?. <i>Journal of the National Cancer Institute</i> , 2005, 97, 621-623. | 6.3 | 22 |
| 19 | High Expression of ErbB Family Members and Their Ligands in Lung Adenocarcinomas That Are Sensitive to Inhibition of Epidermal Growth Factor Receptor. <i>Cancer Research</i> , 2005, 65, 11478-11485. | 0.9 | 135 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 20 | Gefitinib Versus Cetuximab in Lung Cancer: Round One. Journal of the National Cancer Institute, 2005, 97, 1168-1169. | 6.3 | 16 |
| 21 | Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation of ERBB2 rather than EGFR. Clinical Cancer Research, 2005, 11, 8105-8108. | 7.0 | 125 |
| 22 | Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva ®) and Gefitinib (Iressa ®). Oncologist, 2005, 10, 579-589. | 3.7 | 107 |
| 23 | Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. Annals of Oncology, 2005, 16, 1906-1914. | 1.2 | 59 |
| 24 | Targeting HER1/EGFR in cancer therapy: experience with erlotinib. Future Oncology, 2005, 1, 449-460. | 2.4 | 26 |
| 25 | Stable RNA Interference Mediated Suppression of Cyclophilin A Diminishes Non-Small-Cell Lung Tumor Growth In vivo. Cancer Research, 2005, 65, 8853-8860. | 0.9 | 89 |
| 26 | Methyl-CpG Binding Domain 1 Gene Polymorphisms and Risk of Primary Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2474-2480. | 2.5 | 21 |
| 27 | Factors Predicting Response to EGFR Tyrosine Kinase Inhibitors. Seminars in Respiratory and Critical Care Medicine, 2005, 26, 314-322. | 2.1 | 24 |
| 28 | Bronchioloalveolar carcinoma: A Review of the Epidemiology, Pathology, and Treatment. Seminars in Respiratory and Critical Care Medicine, 2005, 26, 342-352. | 2.1 | 21 |
| 29 | Erlotinib hydrochloride. Nature Reviews Drug Discovery, 2005, 4, S14-S15. | 46.4 | 22 |
| 30 | Erlotinib in the treatment of non-small cell lung cancer. Expert Review of Anticancer Therapy, 2005, 5, 767-775. | 2.4 | 21 |
| 31 | Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. British Journal of Cancer, 2005, 93, 355-363. | 6.4 | 152 |
| 32 | EGFR inhibitors: what have we learned from the treatment of lung cancer?. Nature Clinical Practice Oncology, 2005, 2, 554-561. | 4.3 | 77 |
| 33 | TP53 and KRAS Mutation Load and Types in Lung Cancers in Relation to Tobacco Smoke: Distinct Patterns in Never, Former, and Current Smokers. Cancer Research, 2005, 65, 5076-5083. | 0.9 | 237 |
| 34 | Differential Effects of Gefitinib and Cetuximab on Non-small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations. Journal of the National Cancer Institute, 2005, 97, 1185-1194. | 6.3 | 294 |
| 35 | The ALPI Trial: The Italian/European Experience with Adjuvant Chemotherapy in Resectable Non-Small Lung Cancer. Clinical Cancer Research, 2005, 11, 5011s-5016s. | 7.0 | 58 |
| 36 | Predicting the Future From Trials of the Past: Epidermal Growth Factor Receptor Expression and Outcome of Fractionated Radiation Therapy Trials. Journal of Clinical Oncology, 2005, 23, 5437-5439. | 1.6 | 2 |
| 37 | Genetic Classification of Lung Adenocarcinoma Based on Array-Based Comparative Genomic Hybridization Analysis: Its Association with Clinicopathologic Features. Clinical Cancer Research, 2005, 11, 6177-6185. | 7.0 | 103 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 38 | Activated Epidermal Growth Factor Receptorâ€“Stat-3 Signaling Promotes Tumor Survival<i>In vivo</i>in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 8288-8294. | 7.0 | 217 |
| 39 | EGFR Gene Mutations: A Call for Global x Global Views of Cancer. Journal of the National Cancer Institute, 2005, 97, 326-328. | 6.3 | 27 |
| 40 | Molecular targeted therapy for lung cancer. Lancet, The, 2005, 366, 1507-1508. | 13.7 | 8 |
| 41 | Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa) Tj ETQq1 1 0.784314 rgB To Overl | 8.4 | 14 |
| 42 | Epidermal Growth Factor Receptor Mutations and Gene Amplification in Nonâ€“Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials. Journal of Clinical Oncology, 2005, 23, 8081-8092. | 1.6 | 608 |
| 43 | Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 6829-6837. | 1.6 | 701 |
| 44 | Increased<i>HER2</i>Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptorâ€“Positive Nonâ€“Small-Cell Lung Cancer Patients. Journal of Clinical Oncology, 2005, 23, 5007-5018. | 1.6 | 367 |
| 45 | Erlotinib in Lung Cancer â€” Molecular and Clinical Predictors of Outcome. New England Journal of Medicine, 2005, 353, 133-144. | 27.0 | 1,787 |
| 47 | Genomics and the second golden era of cancer drug development. Molecular BioSystems, 2005, 1, 17. | 2.9 | 48 |
| 48 | EGFR Pharmacogenomics. Molecular Diagnosis and Therapy, 2005, 5, 137-139. | 3.3 | 1 |
| 49 | Cancer Diagnostics. Molecular Diagnosis and Therapy, 2005, 5, 357-364. | 3.3 | 28 |
| 50 | The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development. Clinical Cancer Research, 2005, 11, 7967-7985. | 7.0 | 219 |
| 51 | Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Human Pathology, 2005, 36, 1127-1134. | 2.0 | 53 |
| 52 | Erlotinib: Small-molecule targeted therapy in the treatmentof non-small-cell lung cancer. Clinical Therapeutics, 2005, 27, 1513-1534. | 2.5 | 98 |
| 53 | Mechanisms of lung cancer. Drug Discovery Today Disease Mechanisms, 2005, 2, 213-223. | 0.8 | 16 |
| 54 | Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. Lung Cancer, 2005, 50, 1-8. | 2.0 | 112 |
| 55 | Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation. Lung Cancer, 2005, 50, 259-263. | 2.0 | 9 |
| 56 | Pathogenesis of Lung Cancer. American Journal of Respiratory Cell and Molecular Biology, 2005, 33, 216-223. | 2.9 | 120 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 57 | LUNG CANCER PRENEOPLASIA. Annual Review of Pathology: Mechanisms of Disease, 2006, 1, 331-348. | 22.4 | 191 |
| 58 | Aberrant Promoter Methylation of p16 and MGMT Genes in Lung Tumors from Smoking and Never-Smoking Lung Cancer Patients. Neoplasia, 2006, 8, 46-51. | 5.3 | 121 |
| 59 | The place of targeted therapies in the management of non-small cell bronchial carcinoma. Revue Des Maladies Respiratoires, 2006, 23, 137-147. | 1.7 | 2 |
| 60 | Should every lung cancer patient be tested for EGFR mutation?. Expert Opinion on Therapeutic Targets, 2006, 10, 789-791. | 3.4 | 1 |
| 61 | Is EGFR expression important in non-small cell lung cancer?. Thorax, 2006, 61, 98-99. | 5.6 | 35 |
| 62 | Cancer therapies targeted to the epidermal growth factor receptor and its family members. Expert Opinion on Therapeutic Targets, 2006, 16, 147-164. | 5.0 | 3 |
| 63 | Mutational and Epigenetic Evidence for Independent Pathways for Lung Adenocarcinomas Arising in Smokers and Never Smokers. Cancer Research, 2006, 66, 1371-1375. | 0.9 | 147 |
| 64 | Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2006, 24, 5034-5042. | 1.6 | 701 |
| 65 | Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations. Journal of Clinical Oncology, 2006, 24, 3340-3346. | 1.6 | 490 |
| 66 | Epidermal Growth Factor Receptor Mutations and Response to Chemotherapy in Patients with Non-Small-Cell Lung Cancer. Japanese Journal of Clinical Oncology, 2006, 36, 344-350. | 1.3 | 29 |
| 67 | Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients. Lung Cancer, 2006, 52, 225-233. | 2.0 | 31 |
| 68 | Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas. Journal of Clinical Oncology, 2006, 24, 1700-1704. | 1.6 | 202 |
| 69 | Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung. Lung Cancer, 2006, 52, 47-52. | 2.0 | 44 |
| 70 | Uncommon V599E BRAF Mutations in Japanese Patients with Lung Cancer. Journal of Surgical Research, 2006, 133, 203-206. | 1.6 | 64 |
| 71 | Lung Adenocarcinoma Harboring Mutations in the ERBB2 Kinase Domain. Journal of Molecular Diagnostics, 2006, 8, 351-356. | 2.8 | 34 |
| 72 | Novel Therapies Targeting Signaling Pathways in Lung Cancer. Thoracic Surgery Clinics, 2006, 16, 379-396. | 1.0 | 12 |
| 73 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer: Impact of Primary or Secondary Mutations. Clinical Lung Cancer, 2006, 7, S138-S144. | 2.6 | 76 |
| 74 | Ethnic Differences in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of Clinical Oncology, 2006, 24, 2158-2163. | 1.6 | 143 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 75 | A review of erlotinib and its clinical use. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 177-193. | 1.8 | 74 |
| 76 | Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2006, 51, 89-96. | 2.0 | 55 |
| 77 | Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: A Hoosier Oncology Group phase II trial. <i>Lung Cancer</i> , 2006, 52, 93-97. | 2.0 | 96 |
| 78 | Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. <i>Lung Cancer</i> , 2006, 53, 117-121. | 2.0 | 56 |
| 79 | L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer. <i>Lung Cancer</i> , 2006, 54, 103-108. | 2.0 | 29 |
| 80 | Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2006, 53, 311-322. | 2.0 | 74 |
| 81 | Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells. <i>Lung Cancer</i> , 2006, 54, 25-33. | 2.0 | 57 |
| 82 | Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2006, 54, 193-199. | 2.0 | 35 |
| 83 | Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. <i>Lung Cancer</i> , 2006, 54, 387-398. | 2.0 | 92 |
| 84 | Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L. <i>Lung Cancer</i> , 2006, 54, 419-422. | 2.0 | 56 |
| 85 | Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non-Small-Cell Lung Cancer Patients Treated With Gefitinib. <i>Journal of Clinical Oncology</i> , 2006, 24, 2549-2556. | 1.6 | 348 |
| 86 | Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas. <i>Clinical Cancer Research</i> , 2006, 12, 4283-4287. | 7.0 | 154 |
| 87 | Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications. <i>Annals of Diagnostic Pathology</i> , 2006, 10, 306-315. | 1.3 | 36 |
| 88 | An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor. <i>Cell</i> , 2006, 125, 1137-1149. | 28.9 | 1,358 |
| 89 | Epidermal growth factor receptor (EGFR) signaling in cancer. <i>Gene</i> , 2006, 366, 2-16. | 2.2 | 1,744 |
| 90 | Predicting the outcome of chemotherapy for lung cancer. <i>Current Opinion in Pharmacology</i> , 2006, 6, 323-331. | 3.5 | 68 |
| 91 | Mutations of the epidermal growth factor receptor in non-small cell lung cancer – Search and destroy. <i>European Journal of Cancer</i> , 2006, 42, 17-23. | 2.8 | 153 |
| 92 | High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. <i>Human Pathology</i> , 2006, 37, 453-457. | 2.0 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 93 | BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Human Pathology, 2006, 37, 520-527. | 2.0 | 90 |
| 94 | Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression. Human Pathology, 2006, 37, 755-763. | 2.0 | 62 |
| 95 | Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study. Journal of Thoracic Oncology, 2006, 1, 847-855. | 1.1 | 108 |
| 96 | Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Basic Science Discovery with Immediate Clinical Impact. American Journal of the Medical Sciences, 2006, 331, 139-149. | 1.1 | 11 |
| 97 | EGFR: A Prognostic and/or a Predictive Marker?. Journal of Thoracic Oncology, 2006, 1, 395-397. | 1.1 | 4 |
| 98 | The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum of Diseases. Journal of Thoracic Oncology, 2006, 1, 344-359. | 1.1 | 33 |
| 99 | Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2006, 1, 520-525. | 1.1 | 22 |
| 100 | Molecular Biology, Genomics, and Proteomics in Bronchioloalveolar Carcinoma. Journal of Thoracic Oncology, 2006, 1, S8-S12. | 1.1 | 6 |
| 101 | Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tumor cell lines. Oncology Reports, 2006, 15, 1205. | 2.6 | 3 |
| 102 | EGFR Mutation of Tumor and Serum in Gefitinib-Treated Patients with Chemotherapy-Naive Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 260-267. | 1.1 | 64 |
| 103 | Clinico-Pathological and Biological Significance of Tyrosine Kinase Domain Gene Mutations and Overexpression of Epidermal Growth Factor Receptor for Lung Adenocarcinoma. Journal of Thoracic Oncology, 2006, 1, 787-795. | 1.1 | 14 |
| 104 | Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non-small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. Journal of Thoracic Oncology, 2006, 1, 52-60. | 1.1 | 6 |
| 105 | Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study. Journal of Thoracic Oncology, 2006, 1, 847-855. | 1.1 | 157 |
| 106 | The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum of Diseases. Journal of Thoracic Oncology, 2006, 1, 344-359. | 1.1 | 80 |
| 107 | Signal Transduction Therapy for Cancer - Whither Now?. Current Signal Transduction Therapy, 2006, 1, 1-12. | 0.5 | 14 |
| 108 | Clinicopathologic Characteristics of the EGFR Gene Mutation in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 231-239. | 1.1 | 121 |
| 109 | EGFR: A Prognostic and/or a Predictive Marker?. Journal of Thoracic Oncology, 2006, 1, 395-397. | 1.1 | 7 |
| 110 | Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2006, 1, 520-525. | 1.1 | 32 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 111 | A Simple and Sensitive Method for Detecting Major Mutations Within the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Gene in Non-small-cell Lung Carcinoma. Diagnostic Molecular Pathology, 2006, 15, 101-108. | 2.1 | 31 |
| 112 | Rapid Screening for EGFR Mutations. Cancer Journal (Sudbury, Mass), 2006, 12, 17-18. | 2.0 | 0 |
| 113 | Molecular Biology, Genomics, and Proteomics in Bronchioloalveolar Carcinoma. Journal of Thoracic Oncology, 2006, 1, S8-S12. | 1.1 | 14 |
| 114 | Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non- Small Cell Lung Cancer (NSCLC). Reviews on Recent Clinical Trials, 2006, 1, 1-13. | 0.8 | 44 |
| 116 | Clinical experience with erlotinib in non-small-cell lung cancer (NSCLC). Drugs of Today, 2006, 42, 147. | 1.1 | 17 |
| 117 | Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma. Respiriology, 2006, 11, 287-291. | 2.3 | 6 |
| 118 | Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respiriology, 2006, 11, 687-692. | 2.3 | 32 |
| 119 | Worldwide trends in lung cancer pathology. Respiriology, 2006, 11, 533-538. | 2.3 | 124 |
| 120 | Targeted cancer therapy: The prime time show in oncology. Asia-Pacific Journal of Clinical Oncology, 2006, 2, 1-2. | 1.1 | 0 |
| 121 | Targeting epidermal growth factor receptor in lung cancer: Perspective from the Asia-Pacific region. Asia-Pacific Journal of Clinical Oncology, 2006, 2, 22-31. | 1.1 | 2 |
| 122 | Molecular diagnostics of non-small cell lung cancer using mediastinal lymph nodes sampled by endoscopic ultrasound-guided needle aspiration. Cytopathology, 2006, 17, 3-9. | 0.7 | 10 |
| 123 | Recent trends in the treatment of advanced lung cancer. Cancer Science, 2006, 97, 448-452. | 3.9 | 16 |
| 124 | High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Science, 2006, 97, 642-648. | 3.9 | 138 |
| 125 | EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Science, 2006, 97, 753-759. | 3.9 | 73 |
| 126 | A critical appraisal of prognostic and predictive factors for common lung cancers. Histopathology, 2006, 48, 779-786. | 2.9 | 21 |
| 127 | Comparing antibody and small-molecule therapies for cancer. Nature Reviews Cancer, 2006, 6, 714-727. | 28.4 | 661 |
| 128 | Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. British Journal of Cancer, 2006, 94, 896-903. | 6.4 | 132 |
| 129 | Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma. Modern Pathology, 2006, 19, 541-547. | 5.5 | 38 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 130 | Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas. <i>Modern Pathology</i> , 2006, 19, 986-998. | 5.5 | 17 |
| 131 | Epidermal growth factor receptor directed therapy in head and neck cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 57, 25-43. | 4.4 | 46 |
| 132 | Clinical experience with gefitinib: An update. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 58, 31-45. | 4.4 | 50 |
| 134 | Carcinogen Exposure and Epigenetic Silencing in Bladder Cancer. <i>Annals of the New York Academy of Sciences</i> , 2006, 1076, 810-821. | 3.8 | 49 |
| 135 | Biological and clinical implications of EGFR mutations in lung cancer. <i>International Journal of Clinical Oncology</i> , 2006, 11, 190-198. | 2.2 | 194 |
| 136 | Resistance to gefitinib. <i>International Journal of Clinical Oncology</i> , 2006, 11, 487-491. | 2.2 | 31 |
| 137 | Defining clinically relevant molecular subsets of lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 11-15. | 2.3 | 17 |
| 138 | Molecular classification of tumors with special reference to EGFR mutation in lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 17-23. | 2.3 | 6 |
| 139 | The impact and role of EGFR gene mutation on non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 25-31. | 2.3 | 7 |
| 141 | The future of epidemiology. <i>Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz</i> , 2006, 49, 622-627. | 7.2 | 5 |
| 142 | From the bench to the bed: individualizing treatment in non-small-cell lung cancer. <i>Clinical and Translational Oncology</i> , 2006, 8, 71-76. | 2.4 | 17 |
| 143 | The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. <i>Cancer Cell</i> , 2006, 9, 485-495. | 16.8 | 427 |
| 144 | EGF receptor mutations in lung cancer: From humans to mice and maybe back to humans. <i>Cancer Cell</i> , 2006, 9, 421-423. | 16.8 | 47 |
| 145 | 2006 Highlights From: The European Society for Medical Oncology Congress Istanbul, Turkey; Sept. 29-Oct. 3, 2006 International Association for the Study of Lung Cancer Early Invasive Lung Cancer Workshop Turin, Italy; Sept. 25-26, 2006. <i>Clinical Lung Cancer</i> , 2006, 8, 170-178. | 2.6 | 0 |
| 146 | Geographic Variation in the Second-Line Treatment of Non-Small Cell Lung Cancer. <i>Seminars in Oncology</i> , 2006, 33, 39-44. | 2.2 | 6 |
| 147 | Optimizing Therapy in Previously Treated Non-Small Cell Lung Cancer. <i>Seminars in Oncology</i> , 2006, 33, 25-31. | 2.2 | 7 |
| 148 | Epidermal Growth Factor Receptor Targeting in Cancer. <i>Seminars in Oncology</i> , 2006, 33, 369-385. | 2.2 | 645 |
| 149 | K-ras Mutations in Non-Small-Cell Lung Carcinoma: A Review. <i>Clinical Lung Cancer</i> , 2006, 8, 30-38. | 2.6 | 212 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 150 | The Way Forward: New Drugs and New Therapeutic Strategies in Lung Cancer Therapy. <i>Clinical Lung Cancer</i> , 2006, 7, S109-S110. | 2.6 | 0 |
| 151 | Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. <i>Cancer</i> , 2006, 106, 2200-2207. | 4.1 | 132 |
| 152 | A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. <i>Cancer</i> , 2006, 107, 1034-1041. | 4.1 | 72 |
| 153 | Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer. <i>Cancer</i> , 2006, 107, 1866-1872. | 4.1 | 3 |
| 154 | Nuclear factor- κ B (NF- κ B) is frequently expressed in lung cancer and preneoplastic lesions. <i>Cancer</i> , 2006, 107, 2637-2646. | 4.1 | 179 |
| 155 | Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer. <i>Cancer</i> , 2006, 107, 2858-2865. | 4.1 | 59 |
| 156 | EGFR and erbB2 mutation status in Japanese lung cancer patients. <i>International Journal of Cancer</i> , 2006, 118, 180-184. | 5.1 | 157 |
| 157 | Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2006, 118, 963-969. | 5.1 | 151 |
| 158 | Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. <i>International Journal of Cancer</i> , 2006, 118, 257-262. | 5.1 | 601 |
| 159 | Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma. <i>International Journal of Cancer</i> , 2006, 118, 2498-2504. | 5.1 | 43 |
| 160 | Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2006, 119, 727-734. | 5.1 | 20 |
| 161 | Sex differences in risk of lung cancer: Expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts. <i>International Journal of Cancer</i> , 2006, 119, 741-744. | 5.1 | 128 |
| 162 | Frequent EGFR mutations in brain metastases of lung adenocarcinoma. <i>International Journal of Cancer</i> , 2006, 119, 1491-1494. | 5.1 | 183 |
| 163 | Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features. <i>International Journal of Cancer</i> , 2006, 119, 2586-2591. | 5.1 | 170 |
| 164 | Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. <i>International Journal of Cancer</i> , 2006, 119, 2353-2358. | 5.1 | 102 |
| 165 | The epidermal growth factor receptor gene sequence is highly conserved in primary gastric cancers. <i>Journal of Surgical Oncology</i> , 2006, 93, 44-46. | 1.7 | 12 |
| 166 | EGFR Targeted Therapy: View from Biological Standpoint. <i>Cell Cycle</i> , 2006, 5, 2072-2076. | 2.6 | 32 |
| 167 | Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling. <i>Cancer Research</i> , 2006, 66, 11389-11398. | 0.9 | 112 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 168 | Overexpression of Glycosylphosphatidylinositol (GPI) Transamidase Subunits Phosphatidylinositol Glycan Class T and/or GPI Anchor Attachment 1 Induces Tumorigenesis and Contributes to Invasion in Human Breast Cancer. <i>Cancer Research</i> , 2006, 66, 9829-9836. | 0.9 | 62 |
| 169 | Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. <i>Annals of Oncology</i> , 2006, 17, 981-985. | 1.2 | 118 |
| 170 | Wnt/ β -Catenin Signaling Mediates Antineoplastic Effects of Imatinib Mesylate (Gleevec) in Anaplastic Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 159-168. | 3.6 | 38 |
| 171 | EUS-FNA and biomarkers for the staging of non-small cell lung cancer. <i>Endoscopy</i> , 2006, 38, 114-117. | 1.8 | 9 |
| 172 | Reporting of ethnicity in research on chronic disease: update. <i>Postgraduate Medical Journal</i> , 2006, 82, 737-742. | 1.8 | 9 |
| 173 | Erlotinib for Frontline Treatment of Advanced Nonâ€“Small Cell Lung Cancer: a Phase II Study. <i>Clinical Cancer Research</i> , 2006, 12, 6049-6055. | 7.0 | 197 |
| 174 | Re: Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. <i>Journal of the National Cancer Institute</i> , 2006, 98, 362-363. | 6.3 | 8 |
| 175 | Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 2038-2043. | 1.6 | 620 |
| 176 | Molecular Context of the EGFR Mutations: Evidence for the Activation of mTOR/S6K Signaling. <i>Clinical Cancer Research</i> , 2006, 12, 710-717. | 7.0 | 116 |
| 177 | Joint effect of asthma/atopy and an IL-6 gene polymorphism on lung cancer risk among lifetime non-smoking Chinese women. <i>Carcinogenesis</i> , 2006, 27, 1240-1244. | 2.8 | 47 |
| 178 | Baseline Gene Expression Predicts Sensitivity to Gefitinib in Nonâ€“Small Cell Lung Cancer Cell Lines. <i>Molecular Cancer Research</i> , 2006, 4, 521-528. | 3.4 | 129 |
| 179 | RESPONSE: Re: Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. <i>Journal of the National Cancer Institute</i> , 2006, 98, 363-364. | 6.3 | 1 |
| 180 | Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 3078-3084. | 7.0 | 97 |
| 181 | Multiple Oncogenic Changes (<i>K-RASV12</i>, p53 Knockdown,<i>Mutant EGFRs, p16</i>Bypass,) Tj ETQq1 1 0.784314 rgBT /Overl Cells. <i>Cancer Research</i> , 2006, 66, 2116-2128. | 0.9 | 247 |
| 182 | Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway. <i>Clinical Cancer Research</i> , 2006, 12, 7222-7231. | 7.0 | 84 |
| 183 | Update on<i>Epidermal Growth Factor Receptor</i>Mutations in Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 7232-7241. | 7.0 | 357 |
| 184 | A Rapid and Sensitive Enzymatic Method for Epidermal Growth Factor Receptor Mutation Screening. <i>Clinical Cancer Research</i> , 2006, 12, 751-758. | 7.0 | 212 |
| 185 | EGFRMutations in Small-Cell Lung Cancers in Patients Who Have Never Smoked. <i>New England Journal of Medicine</i> , 2006, 355, 213-215. | 27.0 | 241 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 186 | Detection of EGFR Gene Mutation in Lung Cancer by Mutant-Enriched Polymerase Chain Reaction Assay. <i>Clinical Cancer Research</i> , 2006, 12, 43-48. | 7.0 | 191 |
| 187 | Detection of EGFR Mutations in Archived Cytologic Specimens of Non-Small Cell Lung Cancer Using High-Resolution Melting Analysis. <i>American Journal of Clinical Pathology</i> , 2006, 126, 608-615. | 0.7 | 138 |
| 188 | Exercise induced bronchoconstriction in elite athletes: measuring the fall. <i>Thorax</i> , 2006, 61, 94-96. | 5.6 | 24 |
| 189 | Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer. <i>Journal of Medical Genetics</i> , 2006, 44, 166-172. | 3.2 | 47 |
| 190 | Clinical Course of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib. <i>Clinical Cancer Research</i> , 2006, 12, 839-844. | 7.0 | 688 |
| 191 | Mutations Within the Kinase Domain and Truncations of the Epidermal Growth Factor Receptor Are Rare Events in Bladder Cancer: Implications for Therapy. <i>Clinical Cancer Research</i> , 2006, 12, 4671-4677. | 7.0 | 59 |
| 192 | Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 1680-1685. | 7.0 | 151 |
| 193 | Erlotinib: Optimizing Therapy with Predictors of Response?. <i>Clinical Cancer Research</i> , 2006, 12, 2961-2963. | 7.0 | 20 |
| 194 | Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. <i>Genes and Development</i> , 2006, 20, 1496-1510. | 5.9 | 426 |
| 195 | Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Clinical Cancer Research</i> , 2006, 12, 4416s-4420s. | 7.0 | 127 |
| 196 | A Blood-Based Test for Epidermal Growth Factor Receptor Mutations in Lung Cancer: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 3875-3877. | 7.0 | 11 |
| 197 | Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non-Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features. <i>Clinical Cancer Research</i> , 2006, 12, 1647-1653. | 7.0 | 402 |
| 198 | Gefitinib for Epidermal Growth Factor Receptor Mutant Lung Cancers: Searching for a Weapon of Mass Destruction. <i>Journal of Clinical Oncology</i> , 2006, 24, 3319-3321. | 1.6 | 7 |
| 199 | Expression Profile-Defined Classification of Lung Adenocarcinoma Shows Close Relationship With Underlying Major Genetic Changes and Clinicopathologic Behaviors. <i>Journal of Clinical Oncology</i> , 2006, 24, 1679-1688. | 1.6 | 296 |
| 200 | Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization-Why, When, and How?. <i>Clinical Cancer Research</i> , 2006, 12, 4409s-4415s. | 7.0 | 52 |
| 201 | Targeted Therapies in Combination with Chemotherapy in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 4451s-4457s. | 7.0 | 20 |
| 203 | Lung cancer in never-smokers. <i>Journal of Clinical Pathology</i> , 2006, 60, 337-340. | 2.0 | 39 |
| 204 | Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib. <i>Cancer Research</i> , 2006, 66, 8163-8171. | 0.9 | 388 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 205 | Biological Markers for Non-Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2006, 12, 3652-3656. | 7.0 | 62 |
| 206 | Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib. <i>Clinical Cancer Research</i> , 2006, 12, 3908-3914. | 7.0 | 550 |
| 207 | Glu346Lys Polymorphism in the Methyl-CpG Binding Domain 4 Gene and the Risk of Primary Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2006, 36, 483-488. | 1.3 | 20 |
| 208 | Optimization of Patient Selection for Gefitinib in Non-Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation. <i>Clinical Cancer Research</i> , 2006, 12, 2538-2544. | 7.0 | 245 |
| 209 | Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity. <i>Journal of Clinical Oncology</i> , 2006, 24, 2245-2251. | 1.6 | 334 |
| 210 | Genomic Approaches to Lung Cancer: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 4384s-4391s. | 7.0 | 49 |
| 211 | Lung cancer genetics and pharmacogenomics. <i>Cytogenetic and Genome Research</i> , 2006, 115, 298-302. | 1.1 | 2 |
| 212 | Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. <i>Annals of Oncology</i> , 2006, 17, ii42-ii45. | 1.2 | 28 |
| 213 | Epidermal Growth Factor Receptor Inhibition and Non-Small Cell Lung cancer. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2006, 43, 291-323. | 6.1 | 15 |
| 214 | Epidermal Growth Factor Receptor (EGFR) Antibody Down-regulates Mutant Receptors and Inhibits Tumors Expressing EGFR Mutations. <i>Journal of Biological Chemistry</i> , 2006, 281, 40183-40192. | 3.4 | 85 |
| 215 | Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 7817-7822. | 7.1 | 248 |
| 216 | Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non-Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 3915-3921. | 7.0 | 312 |
| 217 | Epidermal Growth Factor Receptor Copy Number Alterations Correlate With Poor Clinical Outcome in Patients With Head and Neck Squamous Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2164-2170. | 1.6 | 356 |
| 218 | Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. <i>Expert Review of Molecular Diagnostics</i> , 2007, 7, 821-836. | 3.1 | 12 |
| 219 | Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2642-2651. | 4.1 | 53 |
| 220 | The Impact of Sex and Smoking Status on the Mutational Spectrum of Epidermal Growth Factor Receptor Gene in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 5763-5768. | 7.0 | 81 |
| 221 | Telomere Length and Telomerase Expression in Atypical Adenomatous Hyperplasia and Small Bronchioloalveolar Carcinoma of the Lung. <i>American Journal of Clinical Pathology</i> , 2007, 127, 254-262. | 0.7 | 29 |
| 222 | International comparisons of survival from lung cancer: pitfalls and warnings. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 570-577. | 4.3 | 73 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 223 | “Classical” but not “other” mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. British Journal of Cancer, 2007, 97, 1560-1566. | 6.4 | 74 |
| 224 | BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations. PLoS Medicine, 2007, 4, e315. | 8.4 | 444 |
| 225 | Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor. Current Respiratory Medicine Reviews, 2007, 3, 69-77. | 0.2 | 6 |
| 226 | Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt. Cancer Research, 2007, 67, 5779-5788. | 0.9 | 107 |
| 227 | Optimizing Anti-EGFR Strategies in Cancer Treatment. Current Cancer Therapy Reviews, 2007, 3, 267-275. | 0.3 | 0 |
| 228 | Neutrophils Promote Aerogenous Spread of Lung Adenocarcinoma with Bronchioloalveolar Carcinoma Features. Clinical Cancer Research, 2007, 13, 3518-3527. | 7.0 | 46 |
| 229 | Genetics of Preneoplasia: Lessons from Lung Cancer. Current Molecular Medicine, 2007, 7, 3-14. | 1.3 | 103 |
| 230 | Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Oncologist, 2007, 12, 211-220. | 3.7 | 44 |
| 231 | Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development. Oncologist, 2007, 12, 840-849. | 3.7 | 100 |
| 232 | Detection of Epidermal Growth Factor Receptor Variations by Partially Denaturing HPLC. Clinical Chemistry, 2007, 53, 62-70. | 3.2 | 41 |
| 233 | Detection of Epidermal Growth Factor Receptor Mutation in Transbronchial Needle Aspirates of Non-Small Cell Lung Cancer. Chest, 2007, 131, 1628-1634. | 0.8 | 106 |
| 234 | A Translational View of the Molecular Pathogenesis of Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 327-343. | 1.1 | 274 |
| 235 | Molecular Pathogenesis of Early-Stage Non-small Cell Lung Cancer and a Proposal for Tissue Banking to Facilitate Identification of New Biomarkers. Journal of Thoracic Oncology, 2007, 2, S128-S135. | 1.1 | 19 |
| 236 | EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2007, 2, 423-429. | 1.1 | 84 |
| 237 | Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies. Pharmacogenomics, 2007, 8, 1211-1220. | 1.3 | 2 |
| 238 | Expression Profiling and Lung Cancer Development. Proceedings of the American Thoracic Society, 2007, 4, 127-132. | 3.5 | 29 |
| 240 | Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biology and Therapy, 2007, 6, 661-667. | 3.4 | 83 |
| 241 | Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors. Biomarkers in Medicine, 2007, 1, 203-207. | 1.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 242 | Absence of Activating Mutations in the <i>EGFR</i> Kinase Domain in Spanish Head and Neck Cancer Patients. <i>Tumor Biology</i> , 2007, 28, 273-279. | 1.8 | 34 |
| 243 | Erlotinib in cancer treatment. <i>Annals of Oncology</i> , 2007, 18, vi35-vi41. | 1.2 | 111 |
| 245 | Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Nonâ€“Small Cell Lung Cancer Cell Line. <i>Cancer Research</i> , 2007, 67, 7807-7814. | 0.9 | 170 |
| 246 | Epidermal Growth Factor Receptors with Tyrosine Kinase Domain Mutations Exhibit Reduced Cbl Association, Poor Ubiquitylation, and Down-regulation but Are Efficiently Internalized. <i>Cancer Research</i> , 2007, 67, 7695-7702. | 0.9 | 39 |
| 247 | Differential Constitutive Activation of the Epidermal Growth Factor Receptor in Nonâ€“Small Cell Lung Cancer Cells Bearing<i>EGFR</i>Gene Mutation and Amplification. <i>Cancer Research</i> , 2007, 67, 2046-2053. | 0.9 | 166 |
| 248 | CETUXIMAB (ERBITUX®), AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER. , 2007, , 43-67. | | 0 |
| 249 | Clonality and Prognostic Implications of p53 and Epidermal Growth Factor Receptor Somatic Aberrations in Multiple Primary Lung Cancers. <i>Clinical Cancer Research</i> , 2007, 13, 52-58. | 7.0 | 98 |
| 250 | Distinctive Evaluation of Nonmucinous and Mucinous Subtypes of Bronchioloalveolar Carcinomas inEGFRand K-rasGene-Mutation Analyses for Japanese Lung Adenocarcinomas. <i>American Journal of Clinical Pathology</i> , 2007, 128, 100-108. | 0.7 | 121 |
| 251 | An Alternative Approach to Determining Therapeutic Choices in Advanced Non-small Cell Lung Carcinoma (NSCLC): Maximizing the Diagnostic Procedure and the Use of Low-Volume Lung Biopsies. <i>Journal of Thoracic Oncology</i> , 2007, 2, 387-396. | 1.1 | 17 |
| 252 | Targeting of Epidermal Growth Factor Receptor in Patients Affected by Biliary Tract Carcinoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 1145-1145. | 1.6 | 6 |
| 253 | Use of a Cytokine Gene Expression Signature in Lung Adenocarcinoma and the Surrounding Tissue as a Prognostic Classifier. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1257-1269. | 6.3 | 131 |
| 254 | Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes. <i>Clinical Cancer Research</i> , 2007, 13, 3731-3737. | 7.0 | 283 |
| 255 | HKI-272 in Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 4593s-4596s. | 7.0 | 47 |
| 256 | Targeted therapies in lung cancer. <i>Annals of Oncology</i> , 2007, 18, ix135-ix142. | 1.2 | 35 |
| 257 | Pulmonary adenocarcinomaâ€“targeted gene therapy by a cancer- and tissue-specific promoter system. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 244-252. | 4.1 | 19 |
| 258 | Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors. <i>Clinical Cancer Research</i> , 2007, 13, 4606s-4612s. | 7.0 | 51 |
| 259 | Adenocarcinoma, a molecular perspective. <i>Annals of Oncology</i> , 2007, 18, ix147-ix149. | 1.2 | 19 |
| 260 | Pharmacogenomics of Non-Small Cell Lung Cancer. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2007, 5, 228-234. | 0.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 261 | Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors. <i>Current Cancer Therapy Reviews</i> , 2007, 3, 276-283. | 0.3 | 0 |
| 262 | Small Molecule Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer Treatment. <i>Current Cancer Therapy Reviews</i> , 2007, 3, 226-235. | 0.3 | 0 |
| 263 | Smoking and Lung Cancer: Future Research Directions. <i>International Journal of Toxicology</i> , 2007, 26, 353-364. | 1.2 | 21 |
| 264 | EGFR activating aberration occurs independently of other genetic aberrations or telomerase activation in adenocarcinoma of the lung. <i>Oncology Reports</i> , 2007, 17, 1405. | 2.6 | 2 |
| 265 | Presentation and Stage-Specific Outcomes of Lifelong Never-smokers with Non-small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2007, 2, 827-830. | 1.1 | 56 |
| 266 | Mutational Analysis in Cytological Specimens of Advanced Lung Adenocarcinoma: A Sensitive Method for Molecular Diagnosis. <i>Journal of Thoracic Oncology</i> , 2007, 2, 1086-1090. | 1.1 | 102 |
| 267 | Microsatellite DNA analysis does not distinguish malignant from benign pleural effusions. <i>Oncology Reports</i> , 2007, 18, 1507-12. | 2.6 | 4 |
| 268 | PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. <i>Oncology Reports</i> , 2007, 17, 853. | 2.6 | 26 |
| 269 | M02-03: Tumor hypoxia and metastasis in non-small cell lung cancers. <i>Journal of Thoracic Oncology</i> , 2007, 2, S154-S155. | 1.1 | 2 |
| 270 | Clinical Significance of Epidermal Growth Factor Receptor Gene Mutations on Treatment Outcome after First-line Cytotoxic Chemotherapy in Japanese Patients with Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 632-637. | 1.1 | 62 |
| 271 | Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China. <i>Journal of Thoracic Oncology</i> , 2007, 2, 430-439. | 1.1 | 180 |
| 273 | Combination of Standard Chemotherapy and Targeted Agents. <i>Journal of Thoracic Oncology</i> , 2007, 2, S19-S23. | 1.1 | 2 |
| 274 | M02-02: Update of EGFR inhibitors and radiation in the management of non-small cell lung cancer—where do we go next?. <i>Journal of Thoracic Oncology</i> , 2007, 2, S153-S154. | 1.1 | 3 |
| 275 | Surrogate Predictive Biomarkers for Response to Anti-EGFR Agents: State of the Art and Challenges. <i>International Journal of Biological Markers</i> , 2007, 22, 10-23. | 1.8 | 5 |
| 276 | Microsatellite and EGFR, HER2 and K-RAS Analyses in Sclerosing Hemangioma of the Lung. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1512-1520. | 3.7 | 36 |
| 277 | Apoptosis Induced by Depsipeptide FK228 Coincides with Inhibition of Survival Signaling in Lung Cancer Cells. <i>Cancer Journal (Sudbury, Mass)</i> , 2007, 13, 105-113. | 2.0 | 36 |
| 278 | Targeting the Epidermal Growth Factor Receptor in Colorectal Carcinoma. <i>Cancer Nursing</i> , 2007, 30, S1-S9. | 1.5 | 5 |
| 279 | Diagnosis and treatment of bronchioloalveolar carcinoma. <i>Current Opinion in Pulmonary Medicine</i> , 2007, 13, 290-296. | 2.6 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 280 | Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 22-28. | 1.1 | 71 |
| 281 | Small Peripheral Pulmonary Adenocarcinoma. <i>Advances in Anatomic Pathology</i> , 2007, 14, 120-128. | 4.3 | 7 |
| 282 | EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. <i>European Journal of Cancer</i> , 2007, 43, 520-526. | 2.8 | 71 |
| 283 | Rational bases for the development of EGFR inhibitors for cancer treatment. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1416-1431. | 2.8 | 115 |
| 284 | Targeting novel and established therapies for non-small cell lung cancer. <i>Cancer Letters</i> , 2007, 250, 9-16. | 7.2 | 10 |
| 285 | The HER family and cancer: emerging molecular mechanisms and therapeutic targets. <i>Trends in Molecular Medicine</i> , 2007, 13, 527-534. | 6.7 | 117 |
| 286 | Transcriptional Profiling of Non-Small Cell Lung Cancer Cells with Activating EGFR Somatic Mutations. <i>PLoS ONE</i> , 2007, 2, e1226. | 2.5 | 31 |
| 287 | Src-Family Kinases Are Activated in Non-Small Cell Lung Cancer and Promote the Survival of Epidermal Growth Factor Receptor-Dependent Cell Lines. <i>American Journal of Pathology</i> , 2007, 170, 366-376. | 3.8 | 141 |
| 288 | EGFR exon 20 insertion mutation in Japanese lung cancer. <i>Lung Cancer</i> , 2007, 58, 324-328. | 2.0 | 81 |
| 289 | Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung. <i>Lung Cancer</i> , 2007, 58, 30-35. | 2.0 | 20 |
| 290 | Epidermal Growth Factor Receptor Mutation Status and Adjuvant Chemotherapy With Uracil-Tegafur for Adenocarcinoma of the Lung. <i>Journal of Clinical Oncology</i> , 2007, 25, 3952-3957. | 1.6 | 42 |
| 291 | The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression. <i>Lung Cancer</i> , 2007, 57, 96-102. | 2.0 | 15 |
| 292 | Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization-Positive/Phospho-Akt-Positive or Never Smoker Patients With Advanced Non-Small-Cell Lung Cancer: The ONCOBELL Trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 2248-2255. | 1.6 | 218 |
| 293 | Response to Treatment and Survival of Patients with Non-Small Cell Lung Cancer Undergoing Somatic EGFR Mutation Testing. <i>Oncologist</i> , 2007, 12, 90-98. | 3.7 | 156 |
| 294 | Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. <i>Annals of Oncology</i> , 2007, 18, 752-760. | 1.2 | 257 |
| 295 | Polymorphisms, Mutations, and Amplification of the EGFR Gene in Non-Small Cell Lung Cancers. <i>PLoS Medicine</i> , 2007, 4, e125. | 8.4 | 130 |
| 296 | Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 760-766. | 1.6 | 306 |
| 297 | EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2007, 18, 99-103. | 1.2 | 136 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 298 | How could pharmacogenomics help improve patient survival?. Lung Cancer, 2007, 57, S35-S41. | 2.0 | 10 |
| 300 | <i>KRAS</i> Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 2890-2896. | 7.0 | 597 |
| 301 | Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar Features. Journal of Molecular Diagnostics, 2007, 9, 320-326. | 2.8 | 188 |
| 302 | EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?. Expert Opinion on Medical Diagnostics, 2007, 1, 183-191. | 1.6 | 2 |
| 303 | Lung Cancer in Never Smokers: A Review. Journal of Clinical Oncology, 2007, 25, 561-570. | 1.6 | 587 |
| 304 | Personalized Medicine and Proteomics: Lessons from Non-Small Cell Lung Cancer. Journal of Proteome Research, 2007, 6, 2925-2935. | 3.7 | 56 |
| 305 | Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2007, 25, 587-595. | 1.6 | 593 |
| 308 | Patterns of EGFR, HER2, TP53, and KRAS Mutations of p14arf Expression in Non-Small Cell Lung Cancers in Relation to Smoking History. Cancer Research, 2007, 67, 5667-5672. | 0.9 | 111 |
| 309 | Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer, 2007, 56, 383-389. | 2.0 | 131 |
| 310 | Up-regulation of PTEN at the transcriptional level is an adverse prognostic factor in female lung adenocarcinomas. Lung Cancer, 2007, 57, 201-206. | 2.0 | 18 |
| 311 | Chromosomal aberrations of malignant pleural effusions of lung adenocarcinoma: Different cytogenetic changes are correlated with genders and smoking habits. Lung Cancer, 2007, 57, 292-301. | 2.0 | 22 |
| 312 | Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. Lung Cancer, 2007, 58, 411-413. | 2.0 | 105 |
| 313 | Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer, 2007, 58, 95-103. | 2.0 | 154 |
| 314 | Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer. Drugs, 2007, 67, 1125-1138. | 10.9 | 15 |
| 315 | Erlotinib in non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2007, 8, 2579-2592. | 1.8 | 11 |
| 316 | MTP23-01: Salvage therapy for NSCLC. Journal of Thoracic Oncology, 2007, 2, S289-S290. | 1.1 | 0 |
| 317 | Clinical Features Reflect Exon Sites of EGFR Mutations in Patients with Resected Non-Small-Cell Lung Cancer. Journal of Korean Medical Science, 2007, 22, 393. | 2.5 | 11 |
| 318 | Predictive Factors for Response and for Resistance to Tyrosine Kinase Inhibitor Therapy in Lung Cancer. Journal of Thoracic Oncology, 2007, 2, S12-S14. | 1.1 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 319 | Clinical and Preclinical Experience with Gefitinib and Sunitinib. <i>Breast Care</i> , 2007, 2, 68-73. | 1.4 | 2 |
| 321 | Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature. <i>Human Mutation</i> , 2007, 28, 760-770. | 2.5 | 51 |
| 322 | Amplification, mutation and loss of heterozygosity of the <i>EGFR</i> gene in metastatic lung cancer. <i>International Journal of Cancer</i> , 2007, 120, 1828-1831. | 5.1 | 9 |
| 323 | The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. <i>International Journal of Cancer</i> , 2007, 120, 1239-1247. | 5.1 | 120 |
| 324 | Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. <i>Cancer</i> , 2007, 109, 581-587. | 4.1 | 117 |
| 325 | Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas. <i>Cancer</i> , 2007, 109, 741-750. | 4.1 | 74 |
| 326 | Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer. <i>Cancer</i> , 2007, 109, 1836-1844. | 4.1 | 69 |
| 327 | Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer. <i>Journal of Surgical Oncology</i> , 2007, 95, 63-69. | 1.7 | 30 |
| 328 | Epidermal Growth Factor Receptor Double Activating Mutations Involving Both Exons 19 and 21 Exist in Chinese Non-small Cell Lung Cancer Patients. <i>Clinical Oncology</i> , 2007, 19, 499-506. | 1.4 | 47 |
| 329 | Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. <i>Journal of Pathology</i> , 2007, 212, 287-294. | 4.5 | 120 |
| 330 | EGFR kinase domain mutations – functional impact and relevance for lung cancer therapy. <i>Oncogene</i> , 2007, 26, 5693-5701. | 5.9 | 76 |
| 331 | Epidermal growth factor receptor mutations in lung cancer. <i>Nature Reviews Cancer</i> , 2007, 7, 169-181. | 28.4 | 2,741 |
| 332 | Lung cancer in never smokers – a different disease. <i>Nature Reviews Cancer</i> , 2007, 7, 778-790. | 28.4 | 1,276 |
| 333 | Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?. <i>British Journal of Cancer</i> , 2007, 96, 857-863. | 6.4 | 90 |
| 334 | Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. <i>British Journal of Cancer</i> , 2007, 96, 1191-1196. | 6.4 | 46 |
| 335 | Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). <i>British Journal of Cancer</i> , 2007, 97, 778-784. | 6.4 | 198 |
| 336 | Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition. <i>British Journal of Cancer</i> , 2007, 97, 741-744. | 6.4 | 45 |
| 337 | Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lung. <i>Modern Pathology</i> , 2007, 20, 967-973. | 5.5 | 33 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 338 | Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. <i>Modern Pathology</i> , 2007, 20, 1028-1035. | 5.5 | 51 |
| 339 | Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. <i>Differentiation</i> , 2007, 75, 788-799. | 1.9 | 72 |
| 340 | Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. <i>Cancer Science</i> , 2007, 98, 96-101. | 3.9 | 86 |
| 341 | Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. <i>Cancer Science</i> , 2007, 98, 357-363. | 3.9 | 48 |
| 342 | Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma. <i>Cancer Science</i> , 2007, 98, 985-991. | 3.9 | 30 |
| 343 | Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. <i>Cancer Science</i> , 2007, 98, 1275-1280. | 3.9 | 238 |
| 344 | Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. <i>Cancer Science</i> , 2007, 98, 1817-1824. | 3.9 | 554 |
| 345 | Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives. <i>Acta Pharmacologica Sinica</i> , 2007, 28, 1476-1493. | 6.1 | 39 |
| 346 | Correlation between EGFR gene mutation pattern and Akt phosphorylation in pulmonary adenocarcinomas. <i>Pathology International</i> , 2007, 57, 268-275. | 1.3 | 12 |
| 347 | Epidermal growth factor receptor mutations in lung cancers. <i>Pathology International</i> , 2007, 57, 233-244. | 1.3 | 72 |
| 348 | Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients. <i>BMC Cancer</i> , 2007, 7, 128. | 2.6 | 36 |
| 349 | Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers. <i>BMC Cancer</i> , 2007, 7, 74. | 2.6 | 35 |
| 350 | Sequence variations in DNA repair gene XPC is associated with lung cancer risk in a Chinese population: a case-control study. <i>BMC Cancer</i> , 2007, 7, 81. | 2.6 | 31 |
| 351 | EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. <i>Cancer Genetics and Cytogenetics</i> , 2007, 173, 107-113. | 1.0 | 79 |
| 352 | Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma. <i>Diagnostic Cytopathology</i> , 2007, 35, 257-262. | 1.0 | 14 |
| 353 | Who Should Receive Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer and When? Current Treatment Options in Oncology, 2007, 8, 28-37. | 3.0 | 18 |
| 354 | Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer. <i>Medical Oncology</i> , 2007, 24, 388-393. | 2.5 | 21 |
| 355 | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues. <i>Internal and Emergency Medicine</i> , 2007, 2, 3-12. | 2.0 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 356 | Simple method to detect important epidermal growth factor receptor gene mutations with bronchoscopic specimens of lung cancer patients for gefitinib treatment. Targeted Oncology, 2007, 2, 145-151. | 3.6 | 3 |
| 357 | Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. Cancer and Metastasis Reviews, 2008, 27, 387-402. | 5.9 | 26 |
| 358 | Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2008, 61, 489-496. | 2.3 | 75 |
| 359 | EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?. Targeted Oncology, 2008, 3, 173-186. | 3.6 | 3 |
| 360 | Accuracy of epidermal growth factor receptor gene mutation analysis by direct sequencing method based on small biopsy specimens from patients with non-small cell lung cancer: analysis of results in 19 patients. International Journal of Clinical Oncology, 2008, 13, 442-446. | 2.2 | 14 |
| 361 | Place des thérapies biologiques ciblées. Oncologie, 2008, 10, 540-544. | 0.7 | 0 |
| 362 | EGFR / HER2 / HER3 expression in tumour and gefitinib treatment in Chinese patients with advanced non-small cell lung cancer. Chinese-German Journal of Clinical Oncology, 2008, 7, 440-446. | 0.1 | 1 |
| 363 | Elevated expression level of laminin 5 may be a negative predictive factor for the response to gefitinib in lung cancer patients. Chinese-German Journal of Clinical Oncology, 2008, 7, 677-681. | 0.1 | 0 |
| 364 | Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. Journal of Cancer Research and Clinical Oncology, 2008, 134, 569-577. | 2.5 | 64 |
| 365 | A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer. Journal of Cancer Research and Clinical Oncology, 2008, 134, 1371-1376. | 2.5 | 12 |
| 366 | Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer. Prostate, 2008, 68, 803-808. | 2.3 | 19 |
| 367 | Clinical significance of aberrant methylation of prostaglandin E receptor 2 (<i>PTGER2</i>) in nonsmall cell lung cancer. Cancer, 2008, 113, 1396-1403. | 4.1 | 21 |
| 368 | Reversed mutation rates of <i>KRAS</i> and <i>EGFR</i> genes in adenocarcinoma of the lung in Taiwan and their implications. Cancer, 2008, 113, 3199-3208. | 4.1 | 84 |
| 369 | EGFR inhibition in the treatment of non-small cell lung cancer. Drug Development Research, 2008, 69, 359-372. | 2.9 | 51 |
| 370 | Chronic rhinosinusitis and risk of lung cancer in the Singapore Chinese Health Study. International Journal of Cancer, 2008, 123, 1398-1402. | 5.1 | 20 |
| 371 | Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study. Modern Pathology, 2008, 21, 1168-1175. | 5.5 | 79 |
| 372 | Molecular epidemiology of cancer. Biochemistry (Moscow), 2008, 73, 532-542. | 1.5 | 28 |
| 373 | Molecular diagnosis in oncology. Molecular Biology, 2008, 42, 687-698. | 1.3 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 374 | EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids. <i>Oncogene</i> , 2008, 27, 4336-4343. | 5.9 | 72 |
| 375 | Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). <i>British Journal of Cancer</i> , 2008, 98, 907-914. | 6.4 | 200 |
| 376 | Emerging ethnic differences in lung cancer therapy. <i>British Journal of Cancer</i> , 2008, 99, 1757-1762. | 6.4 | 122 |
| 377 | Absence of epidermal growth factor receptor mutations in cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 749-754. | 2.5 | 33 |
| 378 | Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. <i>Cancer Science</i> , 2008, 99, 303-308. | 3.9 | 37 |
| 379 | Occurrence of mutations in the epidermal growth factor receptor gene in X-ray-induced rat lung tumors. <i>Cancer Science</i> , 2008, 99, 241-245. | 3.9 | 15 |
| 380 | Soy consumption reduces the risk of non-small cell lung cancers with epidermal growth factor receptor mutations among Japanese. <i>Cancer Science</i> , 2008, 99, 1202-1208. | 3.9 | 28 |
| 381 | Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. <i>Cancer Science</i> , 2008, 99, 1589-1594. | 3.9 | 92 |
| 382 | Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP promoter. <i>Cancer Science</i> , 2008, 99, 1747-1753. | 3.9 | 27 |
| 383 | Clinical significance of pretreatment serum amphiregulin and transforming growth factor- α , and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer. <i>Cancer Science</i> , 2008, 99, 2295-2301. | 3.9 | 29 |
| 384 | Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. <i>Cancer Science</i> , 2008, 99, 2349-2355. | 3.9 | 209 |
| 385 | Tyrosine kinase activating mutations in human malignancies: Implications for diagnostic pathology. <i>Experimental and Molecular Pathology</i> , 2008, 85, 68-75. | 2.1 | 10 |
| 386 | High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. <i>BMC Cancer</i> , 2008, 8, 142. | 2.6 | 184 |
| 387 | Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-associated oral carcinomas. <i>Oral Oncology</i> , 2008, 44, 270-276. | 1.5 | 55 |
| 388 | Stepwise progression from ground-glass opacity towards invasive adenocarcinoma: Long-term follow-up of radiological findings. <i>Lung Cancer</i> , 2008, 60, 298-301. | 2.0 | 30 |
| 389 | ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. <i>Lung Cancer</i> , 2008, 60, 401-407. | 2.0 | 78 |
| 390 | EGFR FISH versus mutation: Different tests, different end-points. <i>Lung Cancer</i> , 2008, 60, 160-165. | 2.0 | 44 |
| 391 | Bronchioloalveolar Carcinoma: The Case for Two Diseases. <i>Clinical Lung Cancer</i> , 2008, 9, 24-29. | 2.6 | 70 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 392 | Extensive-Stage Small-Cell Lung Cancer: Evolution of Systemic Therapy and Future Directions. <i>Clinical Lung Cancer</i> , 2008, 9, 262-270. | 2.6 | 15 |
| 393 | EGFR/KRAS Mutations and Gefitinib Therapy in Chinese NSCLC Patients. <i>Onkologie</i> , 2008, 31, 174-178. | 0.8 | 22 |
| 394 | Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment. <i>Expert Review of Respiratory Medicine</i> , 2008, 2, 167-178. | 2.5 | 56 |
| 395 | Signalling by the EGF receptor in human cancers: accentuate the positive, eliminate the negative. , 2008, , 224-244. | | 1 |
| 396 | EGFR Signaling Networks in Cancer Therapy. , 2008, , . | | 11 |
| 397 | Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-â€‘small cell lung cancer. <i>Human Pathology</i> , 2008, 39, 126-136. | 2.0 | 76 |
| 398 | Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma. <i>Human Pathology</i> , 2008, 39, 316-323. | 2.0 | 22 |
| 399 | EGFR Polymorphism of the Kinase Domain in Japanese Lung Cancer. <i>Journal of Surgical Research</i> , 2008, 148, 260-263. | 1.6 | 16 |
| 400 | EGFR Mutations and EGFR Tyrosine Kinase Inhibition in Non-â€‘Small Cell Lung Cancer. <i>Seminars in Oncology Nursing</i> , 2008, 24, 27-33. | 1.5 | 11 |
| 401 | EGFR Antagonists in Cancer Treatment. <i>New England Journal of Medicine</i> , 2008, 358, 1160-1174. | 27.0 | 1,869 |
| 402 | Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. <i>Cancer Letters</i> , 2008, 265, 307-317. | 7.2 | 112 |
| 403 | Acquired resistance to tyrosine kinase inhibitors during cancer therapy. <i>Current Opinion in Genetics and Development</i> , 2008, 18, 73-79. | 3.3 | 269 |
| 404 | Advances in the treatment of non-small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2008, 34, 521-526. | 7.7 | 6 |
| 405 | Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2008, 60, S10-S18. | 2.0 | 21 |
| 406 | EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. <i>Lung Cancer</i> , 2008, 60, S23-S30. | 2.0 | 46 |
| 407 | KRAS mutational testing in the selection of patients for EGFR-targeted therapies. <i>Seminars in Diagnostic Pathology</i> , 2008, 25, 288-294. | 1.5 | 16 |
| 408 | Role of <i>KRAS</i> and <i>EGFR</i> As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. <i>Journal of Clinical Oncology</i> , 2008, 26, 4268-4275. | 1.6 | 674 |
| 409 | First-Line Gefitinib in Patients With Advanced Non-â€‘Small-Cell Lung Cancer Harboring Somatic<i>EGFR</i>Mutations. <i>Journal of Clinical Oncology</i> , 2008, 26, 2442-2449. | 1.6 | 812 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 410 | Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer, 2008, 59, 111-118. | 2.0 | 91 |
| 411 | Molecular genetics of lung cancer in people who have never smoked. Lancet Oncology, The, 2008, 9, 676-682. | 10.7 | 113 |
| 412 | Refining the bipartite model of lung cancer. Lancet Oncology, The, 2008, 9, 918-919. | 10.7 | 1 |
| 413 | Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clinical Cancer Research, 2008, 14, 2895-2899. | 7.0 | 649 |
| 414 | Molecular Pathology-Translating Research into Clinical Practice: An Expanding Frontier in Surgical Oncology. Surgical Oncology Clinics of North America, 2008, 17, 303-321. | 1.5 | 1 |
| 415 | Combined anti-proliferative and anti-angiogenic strategies for cancer. Expert Opinion on Pharmacotherapy, 2008, 9, 701-715. | 1.8 | 18 |
| 416 | EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story. Annual Review of Medicine, 2008, 59, 429-442. | 12.2 | 152 |
| 417 | Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer. Journal of Clinical Oncology, 2008, 26, 1742-1751. | 1.6 | 267 |
| 418 | A mouse model for EML4-ALK-positive lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19893-19897. | 7.1 | 490 |
| 419 | EGFR Mutations in Lung Adenocarcinomas. Journal of Molecular Diagnostics, 2008, 10, 242-248. | 2.8 | 180 |
| 420 | Epidermal Growth Factor Receptor (EGFR) High Gene Copy Number and Activating Mutations in Lung Adenocarcinomas Are Not Consistently Accompanied by Positivity for EGFR Protein by Standard Immunohistochemistry. Journal of Molecular Diagnostics, 2008, 10, 160-168. | 2.8 | 58 |
| 421 | First- or Second-line Therapy with Gefitinib Produces Equal Survival in Non-Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 847-853. | 5.6 | 66 |
| 422 | Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer. Cancer Research, 2008, 68, 9375-9383. | 0.9 | 235 |
| 423 | Aberrations of chromosome 19 in asbestos-associated lung cancer and in asbestos-induced micronuclei of bronchial epithelial cells in vitro. Carcinogenesis, 2008, 29, 913-917. | 2.8 | 28 |
| 424 | Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response. Clinical Cancer Research, 2008, 14, 162-168. | 7.0 | 140 |
| 425 | Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. European Respiratory Journal, 2008, 32, 924-930. | 6.7 | 112 |
| 426 | Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer. Clinical Cancer Research, 2008, 14, 6092-6096. | 7.0 | 159 |
| 427 | Trichomegaly of the Eyelashes After Lung Cancer Treatment with the Epidermal Growth Factor Receptor Inhibitor Erlotinib. Journal of Clinical Oncology, 2008, 26, 3460-3462. | 1.6 | 40 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 428 | Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis. Journal of Clinical Pathology, 2008, 61, 487-493. | 2.0 | 86 |
| 429 | Epidermal Growth Factor Receptor Gene Amplification Is Acquired in Association with Tumor Progression of EGFR-Mutated Lung Cancer. Cancer Research, 2008, 68, 2106-2111. | 0.9 | 134 |
| 430 | Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non-Small Cell Lung Cancer. Cancer Research, 2008, 68, 4971-4976. | 0.9 | 419 |
| 431 | Good Response to Gefitinib in Lung Adenocarcinoma of Complex Epidermal Growth Factor Receptor (EGFR) Mutations with the Classical Mutation Pattern. Oncologist, 2008, 13, 1276-1284. | 3.7 | 70 |
| 432 | EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers. Journal of Thoracic Oncology, 2008, 3, 13-17. | 1.1 | 441 |
| 433 | Targeting Growth Factors in Lung Cancer. Chest, 2008, 133, 1209-1216. | 0.8 | 39 |
| 434 | Establishment of Patient-Derived Non-Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers. Clinical Cancer Research, 2008, 14, 6456-6468. | 7.0 | 268 |
| 435 | Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. British Journal of Cancer, 2008, 98, 154-160. | 6.4 | 100 |
| 436 | The role of gefitinib in the management of Asian patients with non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2008, 17, 401-411. | 4.1 | 12 |
| 437 | Mechanisms of Disease: signal transduction in lung carcinogenesis—a comparison of smokers and never-smokers. Nature Clinical Practice Oncology, 2008, 5, 610-618. | 4.3 | 22 |
| 438 | Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14112-14117. | 7.1 | 113 |
| 439 | Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers. Clinical Cancer Research, 2008, 14, 6963-6973. | 7.0 | 112 |
| 441 | Laser Capture Microdissection and Protein Microarray Analysis of Human Non-small Cell Lung Cancer. Molecular and Cellular Proteomics, 2008, 7, 1902-1924. | 3.8 | 103 |
| 442 | Cyclic AMP Response Element-Binding Protein Overexpression: A Feature Associated with Negative Prognosis in Never Smokers with Non-Small Cell Lung Cancer. Cancer Research, 2008, 68, 6065-6073. | 0.9 | 92 |
| 443 | The Potential Role of Pharmacogenomic and Genomic in the Adjuvant Treatment of Early Stage Non Small Cell Lung Cancer. Current Genomics, 2008, 9, 252-262. | 1.6 | 20 |
| 444 | Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response. Clinical Cancer Research, 2008, 14, 4877-4882. | 7.0 | 294 |
| 445 | EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. European Respiratory Journal, 2008, 33, 436-440. | 6.7 | 39 |
| 446 | Overview of Gefitinib in Non-small Cell Lung Cancer: An Asian Perspective. Japanese Journal of Clinical Oncology, 2008, 39, 137-150. | 1.3 | 72 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 447 | A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2008, 14, 3867-3874. | 7.0 | 73 |
| 448 | Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib. <i>Clinical Cancer Research</i> , 2008, 14, 7060-7067. | 7.0 | 156 |
| 449 | Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung Adenocarcinomas. <i>Cancer Prevention Research</i> , 2008, 1, 192-200. | 1.5 | 84 |
| 450 | A Subset of Lung Adenocarcinomas and Atypical Adenomatous Hyperplasia-Associated Foci Are Genotypically Related. <i>American Journal of Clinical Pathology</i> , 2008, 129, 202-210. | 0.7 | 46 |
| 451 | MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort. <i>Journal of Thoracic Oncology</i> , 2008, 3, 331-339. | 1.1 | 181 |
| 452 | EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan. <i>Journal of Clinical Oncology</i> , 2008, 26, 5589-5595. | 1.6 | 210 |
| 453 | Increased Prevalence of EGFR-Mutant Lung Cancer in Women and in East Asian Populations: Analysis of Estrogen-Related Polymorphisms. <i>Clinical Cancer Research</i> , 2008, 14, 4079-4084. | 7.0 | 71 |
| 454 | PIK3CA Mutations and Copy Number Gains in Human Lung Cancers. <i>Cancer Research</i> , 2008, 68, 6913-6921. | 0.9 | 399 |
| 455 | Somatic pharmacogenomics in cancer. <i>Pharmacogenomics Journal</i> , 2008, 8, 305-314. | 2.0 | 22 |
| 458 | Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion. <i>Cancer Research</i> , 2008, 68, 132-142. | 0.9 | 114 |
| 459 | Gefitinib First or Gefitinib Second. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 783-785. | 5.6 | 0 |
| 460 | Biomarkers in oncology drug development: rescuers or troublemakers?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 1391-1402. | 3.3 | 16 |
| 461 | Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2008, 3, 111-116. | 1.1 | 248 |
| 462 | Detection of EGFR Gene Mutations Using the Wash Fluid of CT-Guided Biopsy Needle in NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2008, 3, 472-476. | 1.1 | 38 |
| 463 | Personalizing protein-drug interactions. <i>Pure and Applied Chemistry</i> , 2008, 80, 1811-1820. | 1.9 | 1 |
| 464 | Wood-Smoke Exposure as a Response and Survival Predictor in Erlotinib-treated Non-small Cell Lung Cancer Patients: An Open Label Phase II Study. <i>Journal of Thoracic Oncology</i> , 2008, 3, 887-893. | 1.1 | 28 |
| 465 | Clinical Experience with Gefitinib in Indian Patients. <i>Journal of Thoracic Oncology</i> , 2008, 3, 380-385. | 1.1 | 24 |
| 466 | Sequential Molecular Changes during Multistage Pathogenesis of Small Peripheral Adenocarcinomas of the Lung. <i>Journal of Thoracic Oncology</i> , 2008, 3, 340-347. | 1.1 | 78 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 467 | Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer. <i>Current Signal Transduction Therapy</i> , 2008, 3, 234-243. | 0.5 | 0 |
| 468 | Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis. <i>American Journal of Surgical Pathology</i> , 2008, 32, 810-827. | 3.7 | 352 |
| 469 | Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. <i>Current Opinion in Oncology</i> , 2008, 20, 162-175. | 2.4 | 46 |
| 470 | Molecularly Targeted Therapy for Lung Cancer: Recent Topics. <i>Journal of Lung Cancer</i> , 2008, 7, 1. | 0.2 | 2 |
| 471 | Role of Epidermal Growth Factor Receptor and the HER-2 Gene in Hormone Refractory Prostate Cancer. <i>Korean Journal of Urology</i> , 2008, 49, 24. | 0.2 | 0 |
| 472 | Molecular Predictors of EGFR-TKI Sensitivity in Advanced Nonâ€‘small Cell Lung Cancer. <i>International Journal of Medical Sciences</i> , 2008, 5, 209-217. | 2.5 | 67 |
| 473 | Targeted therapies in non-small cell lung cancer. <i>Cancer Imaging</i> , 2008, 8, 199-205. | 2.8 | 6 |
| 474 | Molecular Basis of Pulmonary Disease. , 2009, , 305-364. | | 4 |
| 478 | Hormone Replacement Therapy and Outcomes for Women with Non-Small-Cell Lung Cancer: Can An Association be Confirmed?. <i>Current Oncology</i> , 2009, 16, 21-25. | 2.2 | 31 |
| 479 | Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors. <i>Journal of Oncology</i> , 2009, 2009, 1-12. | 1.3 | 53 |
| 480 | Second Line Treatments in Advanced Platinum-Resistant Non Small Cell Lung Cancer. A Critical Review of Literature. <i>Reviews on Recent Clinical Trials</i> , 2009, 4, 27-33. | 0.8 | 8 |
| 481 | Characterizing the developmental pathways <i>TTF-1</i> , <i>NKX2-8</i> , and <i>PAX9</i> in lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 5312-5317. | 7.1 | 50 |
| 482 | First-Line Gefitinib for Patients With Advanced Nonâ€‘Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 1394-1400. | 1.6 | 480 |
| 483 | Micropapillary Histology. <i>American Journal of Clinical Pathology</i> , 2009, 131, 615-617. | 0.7 | 7 |
| 484 | The â€‘Lazarus Responseâ€‘ in Treatment-Naï‘ve, Poor Performance Status Patients With Nonâ€‘Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Mutation. <i>Journal of Clinical Oncology</i> , 2009, 27, 1350-1354. | 1.6 | 69 |
| 486 | Erlotinib: applications in therapy and current status of research. <i>Expert Review of Clinical Pharmacology</i> , 2009, 2, 15-36. | 3.1 | 1 |
| 487 | Noninvasive Detection of <i>EGFR</i> T790M in Gefitinib or Erlotinib Resistant Nonâ€‘Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 2630-2636. | 7.0 | 229 |
| 488 | Mutations and Response to Epidermal Growth Factor Receptor Inhibitors: Fig. 1.. <i>Clinical Cancer Research</i> , 2009, 15, 1133-1139. | 7.0 | 120 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 489 | Uncovering Disparities in Survival after Nonâ€‘Smallâ€‘Cell Lung Cancer among Asian/Pacific Islander Ethnic Populations in California. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2248-2255. | 2.5 | 19 |
| 490 | Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Nonâ€‘small cell Lung Cancer Cell Lines with<i>MET</i> Amplification. <i>Clinical Cancer Research</i> , 2009, 15, 907-913. | 7.0 | 47 |
| 491 | HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 4829-4837. | 7.0 | 151 |
| 492 | <i>EGFR/KRAS/BRAF</i> Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases. <i>Clinical Cancer Research</i> , 2009, 15, 4554-4560. | 7.0 | 258 |
| 493 | Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: A population-based prospective study. <i>Oncology Reports</i> , 2009, 22, 683-91. | 2.6 | 25 |
| 494 | Gefitinib in lung cancer therapy: Clinical results, predictive markers of response and future perspectives. <i>Cancer Biology and Therapy</i> , 2009, 8, 206-212. | 3.4 | 10 |
| 495 | Second-Line Treatments in Non-small Cell Lung Cancer. <i>Chest</i> , 2009, 135, 1596-1609. | 0.8 | 33 |
| 497 | Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines. <i>Journal of Thoracic Oncology</i> , 2009, 4, 161-166. | 1.1 | 59 |
| 498 | Theme: Oncology - Molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates. <i>Biomarkers in Medicine</i> , 2009, 3, 139-151. | 1.4 | 4 |
| 499 | IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumors. <i>Future Oncology</i> , 2009, 5, 305-308. | 2.4 | 9 |
| 500 | Genomics of Lung Cancer. <i>Proceedings of the American Thoracic Society</i> , 2009, 6, 152-158. | 3.5 | 36 |
| 501 | Reasons for response differences seen in the V15-32, INTEREST and IPASS trials. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 287-294. | 27.6 | 21 |
| 502 | EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis. <i>Carcinogenesis</i> , 2009, 30, 1155-1160. | 2.8 | 46 |
| 503 | Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines. <i>PLoS ONE</i> , 2009, 4, e4576. | 2.5 | 177 |
| 504 | Immunohistochemical Expression of Estrogen and Progesterone Receptors Identifies a Subset of NSCLCs and Correlates with <i>EGFR</i> Mutation. <i>Clinical Cancer Research</i> , 2009, 15, 5359-5368. | 7.0 | 150 |
| 505 | MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2009, 20, 298-304. | 1.2 | 286 |
| 506 | The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2009, 14, 1116-1130. | 3.7 | 57 |
| 507 | Whole Genome Comparison of Allelic Imbalance between Noninvasive and Invasive Small-Sized Lung Adenocarcinomas. <i>Cancer Research</i> , 2009, 69, 1615-1623. | 0.9 | 33 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 508 | Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 7502-7509. | 7.0 | 136 |
| 510 | Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications. <i>Clinical Cancer Research</i> , 2009, 15, 5646-5661. | 7.0 | 137 |
| 511 | <i>EGFR</i> and K-<i>ras</i> Mutations Along the Spectrum of Pulmonary Epithelial Tumors of the Lung and Elaboration of a Combined Clinicopathologic and Molecular Scoring System to Predict Clinical Responsiveness to EGFR Inhibitors. <i>American Journal of Clinical Pathology</i> , 2009, 131, 478-489. | 0.7 | 67 |
| 512 | Cancer Pharmacoeethnicity: Ethnic Differences in Susceptibility to the Effects of Chemotherapy. <i>Clinical Cancer Research</i> , 2009, 15, 4806-4814. | 7.0 | 212 |
| 513 | Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. <i>Annals of Oncology</i> , 2009, 20, 213-226. | 1.2 | 37 |
| 514 | Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 5714-5723. | 7.0 | 174 |
| 515 | Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naïve non-small-cell lung cancer. <i>Annals of Oncology</i> , 2009, 20, 696-702. | 1.2 | 206 |
| 516 | Chemopreventive Effects of Gefitinib on Nonsmoking-Related Lung Tumorigenesis in Activating Epidermal Growth Factor Receptor Transgenic Mice. <i>Cancer Research</i> , 2009, 69, 7088-7095. | 0.9 | 23 |
| 517 | Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Nonâ€“Small Cell Lung Cancer with <i>EGFR</i> Mutations. <i>Clinical Cancer Research</i> , 2009, 15, 4493-4498. | 7.0 | 182 |
| 518 | Pathogenesis of lung cancer signalling pathways: roadmap for therapies. <i>European Respiratory Journal</i> , 2009, 33, 1485-1497. | 6.7 | 151 |
| 519 | Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2009, 4, 12-21. | 1.1 | 75 |
| 520 | ErbBs in lung cancer. <i>Experimental Cell Research</i> , 2009, 315, 557-571. | 2.6 | 61 |
| 521 | ERBBs in the gastrointestinal tract: Recent progress and new perspectives. <i>Experimental Cell Research</i> , 2009, 315, 583-601. | 2.6 | 46 |
| 522 | Epidermal growth factor receptor (EGFR) double-activating somatic mutations in exons 19 and 21 in Japanese nonâ€“small cell lung cancer patients. <i>Cancer Genetics and Cytogenetics</i> , 2009, 195, 179-182. | 1.0 | 10 |
| 523 | Differential Expression of Biomarkers in Men and Women. <i>Seminars in Oncology</i> , 2009, 36, 553-565. | 2.2 | 52 |
| 524 | EGFR protein overexpression and mutation in areca quidâ€“associated oral cavity squamous cell carcinoma in Taiwan. <i>Head and Neck</i> , 2009, 31, 1068-1077. | 2.0 | 28 |
| 525 | <i>MET</i> gene amplification or <i>EGFR</i> mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. <i>International Journal of Cancer</i> , 2009, 124, 1778-1784. | 5.1 | 131 |
| 526 | Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 1483-1493. | 2.5 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 527 | Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Research and Treatment, 2009, 115, 115-121. | 2.5 | 116 |
| 528 | Resistance mechanisms of tumour cells to EGFR inhibitors. Clinical and Translational Oncology, 2009, 11, 270-275. | 2.4 | 19 |
| 529 | Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors. Clinical and Translational Oncology, 2009, 11, 428-436. | 2.4 | 4 |
| 531 | Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small cell lung cancer for gefitinib treatment. Cancer Science, 2009, 100, 1931-1934. | 3.9 | 15 |
| 532 | Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Modern Pathology, 2009, 22, 668-678. | 5.5 | 134 |
| 533 | EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Modern Pathology, 2009, 22, 508-515. | 5.5 | 429 |
| 534 | Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nature Reviews Clinical Oncology, 2009, 6, 352-366. | 27.6 | 207 |
| 535 | Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene, 2009, 28, S14-S23. | 5.9 | 179 |
| 536 | Clinicopathological features and epidermal growth factor receptor mutations associated with epithelial-mesenchymal transition in non-small cell lung cancer. Respiriology, 2009, 14, 371-376. | 2.3 | 17 |
| 537 | Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions. Current Problems in Cancer, 2009, 33, 245-294. | 2.0 | 9 |
| 538 | American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 6251-6266. | 1.6 | 732 |
| 539 | Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK. Journal of Clinical Oncology, 2009, 27, 4247-4253. | 1.6 | 1,775 |
| 541 | Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 2653-2659. | 1.6 | 281 |
| 542 | The Changing Epidemiology of Lung Cancer. Methods in Molecular Biology, 2009, 472, 397-411. | 0.9 | 64 |
| 543 | Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation. Lung Cancer, 2009, 63, 241-246. | 2.0 | 17 |
| 544 | Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer, 2009, 63, 315-321. | 2.0 | 107 |
| 545 | NAT2 fast acetylator genotypes are associated with an increased risk for lung cancer with wildtype epidermal growth factor receptors in Taiwan. Lung Cancer, 2009, 64, 9-12. | 2.0 | 12 |
| 546 | Improved survival from lung cancer in British Columbia compared to Scotland-Are different treatment rates the whole story?. Lung Cancer, 2009, 64, 358-366. | 2.0 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 547 | Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas. Lung Cancer, 2009, 65, 25-33. | 2.0 | 47 |
| 548 | Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer, 2009, 65, 198-203. | 2.0 | 131 |
| 549 | Gefitinib or Carboplatin+Paclitaxel in Pulmonary Adenocarcinoma. New England Journal of Medicine, 2009, 361, 947-957. | 27.0 | 7,606 |
| 550 | Gefitinib. Drugs, 2009, 69, 2303-2328. | 10.9 | 55 |
| 551 | Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway. Clinical Lung Cancer, 2009, 10, 281-289. | 2.6 | 394 |
| 552 | Gefitinib for the treatment of non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2009, 9, 17-35. | 2.4 | 46 |
| 553 | Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis. Journal of Clinical Pathology, 2009, 62, 886-891. | 2.0 | 46 |
| 554 | Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. New England Journal of Medicine, 2009, 361, 958-967. | 27.0 | 2,213 |
| 555 | Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2009, 18, 293-301. | 4.1 | 15 |
| 556 | Lung Adenocarcinoma with EGFR Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers. Cancer Research, 2009, 69, 8341-8348. | 0.9 | 114 |
| 557 | Phase II Study of Preoperative Gefitinib in Clinical Stage I Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 6229-6236. | 1.6 | 93 |
| 558 | Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer. Lung Cancer, 2009, 66, 107-113. | 2.0 | 20 |
| 559 | Association Between Estrogen Receptor- β Expression and Epidermal Growth Factor Receptor Mutation in the Postoperative Prognosis of Adenocarcinoma of the Lung. Journal of Clinical Oncology, 2009, 27, 411-417. | 1.6 | 158 |
| 560 | First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncology, The, 2009, 10, 1102-1110. | 10.7 | 28 |
| 561 | Estrogen and its signaling pathway in non-small cell lung cancer(NSCLC). Journal of Nanjing Medical University, 2009, 23, 217-223. | 0.1 | 3 |
| 562 | Epidermal Growth Factor Receptor Mutation and Pathologic-Radiologic Correlation Between Multiple Lung Nodules with Ground-Glass Opacity Differentiates Multicentric Origin from Intrapulmonary Spread. Journal of Thoracic Oncology, 2009, 4, 1490-1495. | 1.1 | 103 |
| 563 | Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma. Journal of Thoracic Oncology, 2009, 4, 22-29. | 1.1 | 222 |
| 564 | Germ-Line and Somatic Presentations of the EGFR T790M Mutation in Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 139-141. | 1.1 | 41 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 565 | EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR and KRAS Mutations in a Japanese Cohort. <i>Journal of Thoracic Oncology</i> , 2009, 4, 318-325. | 1.1 | 52 |
| 566 | The status of KRAS mutations in patients with non-small cell lung cancers from mainland China. <i>Oncology Reports</i> , 2009, 22, 1013-20. | 2.6 | 27 |
| 567 | Class IA Phosphatidylinositol 3-Kinase Signaling in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 787-791. | 1.1 | 30 |
| 568 | Erlotinib Combined with Cyclosporine in a Liver-Transplant Recipient with Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 138-139. | 1.1 | 6 |
| 569 | Recent Developments of Targeted Therapies in the Treatment of Non-Small Cell Lung Cancer. <i>Current Drug Discovery Technologies</i> , 2009, 6, 91-102. | 1.2 | 29 |
| 570 | Personalized cancer therapy coming of age: clinical highlights in 2009 and future directions. <i>Personalized Medicine</i> , 2010, 7, 121-124. | 1.5 | 2 |
| 571 | Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method for Epidermal Growth Factor Receptor Mutations. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1551-1558. | 1.1 | 117 |
| 572 | Primary Lung Adenocarcinomas in Children and Adolescents Treated for Pediatric Malignancies. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1764-1771. | 1.1 | 22 |
| 573 | Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1706-1713. | 1.1 | 273 |
| 574 | The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies. <i>Genes and Cancer</i> , 2010, 1, 1200-1210. | 1.9 | 88 |
| 575 | Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1048-1053. | 1.1 | 76 |
| 576 | Gender, Histology, and Time of Diagnosis Are Important Factors for Prognosis: Analysis of 1499 Never-Smokers with Advanced Non-small Cell Lung Cancer in Japan. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1011-1017. | 1.1 | 76 |
| 577 | Frequency of EGFR and KRAS Mutations in Japanese Patients with Lung Adenocarcinoma with Features of the Mucinous Subtype of Bronchioloalveolar Carcinoma. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1197-1200. | 1.1 | 66 |
| 578 | High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 305-313. | 1.1 | 206 |
| 579 | De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 399-400. | 1.1 | 74 |
| 580 | Molecular Diagnostics Testing for Lung Adenocarcinoma. , 2010, 15, 103-110. | | 1 |
| 581 | Are There Imaging Characteristics Associated with Epidermal Growth Factor Receptor and KRAS Mutations in Patients with Adenocarcinoma of the Lung with Bronchioloalveolar Features?. <i>Journal of Thoracic Oncology</i> , 2010, 5, 344-348. | 1.1 | 68 |
| 582 | Correlation between Epidermal Growth Factor Receptor Mutations and Expression of Female Hormone Receptors in East-Asian Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2010, 5, 17-22. | 1.1 | 35 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 583 | Association Between Age at Diagnosis and the Presence of EGFR Mutations in Female Patients with Resected Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1949-1952. | 1.1 | 36 |
| 584 | Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1404-1409. | 1.1 | 50 |
| 585 | Clinicopathological and Therapeutic Significance of CXCL12 Expression in Lung Cancer. <i>International Journal of Immunopathology and Pharmacology</i> , 2010, 23, 153-164. | 2.1 | 28 |
| 586 | Overexpression of EGFR pathway-related genes in the circulation is highly correlated with EGFR mutations and overexpression in paired cancer tissue from patients with non-small cell lung cancer. <i>Oncology Reports</i> , 2010, 23, . | 2.6 | 8 |
| 587 | Spectrum of LKB1, EGFR, and KRAS Mutations in Chinese Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1130-1135. | 1.1 | 91 |
| 588 | Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1382-1390. | 1.1 | 138 |
| 589 | Japanese Lung Cancer Research Trends and Performance in Science Citation Index. <i>Internal Medicine</i> , 2010, 49, 2219-2228. | 0.7 | 130 |
| 590 | Correlation Between HLA Alleles and EGFR Mutation in Japanese Patients with Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1136-1142. | 1.1 | 12 |
| 591 | Biomarkers with Predictive and Prognostic Function in Non-“Small Cell Lung Cancer: Ready for Prime Time?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 822-832. | 4.9 | 36 |
| 592 | Deregulation of p27 and Cyclin D1/D3 Control Over Mitosis Is Associated with Unfavorable Prognosis in Non-small Cell Lung Cancer, as Determined in 405 Operated Patients. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1325-1336. | 1.1 | 41 |
| 593 | A Single Institution-Based Retrospective Study of Surgically Treated Bronchioloalveolar Adenocarcinoma of the Lung: Clinicopathologic Analysis, Molecular Features, and Possible Pitfalls in Routine Practice. <i>Journal of Thoracic Oncology</i> , 2010, 5, 830-836. | 1.1 | 76 |
| 594 | Prognostic Implications of Epidermal Growth Factor Receptor and KRAS Gene Mutations and Epidermal Growth Factor Receptor Gene Copy Numbers in Patients with Surgically Resectable Non-small Cell Lung Cancer in Taiwan. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1175-1184. | 1.1 | 50 |
| 595 | Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1937-1944. | 2.5 | 29 |
| 596 | Impact of biomarkers on non-small cell lung cancer treatment. <i>Targeted Oncology</i> , 2010, 5, 5-17. | 3.6 | 17 |
| 597 | Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib. <i>Medical Oncology</i> , 2010, 27, 950-957. | 2.5 | 13 |
| 598 | Biomarkers in bronchopulmonary cancer. <i>Clinical and Translational Oncology</i> , 2010, 12, 92-99. | 2.4 | 3 |
| 599 | Low correspondence of EGFR mutations in tumor tissue and paired serum of non-small-cell lung cancer patients. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2010, 22, 27-31. | 2.2 | 5 |
| 600 | Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 49-60. | 5.9 | 191 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 601 | Stepwise progression of pulmonary adenocarcinoma—clinical and molecular implications. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 15-21. | 5.9 | 109 |
| 602 | The Emerging Role of Biomarkers in Advanced Non—Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2010, 11, 149-159. | 2.6 | 20 |
| 603 | Use of Cetuximab After Failure of Gefitinib in Patients With Advanced Non—Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2010, 11, 257-263. | 2.6 | 8 |
| 604 | Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. <i>BMC Cancer</i> , 2010, 10, 376. | 2.6 | 70 |
| 605 | Kinases as targets in the treatment of solid tumors. <i>Cellular Signalling</i> , 2010, 22, 984-1002. | 3.6 | 88 |
| 606 | Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy. <i>FEBS Letters</i> , 2010, 584, 2699-2706. | 2.8 | 141 |
| 607 | Sex differences in lung cancer susceptibility: A review. <i>Gender Medicine</i> , 2010, 7, 381-401. | 1.4 | 157 |
| 608 | Mechanisms of resistance to HER family targeting antibodies. <i>Experimental Cell Research</i> , 2010, 316, 1083-1100. | 2.6 | 136 |
| 609 | Clinical outcomes in non—small—cell lung cancer patients with <i>EGFR</i> mutations: pooled analysis. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 51-69. | 3.6 | 126 |
| 610 | Epidermal growth factor receptor mutations detected by denaturing high—performance liquid chromatography in nonsmall cell lung cancer. <i>Cancer</i> , 2010, 116, 4309-4317. | 4.1 | 20 |
| 611 | Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: A review of published data. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 75, 94-109. | 4.4 | 38 |
| 612 | Rapid detection of epidermal growth factor receptor mutations with multiplex PCR and primer extension in lung cancer. <i>Journal of Biomedical Science</i> , 2010, 17, 37. | 7.0 | 9 |
| 613 | Oncogenic <i>NRF2</i> mutations in squamous cell carcinomas of oesophagus and skin. <i>Journal of Pathology</i> , 2010, 220, 446-451. | 4.5 | 311 |
| 614 | Epidermal growth factor receptor (EGFR) expression in periocular and extraocular sebaceous carcinoma. <i>Journal of Cutaneous Pathology</i> , 2010, 37, 231-238. | 1.3 | 22 |
| 615 | Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib—resistant non—small cell lung cancer cells with acquired <i>MET</i> amplification. <i>Cancer Science</i> , 2010, 101, 167-172. | 3.9 | 58 |
| 616 | Predictive advantage of a cell type classification for pulmonary adenocarcinoma coupled with data for <i>p53</i> , <i>Kras</i> and <i>EGFR</i> alterations. <i>Cancer Science</i> , 2010, 101, 1745-1753. | 3.9 | 3 |
| 617 | Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. <i>Nature Reviews Cancer</i> , 2010, 10, 760-774. | 28.4 | 943 |
| 618 | Integrating molecular diagnostics into anticancer drug discovery. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 523-535. | 46.4 | 53 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 619 | Chromosomal imbalances in lung adenocarcinomas with or without mutations in the epidermal growth factor receptor gene. <i>Respirology</i> , 2010, 15, 700-705. | 2.3 | 8 |
| 620 | Gene Expression Analysis for Tumor Profiling. , 2010, , 225-241. | | 0 |
| 621 | Predictive molecular markers for EGFR-TKI in non-small cell lung cancer patients: new insights and critical aspects. <i>Journal of Nucleic Acids Investigation</i> , 2010, 1, 10. | 0.8 | 1 |
| 623 | Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2011, 2, 1. | 2.7 | 2 |
| 624 | Molecular Biology of Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2010, 50, 329-341. | 0.1 | 0 |
| 625 | EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. <i>Frontiers in Bioscience - Landmark</i> , 2010, 15, 65. | 3.0 | 26 |
| 626 | EGFR-mutated lung cancer: a paradigm of molecular oncology. <i>Oncotarget</i> , 2010, 1, 497-514. | 1.8 | 159 |
| 627 | Immunohistochemical Detection of <i>EGFR</i> Mutation Using Mutation-Specific Antibodies in Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 3349-3355. | 7.0 | 108 |
| 628 | Molecular Diagnosis of Activating EGFR Mutations in Non-Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis. <i>Clinical Cancer Research</i> , 2010, 16, 3163-3170. | 7.0 | 108 |
| 629 | Development of Central Nervous System Metastases in Patients with Advanced Non-Small Cell Lung Cancer and Somatic <i>EGFR</i> Mutations Treated with Gefitinib or Erlotinib. <i>Clinical Cancer Research</i> , 2010, 16, 5873-5882. | 7.0 | 209 |
| 630 | cIAP2 Upregulated by E6 Oncoprotein via Epidermal Growth Factor Receptor/Phosphatidylinositol 3-Kinase/AKT Pathway Confers Resistance to Cisplatin in Human Papillomavirus 16/18-Infected Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5200-5210. | 7.0 | 67 |
| 631 | Primary Oncocytic Adenocarcinomas of the Lung. <i>American Journal of Clinical Pathology</i> , 2010, 133, 133-140. | 0.7 | 12 |
| 632 | Reproductive Factors, Hormone Use, and Risk for Lung Cancer in Postmenopausal Women, the Nurses' Health Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2525-2533. | 2.5 | 78 |
| 633 | The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2010, 19, 186-196. | 7.1 | 35 |
| 634 | <i>EGFR</i> Mutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry. <i>American Journal of Clinical Pathology</i> , 2010, 133, 922-934. | 0.7 | 110 |
| 635 | Good Clinical Response to Gefitinib in a Non-small Cell Lung Cancer Patient Harboring a Rare Somatic Epidermal Growth Factor Gene Point Mutation; Codon 768 AGC > ATC in Exon 20 (S768I). <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 1105-1109. | 1.3 | 50 |
| 636 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients with Advanced Non-Small Cell Lung Cancer. <i>Current Gerontology and Geriatrics Research</i> , 2010, 2010, 1-8. | 1.6 | 2 |
| 637 | Power to detect selective allelic amplification in genome-wide scans of tumor data. <i>Bioinformatics</i> , 2010, 26, 518-528. | 4.1 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 638 | Gene Profiling of Clinical Routine Biopsies and Prediction of Survival in Non-Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 181-188. | 5.6 | 44 |
| 639 | A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond. Expert Review of Anticancer Therapy, 2010, 10, 955-965. | 2.4 | 14 |
| 640 | The Evolving Role of Histology in the Management of Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 5311-5320. | 1.6 | 247 |
| 641 | Nrf2 and Keap1 Abnormalities in Non-Small Cell Lung Carcinoma and Association with Clinicopathologic Features. Clinical Cancer Research, 2010, 16, 3743-3753. | 7.0 | 380 |
| 642 | MicroRNA Expression Differentiates Histology and Predicts Survival of Lung Cancer. Clinical Cancer Research, 2010, 16, 430-441. | 7.0 | 316 |
| 643 | Second-line treatments of advanced non-small-cell lung cancer: new evidence for clinical practice. Annals of Oncology, 2010, 21, 428-429. | 1.2 | 9 |
| 644 | Should we continue to use the term non-small-cell lung cancer?. Annals of Oncology, 2010, 21, vii225-vii229. | 1.2 | 35 |
| 645 | Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor-Activating Mutations. Cancer Research, 2010, 70, 8715-8725. | 0.9 | 142 |
| 646 | Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer. Experimental Lung Research, 2010, 36, 531-537. | 1.2 | 12 |
| 647 | Treatment of Brain Metastasis from Lung Cancer. Cancers, 2010, 2, 2100-2137. | 3.7 | 61 |
| 648 | Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro-Oncology, 2010, 12, 1061-1070. | 1.2 | 112 |
| 649 | Identification of a Novel Biomarker, <i>SEMA5A</i> , for Non-Small Cell Lung Carcinoma in Nonsmoking Women. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2590-2597. | 2.5 | 270 |
| 650 | Chromosomal and genomic changes in lung cancer. Cell Adhesion and Migration, 2010, 4, 100-106. | 2.7 | 39 |
| 651 | Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation. Case Reports in Oncology, 2010, 3, 98-105. | 0.7 | 11 |
| 652 | Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in <i>EGFR</i> -T790M Mutant Lung Cancer. Clinical Cancer Research, 2010, 16, 174-183. | 7.0 | 93 |
| 653 | Somatic Mutations in Epidermal Growth Factor Receptor Signaling Pathway Genes in Non-small Cell Lung Cancers. Journal of Thoracic Oncology, 2010, 5, 1734-1740. | 1.1 | 90 |
| 655 | EGFR Mutation Testing in Non-Small Cell Lung Cancer. Current Respiratory Medicine Reviews, 2010, 6, 310-321. | 0.2 | 2 |
| 656 | Past, Present and Future of Targeted Therapy in Solid Tumors. Current Cancer Drug Targets, 2010, 10, 433-461. | 1.6 | 30 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 657 | Novel Agents in the Management of Lung Cancer. <i>Current Medicinal Chemistry</i> , 2010, 17, 4291-4325. | 2.4 | 21 |
| 658 | Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies. <i>Current Cancer Drug Targets</i> , 2010, 10, 799-812. | 1.6 | 28 |
| 660 | Targeted Therapies in Lung Cancer. <i>Surgical Pathology Clinics</i> , 2010, 3, 71-82. | 1.7 | 33 |
| 661 | Tumor size matters differently in pulmonary adenocarcinoma and squamous cell carcinoma. <i>Lung Cancer</i> , 2010, 67, 296-300. | 2.0 | 10 |
| 662 | Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status. <i>Lung Cancer</i> , 2010, 68, 198-203. | 2.0 | 105 |
| 663 | Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke. <i>Lung Cancer</i> , 2010, 67, 12-16. | 2.0 | 15 |
| 664 | Are adenosquamous lung carcinomas a simple mix of adenocarcinomas and squamous cell carcinomas, or more complex at the molecular level?. <i>Lung Cancer</i> , 2010, 68, 1-9. | 2.0 | 39 |
| 665 | PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. <i>Lung Cancer</i> , 2010, 69, 279-283. | 2.0 | 161 |
| 666 | Lung cancer cell lines: Useless artifacts or invaluable tools for medical science?. <i>Lung Cancer</i> , 2010, 68, 309-318. | 2.0 | 109 |
| 667 | Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients. <i>Lung Cancer</i> , 2010, 69, 265-271. | 2.0 | 12 |
| 668 | Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers. <i>Acta Pharmacologica Sinica</i> , 2010, 31, 647-648. | 6.1 | 12 |
| 669 | High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma. <i>Onkologie</i> , 2010, 33, 231-238. | 0.8 | 39 |
| 670 | Clinical Significance of Pretreatment C-Reactive Protein in Patients with Advanced Nonsquamous, Non-Small Cell Lung Cancer Who Received Gefitinib. <i>Oncology</i> , 2010, 79, 355-362. | 1.9 | 20 |
| 671 | Small-Cell Carcinoma With an Epidermal Growth Factor Receptor Mutation in a Never-Smoker With Gefitinib-Responsive Adenocarcinoma of the Lung. <i>Clinical Lung Cancer</i> , 2010, 11, E1-E4. | 2.6 | 53 |
| 673 | A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. <i>Human Pathology</i> , 2010, 41, 94-102. | 2.0 | 81 |
| 674 | The close correlation between 8-hydroxy-2'-deoxyguanosine and epidermal growth factor receptor activating mutation in non-small cell lung cancer. <i>Human Pathology</i> , 2010, 41, 951-959. | 2.0 | 11 |
| 675 | The biology and treatment of EML4-ALK non-small cell lung cancer. <i>European Journal of Cancer</i> , 2010, 46, 1773-1780. | 2.8 | 516 |
| 676 | Absence of hotspot mutations in exons 9 and 20 of the PIK3CA gene in human oral squamous cell carcinoma in the Greek population. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2010, 109, e53-e58. | 1.4 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 677 | Clinical Applications of Kinase Inhibitors in Solid Tumors. , 2010, , 615-631. | | 1 |
| 678 | Co-Activation of Epidermal Growth Factor Receptor and c-MET Defines a Distinct Subset of Lung Adenocarcinomas. American Journal of Pathology, 2010, 177, 2191-2204. | 3.8 | 42 |
| 679 | Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer, 2010, 69, 110-115. | 2.0 | 83 |
| 680 | Impact of Environmental Tobacco Smoke on the Incidence of Mutations in Epidermal Growth Factor Receptor Gene in Never-Smoker Patients With Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 487-492. | 1.6 | 74 |
| 681 | 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: A single-institution retrospective analysis. Lung Cancer, 2010, 67, 76-80. | 2.0 | 66 |
| 682 | Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncology, The, 2010, 11, 75-84. | 10.7 | 121 |
| 683 | Lung cancer in never smokers: a new hot area of research. Lancet Oncology, The, 2010, 11, 304-305. | 10.7 | 21 |
| 684 | Comparison of Antioxidant Activities in Black Soybean Preparations Fermented with Various Microorganisms. Agricultural Sciences in China, 2010, 9, 1065-1071. | 0.6 | 23 |
| 685 | Mutation Detection of Epidermal Growth Factor Receptor and KRAS Genes Using the Smart Amplification Process Version 2 from Formalin-Fixed, Paraffin-Embedded Lung Cancer Tissue. Journal of Molecular Diagnostics, 2010, 12, 257-264. | 2.8 | 38 |
| 686 | The Gender-Specific Aspects of Lung Cancer. , 2010, , 260-269. | | 0 |
| 687 | Genomics in the Diagnosis and Management of Lung Cancer. , 2010, , 432-445. | | 0 |
| 688 | American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. Journal of Clinical Oncology, 2011, 29, 2121-2127. | 1.6 | 476 |
| 689 | A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non-Small-Cell Lung Cancer. Journal of Molecular Diagnostics, 2011, 13, 74-84. | 2.8 | 160 |
| 690 | EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target. British Journal of Cancer, 2011, 105, 420-427. | 6.4 | 62 |
| 691 | Evaluation and Treatment of Patients with Non-Small Cell Lung Cancer. Medical Clinics of North America, 2011, 95, 1041-1054. | 2.5 | 24 |
| 692 | A Decade of Advances in Treatment for Advanced Non-Small Cell Lung Cancer. Clinics in Chest Medicine, 2011, 32, 839-851. | 2.1 | 58 |
| 693 | Molecular Biology of Lung Cancer: Clinical Implications. Clinics in Chest Medicine, 2011, 32, 703-740. | 2.1 | 194 |
| 694 | Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. European Respiratory Journal, 2011, 37, 624-631. | 6.7 | 304 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 695 | Lung cancer in never smokers: Change of a mindset in the molecular era. <i>Lung Cancer</i> , 2011, 72, 9-15. | 2.0 | 78 |
| 697 | Detection of the EGFR mutation in exhaled breath condensate from a heavy smoker with squamous cell carcinoma of the lung. <i>Lung Cancer</i> , 2011, 73, 379-380. | 2.0 | 21 |
| 698 | Late breast metastasis from resected lung cancer diagnosed by epidermal growth factor receptor gene mutation. <i>Lung Cancer</i> , 2011, 74, 352-353. | 2.0 | 10 |
| 699 | Personalized medicine in lung cancer: what we need to know. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 661-668. | 27.6 | 145 |
| 700 | INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. <i>BMC Cancer</i> , 2011, 11, 430. | 2.6 | 74 |
| 701 | Lung Cancer: Epidemiology, Etiology, and Prevention. <i>Clinics in Chest Medicine</i> , 2011, 32, 605-644. | 2.1 | 1,444 |
| 702 | The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. <i>Future Oncology</i> , 2011, 7, 519-541. | 2.4 | 47 |
| 703 | Standardization of Epidermal Growth Factor Receptor (EGFR) Measurement by Quantitative Immunofluorescence and Impact on Antibody-Based Mutation Detection in Non-Small Cell Lung Cancer. <i>American Journal of Pathology</i> , 2011, 179, 580-589. | 3.8 | 21 |
| 704 | Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?. <i>Cancer Treatment Reviews</i> , 2011, 37, 533-542. | 7.7 | 31 |
| 705 | Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2011, 38, 903-910. | 6.7 | 28 |
| 706 | 2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment – First-line therapy. <i>European Journal of Cancer</i> , 2011, 47, S248-S257. | 2.8 | 5 |
| 707 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2011, 12, 735-742. | 10.7 | 3,758 |
| 708 | Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. <i>Lancet Oncology</i> , The, 2011, 12, 795-805. | 10.7 | 199 |
| 709 | Imaging of Lung Cancer in the Era of Molecular Medicine. <i>Academic Radiology</i> , 2011, 18, 424-436. | 2.5 | 37 |
| 710 | Nonfilter and filter cigarette consumption and the incidence of lung cancer by histological type in Japan and the United States: Analysis of 30-year data from population-based cancer registries. <i>International Journal of Cancer</i> , 2011, 128, 1918-1928. | 5.1 | 59 |
| 711 | Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer. <i>Cancer Discovery</i> , 2011, 1, 78-89. | 9.4 | 455 |
| 712 | Epidermal growth factor receptor mutation-guided treatment for lung cancers: Where are we now?. <i>Thoracic Cancer</i> , 2011, 2, 1-6. | 1.9 | 5 |
| 713 | Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles. <i>Breast Cancer Research</i> , 2011, 13, R133. | 5.0 | 37 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 714 | Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFRâ€“TKI for adenocarcinoma of the lung. Lung Cancer, 2011, 71, 350-355. | 2.0 | 39 |
| 715 | The different clinical significance of EGFR mutations in exon 19 and 21 in non-small cell lung cancer patients of China. Neoplasma, 2011, 58, 74-81. | 1.6 | 31 |
| 716 | Detection of EGFR and K-ras mutations for diagnosis of multiple lung adenocarcinomas. Frontiers in Bioscience - Landmark, 2011, 16, 2961. | 3.0 | 2 |
| 717 | Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy. Frontiers in Bioscience - Landmark, 2011, 16, 1714. | 3.0 | 8 |
| 718 | Utilization of Unlabeled Probes for the Detection of Fibroblast Growth Factor Receptor 2 Exons 7 and 12 Mutations in Endometrial Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2011, 19, 341-346. | 1.2 | 4 |
| 719 | Gefitinib Therapy in Patients With Advanced Non-Small Cell Lung Cancer With or Without Testing for Epidermal Growth Factor Receptor (EGFR) Mutations. Medicine (United States), 2011, 90, 159-167. | 1.0 | 30 |
| 720 | C-KIT and PDGFRA Zygosity in Gastrointestinal Stromal Tumors. Applied Immunohistochemistry and Molecular Morphology, 2011, 19, 21-27. | 1.2 | 6 |
| 721 | Tyrosine Kinase Inhibitors and Epidermal Growth Factor Receptor (EGFR) Mutations in Non-Small Cell Lung Cancer. Medicine (United States), 2011, 90, 168-170. | 1.0 | 6 |
| 722 | Novel Therapeutic Targets in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1601-1612. | 1.1 | 127 |
| 723 | Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. Oncology Reports, 2011, 25, 921-8. | 2.6 | 73 |
| 724 | Association of Keap1 and Nrf2 Genetic Mutations and Polymorphisms With Endometrioid Endometrial Adenocarcinoma Survival. International Journal of Gynecological Cancer, 2011, 21, 1428-1435. | 2.5 | 33 |
| 725 | Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes. Current Opinion in Oncology, 2011, 23, 88-92. | 2.4 | 41 |
| 726 | Whatâ€™s new in non-small cell lung cancer for pathologists the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology, 2011, 43, 103-115. | 0.6 | 54 |
| 727 | Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America. Journal of Thoracic Oncology, 2011, 6, 1955-1959. | 1.1 | 113 |
| 728 | Different Efficacies of Erlotinib and Gefitinib in Taiwanese Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Multicenter Study. Journal of Thoracic Oncology, 2011, 6, 148-155. | 1.1 | 26 |
| 729 | Frequency and Type of Epidermal Growth Factor Receptor Mutations in African Americans with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 627-630. | 1.1 | 70 |
| 731 | Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Experimental and Therapeutic Medicine, 2011, 2, 685-693. | 1.8 | 33 |
| 732 | A Phase II Randomized Trial of Gefitinib Alone or with Tegafur/Uracil Treatment in Patients with Pulmonary Adenocarcinoma Who had Failed Previous Chemotherapy. Journal of Thoracic Oncology, 2011, 6, 1110-1116. | 1.1 | 28 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 733 | Comprehensive Analysis of Epidermal Growth Factor Receptor Gene Status in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2011, 6, 1016-1021. | 1.1 | 18 |
| 734 | Evaluation of Kras Gene Mutation and Copy Number Gain in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 15-20. | 1.1 | 48 |
| 735 | NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, S-1-S-32. | 4.9 | 227 |
| 736 | Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma. Ecological Management and Restoration, 2011, 24, 374-380. | 0.4 | 24 |
| 737 | Unique <i>p53</i> and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma-like carcinomas. Cancer Science, 2011, 102, 282-287. | 3.9 | 63 |
| 738 | Pulmonary adenocarcinoma with a micropapillary pattern: a clinicopathological, immunophenotypic and molecular analysis. Histopathology, 2011, 59, 1204-1214. | 2.9 | 40 |
| 739 | Detection of low-level EGFR T790M mutation in lung cancer tissues. Apmis, 2011, 119, 403-411. | 2.0 | 27 |
| 740 | Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry. Oncogene, 2011, 30, 1744-1752. | 5.9 | 35 |
| 741 | Clinicopathologic Factors Affecting the Progression-Free Survival of Patients With Advanced Non-Small-Cell Lung Cancer After Gefitinib Therapy. Clinical Lung Cancer, 2011, 12, 56-61. | 2.6 | 7 |
| 742 | Monoclonal antibodies against EGFR in non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2011, 80, 1-9. | 4.4 | 42 |
| 743 | Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells. Biochemical Pharmacology, 2011, 81, 1263-1270. | 4.4 | 51 |
| 744 | EGFR Mutations and Lung Cancer. Annual Review of Pathology: Mechanisms of Disease, 2011, 6, 49-69. | 22.4 | 644 |
| 745 | Gender aspects in haematology and oncology: Overview and own observations in lung cancer. Memo - Magazine of European Medical Oncology, 2011, 4, 209-216. | 0.5 | 0 |
| 746 | A histology-based algorithm in the molecular diagnosis of mutations of the epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC)*. Memo - Magazine of European Medical Oncology, 2011, 4, 248-253. | 0.5 | 1 |
| 747 | Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer. European Respiratory Journal, 2011, 37, 183-193. | 6.7 | 37 |
| 748 | Comparison of p53 and Epidermal Growth Factor Receptor Gene Status Between Primary Tumors and Lymph Node Metastases in Non-Small Cell Lung Cancers. Annals of Surgical Oncology, 2011, 18, 543-550. | 1.5 | 48 |
| 749 | EGFR and p53 Status of Pulmonary Pleomorphic Carcinoma: Implications for EGFR Tyrosine Kinase Inhibitors Therapy of an Aggressive Lung Malignancy. Annals of Surgical Oncology, 2011, 18, 2952-2960. | 1.5 | 51 |
| 750 | Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Modern Pathology, 2011, 24, 1348-1359. | 5.5 | 299 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 752 | EGFR/erbB-1, HER2/erbB-2, CK7, LP34, Ki67 and P53 expression in preneoplastic lesions of bronchial epithelium: an immunohistochemical and genetic study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 458, 571-581. | 2.8 | 10 |
| 753 | The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 687-694. | 2.5 | 34 |
| 754 | Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 331-338. | 2.3 | 16 |
| 755 | The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib. <i>Medical Oncology</i> , 2011, 28, 697-702. | 2.5 | 42 |
| 756 | Molecular oncology of lung cancer. <i>General Thoracic and Cardiovascular Surgery</i> , 2011, 59, 527-537. | 0.9 | 60 |
| 757 | The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain. <i>BMC Medical Genetics</i> , 2011, 12, 144. | 2.1 | 41 |
| 758 | Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. <i>BMC Cancer</i> , 2011, 11, 406. | 2.6 | 83 |
| 759 | Methylation of the candidate biomarker <i>TCF21</i> is very frequent across a spectrum of early-stage nonsmall cell lung cancers. <i>Cancer</i> , 2011, 117, 606-617. | 4.1 | 59 |
| 760 | Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma. <i>Cancer</i> , 2011, 117, 819-825. | 4.1 | 61 |
| 761 | Activation of the Signal Transducer and Activator of Transcription 3 Pathway Up-Regulates Estrogen Receptor- β Expression in Lung Adenocarcinoma Cells. <i>Molecular Endocrinology</i> , 2011, 25, 1145-1158. | 3.7 | 16 |
| 762 | Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer. <i>Current Drug Targets</i> , 2011, 12, 922-933. | 2.1 | 25 |
| 763 | Targeted Therapies for Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 512-527. | 2.0 | 91 |
| 764 | <i>EGFR</i> L858R Mutation and Polymorphisms of Genes Related to Estrogen Biosynthesis and Metabolism in Never-Smoking Female Lung Adenocarcinoma Patients. <i>Clinical Cancer Research</i> , 2011, 17, 2149-2158. | 7.0 | 28 |
| 765 | Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Harboring <i>BRAF</i> Mutations. <i>Journal of Clinical Oncology</i> , 2011, 29, 3574-3579. | 1.6 | 500 |
| 766 | Genotype-driven therapies for non-small cell lung cancer: focus on <i>EGFR</i> , <i>KRAS</i> and <i>ALK</i> gene abnormalities. <i>Therapeutic Advances in Medical Oncology</i> , 2011, 3, 113-125. | 3.2 | 96 |
| 767 | Long Exposure of Environmental Tobacco Smoke Associated with Activating EGFR Mutations in Never-Smokers with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 39-45. | 7.0 | 27 |
| 768 | Tumor Epidermal Growth Factor Receptor Genotype and Depression in Stage IV Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2011, 16, 1299-1306. | 3.7 | 12 |
| 769 | Soy intake is associated with lower lung cancer risk: results from a meta-analysis of epidemiologic studies. <i>American Journal of Clinical Nutrition</i> , 2011, 94, 1575-1583. | 4.7 | 71 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 770 | Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17761-17766. | 7.1 | 405 |
| 771 | Emerging Concepts in the Pathology and Molecular Biology of Advanced Nonâ€“Small Cell Lung Cancer. American Journal of Clinical Pathology, 2011, 136, 228-238. | 0.7 | 43 |
| 772 | Association of Epidermal Growth Factor Receptor Mutations with Metastatic Presentations in Non-Small Cell Lung Cancer. ISRN Oncology, 2011, 2011, 1-6. | 2.1 | 10 |
| 773 | Clustered Genomic Alterations in Chromosome 7p Dictate Outcomes and Targeted Treatment Responses of Lung Adenocarcinoma With <i>EGFR</i> -Activating Mutations. Journal of Clinical Oncology, 2011, 29, 3435-3442. | 1.6 | 33 |
| 774 | Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors. Clinical Cancer Research, 2011, 17, 1131-1139. | 7.0 | 172 |
| 775 | Part 4: Pharmacogenetic Variability in Anticancer Pharmacodynamic Drug Effects. Oncologist, 2011, 16, 1006-1020. | 3.7 | 13 |
| 776 | Genetic and epigenetic changes in lung carcinoma and their clinical implications. Modern Pathology, 2011, 24, 932-943. | 5.5 | 64 |
| 777 | International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. Journal of Thoracic Oncology, 2011, 6, 244-285. | 1.1 | 4,127 |
| 778 | Polymorphisms in inflammatory pathway genes, host factors and lung cancer risk in Chinese female never-smokers. Carcinogenesis, 2011, 32, 522-529. | 2.8 | 66 |
| 779 | Adenosquamous Carcinoma of the Lung. American Journal of Clinical Pathology, 2011, 135, 783-789. | 0.7 | 82 |
| 780 | Functional <i>EGFR</i> Germline Polymorphisms May Confer Risk for <i>EGFR</i> Somatic Mutations in Nonâ€“Small Cell Lung Cancer, with a Predominant Effect on Exon 19 Microdeletions. Cancer Research, 2011, 71, 2423-2427. | 0.9 | 44 |
| 781 | Epidermal Growth Factor Receptor Mutation Status in Stage I Lung Adenocarcinoma with Different Image Patterns. Journal of Thoracic Oncology, 2011, 6, 1066-1072. | 1.1 | 45 |
| 782 | Role and Relevance of TrkB Mutations and Expression in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2011, 17, 2638-2645. | 7.0 | 54 |
| 783 | Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations. Journal of Thoracic Oncology, 2011, 6, 1895-1901. | 1.1 | 117 |
| 784 | Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Nonâ€“Small-Cell Lung Cancer Receiving Sorafenib. Clinical Cancer Research, 2011, 17, 1190-1199. | 7.0 | 67 |
| 785 | Notch signaling in lung cancer. Expert Review of Anticancer Therapy, 2011, 11, 533-540. | 2.4 | 40 |
| 786 | Effectiveness of Tyrosine Kinase Inhibitors on â€œUncommonâ€“Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2011, 17, 3812-3821. | 7.0 | 413 |
| 787 | Molecular Epidemiology of Female Lung Cancer. Cancers, 2011, 3, 1861-1876. | 3.7 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 788 | Biased Discordance of KRAS Mutation Detection in Archived Colorectal Cancer Specimens Between the ARMS-Scorpion Method and Direct Sequencing. Japanese Journal of Clinical Oncology, 2011, 41, 239-244. | 1.3 | 20 |
| 789 | The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer. Cancers, 2011, 3, 2667-2678. | 3.7 | 7 |
| 790 | The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung Cancer. Oncologist, 2011, 16, 1498-1507. | 3.7 | 44 |
| 791 | Epidermal Growth Factor Receptor in Pancreatic Cancer. Cancers, 2011, 3, 1513-1526. | 3.7 | 114 |
| 792 | Epidermal growth factor receptor mutations in female patients with postoperative recurrent non-small-cell lung cancer. Journal of Cancer Research and Therapeutics, 2012, 8, 373. | 0.9 | 6 |
| 793 | LKB1, TP16, EGFR, and KRAS somatic mutations in lung adenocarcinomas from a Chiba Prefecture, Japan cohort. Drug Discoveries and Therapeutics, 2012, , . | 1.5 | 5 |
| 794 | Ancillary Testing in Lung Cancer Diagnosis. Pulmonary Medicine, 2012, 2012, 1-8. | 1.9 | 14 |
| 795 | Personalized Targeted Therapy for Lung Cancer. International Journal of Molecular Sciences, 2012, 13, 11471-11496. | 4.1 | 61 |
| 796 | Lung cancer in women. Lung Cancer: Targets and Therapy, 2012, 3, 79. | 2.7 | 41 |
| 797 | Sex and SUVmax: Sex-Dependent Prognostication in Early Nonâ€“Small Cell Lung Cancer. Journal of Nuclear Medicine, 2012, 53, 1676-1685. | 5.0 | 10 |
| 798 | Targeted Therapy for Brain Metastases. Advances in Pharmacology, 2012, 65, 109-142. | 2.0 | 11 |
| 799 | Association between a Genome-Wide Association Study-Identified Locus and the Risk of Lung Cancer in Japanese Population. Journal of Thoracic Oncology, 2012, 7, 790-798. | 1.1 | 37 |
| 800 | Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1315-1326. | 1.1 | 175 |
| 801 | Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Annals of Oncology, 2012, 23, 2931-2936. | 1.2 | 35 |
| 802 | Prognostic value of <i>TP53</i>, <i>KRAS</i> and <i>EGFR</i> mutations in nonsmall cell lung cancer: the EUELC cohort. European Respiratory Journal, 2012, 40, 177-184. | 6.7 | 92 |
| 803 | Cost Effectiveness of Personalized Therapy for First-Line Treatment of Stage IV and Recurrent Incurable Adenocarcinoma of the Lung. Journal of Oncology Practice, 2012, 8, 267-274. | 2.5 | 75 |
| 804 | The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC: Figure 1. Journal of Clinical Pathology, 2012, 65, 1-7. | 2.0 | 34 |
| 805 | ROS1 Rearrangements in Lung Cancer: A New Genomic Subset of Lung Adenocarcinoma. Journal of Clinical Oncology, 2012, 30, 878-879. | 1.6 | 42 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 806 | Molecular Epidemiology of <i>EGFR</i> and <i>KRAS</i> Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related <i>KRAS</i> -Mutant Cancers. <i>Clinical Cancer Research</i> , 2012, 18, 6169-6177. | 7.0 | 503 |
| 807 | Cancer Genes in Lung Cancer: Racial Disparities: Are There Any?. <i>Genes and Cancer</i> , 2012, 3, 467-480. | 1.9 | 116 |
| 809 | Role of EGFR Inhibitors in the Treatment of Central Nervous System Metastases from Non-Small Cell Lung Cancer. <i>Current Cancer Drug Targets</i> , 2012, 12, 237-246. | 1.6 | 12 |
| 810 | Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy. <i>Future Oncology</i> , 2012, 8, 451-462. | 2.4 | 48 |
| 811 | Targeting the PI3K pathway for cancer therapy. <i>Future Medicinal Chemistry</i> , 2012, 4, 1153-1169. | 2.3 | 53 |
| 812 | Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence. <i>Clinical Investigation</i> , 2012, 2, 317-325. | 0.0 | 5 |
| 813 | HER2 As Therapeutic Target for Overcoming ATP-Binding Cassette Transporter-Mediated Chemoresistance in Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 830-841. | 4.1 | 26 |
| 814 | Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. <i>OncoTargets and Therapy</i> , 2012, 5, 439. | 2.0 | 35 |
| 815 | The Role of KRAS Mutational Analysis to Determine the Site of Origin of Metastatic Carcinoma to the Lung: A Case Report. <i>Case Reports in Pathology</i> , 2012, 2012, 1-4. | 0.3 | 1 |
| 816 | Genetic and Biochemical Alterations in Non-Small Cell Lung Cancer. <i>Biochemistry Research International</i> , 2012, 2012, 1-18. | 3.3 | 42 |
| 817 | Noninferiority Trials in Second-Line Treatments of Nonsmall Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 593-599. | 1.3 | 4 |
| 818 | Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis. <i>Oncology Reports</i> , 2012, 28, 1815-1821. | 2.6 | 40 |
| 819 | Development of a rapid and practical mutation screening assay for human lung adenocarcinoma. <i>International Journal of Oncology</i> , 2012, 40, 1900-6. | 3.3 | 1 |
| 820 | Personalized medicine for lung cancer. <i>Lung Cancer Management</i> , 2012, 1, 83-86. | 1.5 | 2 |
| 822 | Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer. <i>Cancer Biomarkers</i> , 2012, 10, 63-69. | 1.7 | 41 |
| 823 | Demographic profile of lung cancer patients at the Universitas Academic Hospital Bronchoscopy Unit in Bloemfontein. <i>The Southern African Journal of Epidemiology & Infection: Official Journal of the Sexually Transmitted Diseases, Infectious Diseases and Epidemiological Societies of Southern Africa</i> , 2012, 27, 130-132. | 0.2 | 0 |
| 824 | Systemic Therapies for Pancreatic Cancer - The Role of Pharmacogenetics. <i>Current Drug Targets</i> , 2012, 13, 811-828. | 2.1 | 15 |
| 825 | High Incidence of EGFR Mutations in Korean Men Smokers with No Intratumoral Heterogeneity of Lung Adenocarcinomas: Correlation with Histologic Subtypes, EGFR/TTF-1 Expressions, and Clinical Features. <i>Journal of Thoracic Oncology</i> , 2012, 7, 323-330. | 1.1 | 143 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 826 | A 66-Year-Old Woman With Newly Diagnosed Oligometastatic Nonâ€“Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 297-301. | 4.9 | 1 |
| 827 | Prognostic Models to Predict Survival in Nonâ€“Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab. Journal of Thoracic Oncology, 2012, 7, 1361-1368. | 1.1 | 57 |
| 828 | Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy. International Journal of Oncology, 2012, 40, 1763-9. | 3.3 | 9 |
| 829 | Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations. Experimental and Therapeutic Medicine, 2012, 3, 207-213. | 1.8 | 19 |
| 830 | High Expression of Folate Receptor Alpha in Lung Cancer Correlates with Adenocarcinoma Histology and Mutation. Journal of Thoracic Oncology, 2012, 7, 833-840. | 1.1 | 123 |
| 831 | Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment. Oncology Letters, 2012, 3, 1288-1292. | 1.8 | 18 |
| 832 | Expression and mutation of the c-kit gene and correlation with prognosis of small cell lung cancer. Oncology Letters, 2012, 4, 89-93. | 1.8 | 33 |
| 833 | First- and second-line treatment of non-small-cell lung cancer patients with EGFR mutation-positive tumors. Lung Cancer Management, 2012, 1, 201-217. | 1.5 | 0 |
| 834 | Gene fusions in non-small-cell lung cancer. Lung Cancer Management, 2012, 1, 283-292. | 1.5 | 1 |
| 835 | Association between Tumor Epidermal Growth Factor Receptor Mutation and Pulmonary Tuberculosis in Patients with Adenocarcinoma of the Lungs. Journal of Thoracic Oncology, 2012, 7, 299-305. | 1.1 | 52 |
| 836 | Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma. Journal of Thoracic Oncology, 2012, 7, 993-1000. | 1.1 | 32 |
| 837 | Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Nonâ€“Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Projectâ€“Part 2). Journal of Thoracic Oncology, 2012, 7, 1490-1502. | 1.1 | 69 |
| 838 | Gefitinib for a Poor Performance Status Patient with Squamous Cell Carcinoma of the Lung Harboring EGFR Mutation. Internal Medicine, 2012, 51, 659-661. | 0.7 | 9 |
| 839 | Morphologic and Molecular Analysis of 39 Spontaneous Feline Pulmonary Carcinomas. Veterinary Pathology, 2012, 49, 971-978. | 1.7 | 44 |
| 840 | Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy. Lung Cancer, 2012, 78, 201-206. | 2.0 | 32 |
| 841 | Impact of age on epidermal growth factor receptor mutation in lung cancer. Lung Cancer, 2012, 78, 207-211. | 2.0 | 35 |
| 842 | RUNX3 Downregulation in Human Lung Adenocarcinoma is Independent of p53, EGFR or KRAS Status. Pathology and Oncology Research, 2012, 18, 783-792. | 1.9 | 12 |
| 843 | Advances in Treatment of Lung Cancer With Targeted Therapy. Archives of Pathology and Laboratory Medicine, 2012, 136, 504-509. | 2.5 | 75 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 844 | Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. <i>Lung Cancer</i> , 2012, 77, 319-325. | 2.0 | 102 |
| 845 | Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma. <i>British Journal of Cancer</i> , 2012, 107, 1745-1753. | 6.4 | 23 |
| 846 | Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis. <i>Clinical Cancer Research</i> , 2012, 18, 1947-1953. | 7.0 | 161 |
| 847 | Utility of small biopsies for diagnosis of lung nodules: doing more with less. <i>Modern Pathology</i> , 2012, 25, S43-S57. | 5.5 | 29 |
| 848 | Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2012, 30, 2352-2363. | 2.6 | 62 |
| 849 | EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. <i>Lancet Oncology</i> , The, 2012, 13, e23-e31. | 10.7 | 505 |
| 850 | Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2012, 13, 300-308. | 10.7 | 360 |
| 851 | Direct Comparison of 3 PCR Methods in Detecting EGFR Mutations in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2012, 13, 369-374. | 2.6 | 10 |
| 852 | EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma. <i>Cancer Cell</i> , 2012, 22, 318-330. | 16.8 | 339 |
| 853 | Molecular Pathology of Non-Small Cell Lung Cancer. <i>Surgical Pathology Clinics</i> , 2012, 5, 903-918. | 1.7 | 3 |
| 854 | Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. <i>Revista Da Associação Médica Brasileira</i> , 2012, 58, 263-268. | 0.7 | 6 |
| 855 | Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. <i>Revista Da Associação Médica Brasileira (English Edition)</i> , 2012, 58, 263-268. | 0.1 | 0 |
| 856 | Impact of KRAS and EGFR Gene Mutations on Recurrence and Survival in Patients with Surgically Resected Lung Adenocarcinomas. <i>Annals of Surgical Oncology</i> , 2012, 19, 347-354. | 1.5 | 49 |
| 857 | Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non-Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion. <i>Clinical Cancer Research</i> , 2012, 18, 4449-4457. | 7.0 | 266 |
| 858 | Diagnostic Criteria for Invasive Pulmonary Aspergillosis in Critically Ill Patients. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 8-10. | 5.6 | 21 |
| 859 | Hotspot oncomutations: implications for personalized cancer treatment. <i>Expert Review of Molecular Diagnostics</i> , 2012, 12, 603-620. | 3.1 | 13 |
| 860 | EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 1790-1797. | 7.0 | 134 |
| 861 | Elevated Expression of Fn14 in Non-Small Cell Lung Cancer Correlates with Activated EGFR and Promotes Tumor Cell Migration and Invasion. <i>American Journal of Pathology</i> , 2012, 181, 111-120. | 3.8 | 52 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 862 | Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). <i>Cancer Treatment Reviews</i> , 2012, 38, 173-184. | 7.7 | 31 |
| 863 | EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects. <i>Cancer Treatment Reviews</i> , 2012, 38, 416-430. | 7.7 | 114 |
| 864 | Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib. <i>World Journal of Surgical Oncology</i> , 2012, 10, 235. | 1.9 | 16 |
| 865 | Molecular modeling and description of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer. <i>Diagnostic Pathology</i> , 2012, 7, 146. | 2.0 | 16 |
| 866 | Molecular Pathology of Non-Small Cell Lung Cancer. <i>American Journal of Clinical Pathology</i> , 2012, 138, 332-346. | 0.7 | 115 |
| 867 | Lung Cancer: New Therapeutic Targets, New Definitions. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 7-8. | 5.6 | 3 |
| 868 | Targeting the EGFR signaling pathway in cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 15-31. | 3.4 | 688 |
| 869 | Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases. <i>Pathology International</i> , 2012, 62, 785-791. | 1.3 | 81 |
| 870 | Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 771-781. | 3.4 | 28 |
| 871 | Genomic biomarkers for patient selection and stratification: the cancer paradigm. <i>Bioanalysis</i> , 2012, 4, 2499-2511. | 1.5 | 8 |
| 872 | Loss of TIMP-3 Promotes Tumor Invasion via Elevated IL-6 Production and Predicts Poor Survival and Relapse in HPV-Infected Non-Small Cell Lung Cancer. <i>American Journal of Pathology</i> , 2012, 181, 1796-1806. | 3.8 | 49 |
| 873 | Ethnic variation in response to EGFR inhibitors. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2012, 9, e61-e66. | 0.5 | 1 |
| 874 | Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras. <i>Lung Cancer</i> , 2012, 75, 313-320. | 2.0 | 73 |
| 875 | The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. <i>Lung Cancer</i> , 2012, 76, 1-18. | 2.0 | 206 |
| 876 | Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer. <i>Lung Cancer</i> , 2012, 76, 235-241. | 2.0 | 29 |
| 877 | Aspirin and non-aspirin non-steroidal anti-inflammatory drug use and risk of lung cancer. <i>Lung Cancer</i> , 2012, 77, 246-251. | 2.0 | 31 |
| 878 | Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase III, randomized SATURN study. <i>Lung Cancer</i> , 2012, 77, 339-345. | 2.0 | 34 |
| 879 | EGFR and myosin II inhibitors cooperate to suppress EGFR ^{T790M} mutant NSCLC cells. <i>Molecular Oncology</i> , 2012, 6, 299-310. | 4.6 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 880 | Predictive markers in early research and companion diagnostic developments in oncology. New Biotechnology, 2012, 29, 651-655. | 4.4 | 11 |
| 881 | Do companion diagnostics make economic sense for drug developers?. New Biotechnology, 2012, 29, 695-708. | 4.4 | 11 |
| 882 | Biomarkers That Currently Affect Clinical Practice: EGFR, ALK, MET, KRAS. Current Oncology, 2012, 19, 33-44. | 2.2 | 46 |
| 883 | Targeted therapies: how personal should we go?. Nature Reviews Clinical Oncology, 2012, 9, 87-97. | 27.6 | 94 |
| 884 | Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib. Medical Oncology, 2012, 29, 1614-1621. | 2.5 | 18 |
| 885 | Molecular Diagnosis of Lung Cancer. Molecular Pathology Library, 2012, , 87-97. | 0.1 | 0 |
| 886 | Clinical Outcomes with Erlotinib in Patients with Epidermal Growth Factor Receptor Mutation. Drugs, 2012, 72, 3-10. | 10.9 | 6 |
| 887 | The Peptide Nucleic Acid-Locked Nucleic Acid Polymerase Chain Reaction Clamp-Based Test for Epidermal Growth Factor Receptor Mutations in Bronchoscopic Cytological Specimens of Non-Small Cell Lung Cancer. Oncology, 2012, 82, 341-346. | 1.9 | 11 |
| 889 | Cancer Epigenetics. Methods in Molecular Biology, 2012, , . | 0.9 | 5 |
| 890 | Molecular Pathology of Lung Cancer. Molecular Pathology Library, 2012, , . | 0.1 | 6 |
| 891 | Molecular Basis for the Current Lung Cancer Classification. Molecular Pathology Library, 2012, , 75-85. | 0.1 | 0 |
| 892 | Molecular Pathogenesis of Non-Small Cell Lung Carcinomas. Journal of Lung Cancer, 2012, 11, 12. | 0.2 | 4 |
| 893 | Non-small cell lung cancer: the era of targeted therapy. Lung Cancer: Targets and Therapy, 2012, 3, 31. | 2.7 | 8 |
| 894 | Epidermal Growth Factor Receptor Mutation in Small Cell Lung Cancer Patients Detected by Mutant-Enriched Liquidchip Technology from Plasma. Annals of Oncology, 2012, 23, ix495. | 1.2 | 0 |
| 895 | The Role of Mutation Status of the Epidermal Growth Factor Receptor Gene In Advanced Non-Small Cell Lung Cancer. Medicina (Lithuania), 2012, 48, 25. | 2.0 | 2 |
| 896 | Skin Rash as Useful Marker of Erlotinib Efficacy in NSCLC and Its Impact on Clinical Practice. Neoplasma, 2012, 60, 26-32. | 1.6 | 20 |
| 897 | EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI. Yonsei Medical Journal, 2012, 53, 1128. | 2.2 | 23 |
| 898 | Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer. Wspolczesna Onkologia, 2012, 5, 401-406. | 1.4 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 899 | Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population. <i>Clinics</i> , 2012, 67, 845-847. | 1.5 | 17 |
| 900 | Screening of Epidermal Growth Factor Receptor Gene Mutation in Non-Small Cell Lung Cancer Using a PCR-Based Enzymatic Digestion Method. <i>Journal of Lung Cancer</i> , 2012, 11, 77. | 0.2 | 0 |
| 901 | Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib. <i>Yonsei Medical Journal</i> , 2012, 53, 931. | 2.2 | 17 |
| 902 | Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer Patients Who Received Surgical Resection in China. <i>Neoplasma</i> , 2012, 59, 100-104. | 1.6 | 25 |
| 903 | Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2063-2069. | 1.6 | 225 |
| 904 | Molecular pathology of lung cancer: key to personalized medicine. <i>Modern Pathology</i> , 2012, 25, 347-369. | 5.5 | 215 |
| 905 | p40 (p63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. <i>Modern Pathology</i> , 2012, 25, 405-415. | 5.5 | 343 |
| 906 | Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor <i>BRAF</i> gene mutations but lack mutations in <i>KRAS</i> , <i>NRAS</i> , or <i>MEK1</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E2127-33. | 7.1 | 410 |
| 907 | Epidermal growth factor receptor tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. <i>International Journal of Cancer</i> , 2012, 131, E822-9. | 5.1 | 119 |
| 908 | EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. <i>Cellular Oncology (Dordrecht)</i> , 2012, 35, 189-196. | 4.4 | 104 |
| 909 | The Biology and Clinical Features of Non-small Cell Lung Cancers with EML4-ALK Translocation. <i>Current Oncology Reports</i> , 2012, 14, 105-110. | 4.0 | 35 |
| 910 | Pulmonary adenocarcinoma: A renewed entity in 2011. <i>Respirology</i> , 2012, 17, 50-65. | 2.3 | 65 |
| 911 | Smoking History as a Predictive Factor of Treatment Response in Advanced Non-Small-Cell Lung Cancer: A Systematic Review. <i>Clinical Lung Cancer</i> , 2012, 13, 239-251. | 2.6 | 27 |
| 912 | The Value of Biomarkers in Patients With Sarcomatoid Carcinoma of the Lung: Molecular Analysis of 33 Cases. <i>Clinical Lung Cancer</i> , 2012, 13, 288-296. | 2.6 | 45 |
| 913 | Routine EGFR and KRAS Mutation analysis using COLD-PCR in non-small cell lung cancer. <i>International Journal of Clinical Practice</i> , 2012, 66, 748-752. | 1.7 | 19 |
| 914 | Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012, 8, 267-274. | 1.1 | 3 |
| 915 | The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: a single South East Asian laboratory's analysis of 670 cases. <i>Cytopathology</i> , 2012, 23, 229-236. | 0.7 | 48 |
| 916 | RET finger protein expression is associated with prognosis in lung cancer with epidermal growth factor receptor mutations. <i>Pathology International</i> , 2012, 62, 324-330. | 1.3 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 917 | Biomarkers and transcriptome profiling of lung cancer. <i>Respirology</i> , 2012, 17, 620-626. | 2.3 | 20 |
| 918 | EGFR mutations in non-small-cell lung cancer among smokers and non-smokers: A meta-analysis. <i>Environmental and Molecular Mutagenesis</i> , 2012, 53, 78-82. | 2.2 | 40 |
| 919 | Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor <i>EGFR</i> or <i>KRAS</i> mutations or <i>ALK</i> rearrangement. <i>Cancer</i> , 2012, 118, 729-739. | 4.1 | 132 |
| 920 | Authors' reply to Absence of common activating mutations of the epidermal growth factor receptor gene in thyroid cancers from American and Japanese patients. <i>International Journal of Cancer</i> , 2012, 130, 2217-2218. | 5.1 | 2 |
| 921 | Absence of common activating mutations of the epidermal growth factor receptor gene in thyroid cancers from American and Japanese patients. <i>International Journal of Cancer</i> , 2012, 130, 2215-2217. | 5.1 | 7 |
| 922 | Mitochondrial DNA mutations in respiratory complex in never-smoker lung cancer patients contribute to lung cancer progression and associated with <i>EGFR</i> gene mutation. <i>Journal of Cellular Physiology</i> , 2012, 227, 2451-2460. | 4.1 | 74 |
| 923 | Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 289-299. | 2.3 | 50 |
| 924 | Second-line epidermal growth factor receptor inhibitors followed by third-line pemetrexed or the reverse sequence: a retrospective analysis of 83 Chinese patients with advanced lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 285-291. | 2.5 | 1 |
| 925 | The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations. <i>Human Genetics</i> , 2012, 131, 365-372. | 3.8 | 45 |
| 926 | <i>EGFR</i> exon 19 in-frame deletion and polymorphisms of DNA repair genes in never-smoking female lung adenocarcinoma patients. <i>International Journal of Cancer</i> , 2013, 132, 449-458. | 5.1 | 12 |
| 927 | Frequent <i>EGFR</i> mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis. <i>European Respiratory Journal</i> , 2013, 41, 417-424. | 6.7 | 41 |
| 928 | Advanced non-squamous non-small-cell lung cancer: who and when should be biologically screened today? Tomorrow?. <i>Current Respiratory Care Reports</i> , 2013, 2, 17-21. | 0.6 | 1 |
| 930 | Determinants of Survival in Advanced Non-Small-Cell Lung Cancer in the Era of Targeted Therapies. <i>Clinical Lung Cancer</i> , 2013, 14, 581-591. | 2.6 | 39 |
| 931 | Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. <i>BMC Cancer</i> , 2013, 13, 354. | 2.6 | 42 |
| 932 | Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis. <i>BMC Cancer</i> , 2013, 13, 39. | 2.6 | 20 |
| 933 | Allelotypes of lung adenocarcinomas featuring ALK fusion demonstrate fewer onco- and suppressor gene changes. <i>BMC Cancer</i> , 2013, 13, 8. | 2.6 | 4 |
| 934 | Journey of the ALK-inhibitor CH5424802 to phase II clinical trial. <i>Archives of Pharmacal Research</i> , 2013, 36, 1051-1054. | 6.3 | 17 |
| 936 | Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 859-865. | 2.3 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 937 | Erlotinib in patients with advanced lung squamous cell carcinoma. Cancer Chemotherapy and Pharmacology, 2013, 71, 203-208. | 2.3 | 7 |
| 938 | Skin rash by gefitinib is a sign of favorable outcomes for patients of advanced lung adenocarcinoma in Japanese patients. SpringerPlus, 2013, 2, 22. | 1.2 | 7 |
| 939 | First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments. Drugs, 2013, 73, 357-369. | 10.9 | 12 |
| 940 | Molecular sputum analysis for the diagnosis of lung cancer. British Journal of Cancer, 2013, 109, 530-537. | 6.4 | 92 |
| 941 | EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. British Journal of Cancer, 2013, 109, 1821-1828. | 6.4 | 118 |
| 942 | Molecular Surgical Pathology. , 2013, , . | | 23 |
| 943 | Clinicopathological characteristics of <scp>EGFR</scp> mutated adenosquamous carcinoma of the lung. Pathology International, 2013, 63, 77-84. | 1.3 | 22 |
| 944 | Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma. Lung Cancer, 2013, 80, 159-164. | 2.0 | 28 |
| 945 | Genetically engineered mouse models of pancreatic adenocarcinoma. Molecular Oncology, 2013, 7, 232-247. | 4.6 | 140 |
| 946 | Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Cancer Treatment Reviews, 2013, 39, 839-850. | 7.7 | 100 |
| 947 | Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation. Human Pathology, 2013, 44, 2636-2642. | 2.0 | 41 |
| 948 | Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. Expert Review of Anticancer Therapy, 2013, 13, 1207-1218. | 2.4 | 13 |
| 949 | Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer, 2013, 82, 179-189. | 2.0 | 262 |
| 950 | Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer. Science Translational Medicine, 2013, 5, 216ra177. | 12.4 | 438 |
| 951 | Next-generation sequencing for lung cancer. Future Oncology, 2013, 9, 1323-1336. | 2.4 | 38 |
| 952 | Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning. Respiratory Medicine, 2013, 107, 1755-1762. | 2.9 | 30 |
| 953 | Role of the Pulmonologist in Ordering Post-Procedure Molecular Markers in Non-“Small-Cell Lung Cancer: Implications for Personalized Medicine. Clinical Lung Cancer, 2013, 14, 609-626. | 2.6 | 15 |
| 954 | Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma. Critical Reviews in Oncology/Hematology, 2013, 88, 477-493. | 4.4 | 71 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 955 | HER2 and lung cancer. Expert Review of Anticancer Therapy, 2013, 13, 1219-1228. | 2.4 | 63 |
| 956 | KRAS Mutations in Lung Cancer. Clinical Lung Cancer, 2013, 14, 205-214. | 2.6 | 182 |
| 957 | <i>ALK</i> Rearrangements Are Mutually Exclusive with Mutations in <i>EGFR</i> or <i>KRAS</i> : An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer. Clinical Cancer Research, 2013, 19, 4273-4281. | 7.0 | 521 |
| 958 | Detecting EGFR alterations in clinical specimens—pitfalls and necessities. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 755-764. | 2.8 | 7 |
| 959 | Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncology, The, 2013, 14, 953-961. | 10.7 | 389 |
| 961 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistant Disease. Journal of Clinical Oncology, 2013, 31, 1070-1080. | 1.6 | 425 |
| 962 | <i>EGFR</i> mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating <i>EGFR</i> mutations in lung adenocarcinoma. Journal of Clinical Pathology, 2013, 66, 744-748. | 2.0 | 19 |
| 963 | <i>EGFR</i> mutational status in penile cancer. Expert Opinion on Therapeutic Targets, 2013, 17, 501-505. | 3.4 | 14 |
| 964 | LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both. Journal of Clinical Oncology, 2013, 31, 3335-3341. | 1.6 | 303 |
| 965 | Hyperactivation of constitutively dimerized oncogenic EGF receptors by autocrine loops. Oncogene, 2013, 32, 2403-2411. | 5.9 | 15 |
| 966 | EGFR mutation status in brain metastases of non-small cell lung carcinoma. Journal of Neuro-Oncology, 2013, 111, 1-10. | 2.9 | 62 |
| 967 | New Targetable Oncogenes in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, 1097-1104. | 1.6 | 280 |
| 968 | <i>KRAS</i> Mutation: Should We Test for It, and Does It Matter?. Journal of Clinical Oncology, 2013, 31, 1112-1121. | 1.6 | 219 |
| 969 | Clinical testing for molecular targets for personalized treatment in lung cancer. Respiriology, 2013, 18, 233-237. | 2.3 | 4 |
| 970 | <i>EGFR</i> Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics. Molecular Cancer Therapeutics, 2013, 12, 220-229. | 4.1 | 367 |
| 971 | Molecular profile of lung cancer in never smokers. European Journal of Cancer, Supplement, 2013, 11, 248-253. | 2.2 | 30 |
| 972 | Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer. Cancer Genetics, 2013, 206, 73-80. | 0.4 | 39 |
| 973 | Epidermal Growth Factor Receptor Exon 20 Mutation Increased in Post-Chemotherapy Patients with Non-Small Cell Lung Cancer Detected with Patients' Blood Samples. Translational Oncology, 2013, 6, 504-510. | 3.7 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 974 | The Importance of Molecular Profiling in Predicting Response to Epidermal Growth Factor Receptor Family Inhibitors in Non-Small-Cell Lung Cancer: Focus on Clinical Trial Results. <i>Clinical Lung Cancer</i> , 2013, 14, 311-321. | 2.6 | 11 |
| 975 | Impact of family history of cancer on the incidence of mutation in epidermal growth factor receptor gene in non-small cell lung cancer patients. <i>Lung Cancer</i> , 2013, 81, 162-166. | 2.0 | 26 |
| 976 | Distinct features of distant metastasis and lymph node stage in lung adenocarcinoma patients with epidermal growth factor receptor gene mutations. <i>Respiratory Investigation</i> , 2013, 51, 153-157. | 1.8 | 26 |
| 977 | Medical treatment of advanced non-small cell lung cancer in elderly patients: A review of the role of chemotherapy and targeted agents. <i>Journal of Geriatric Oncology</i> , 2013, 4, 282-290. | 1.0 | 41 |
| 978 | Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. <i>Lung Cancer</i> , 2013, 80, 235-241. | 2.0 | 96 |
| 979 | Comparison Study of the Performance of the QIAGEN EGFR RQO and EGFR Pyro Assays for Mutation Analysis in Non-Small Cell Lung Cancer. <i>American Journal of Clinical Pathology</i> , 2013, 140, 7-19. | 0.7 | 12 |
| 980 | Prognostic factors after complete resection of pN2 non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 146, 788-795. | 0.8 | 34 |
| 981 | Estudo da mutação do recetor do fator de crescimento epidérmico, durante 5 anos, numa população de doentes com cancro do pulmão de células pequenas. <i>Revista Portuguesa De Pneumologia</i> , 2013, 19, 7-12. | 0.7 | 17 |
| 982 | Suitability of Computed Tomography-Guided Biopsy Specimens for Subtyping and Genotyping of Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 719-725. | 2.6 | 19 |
| 983 | Epidermal Growth Factor Recetor mutation study for 5 years, in a population of patients with non-small cell lung cancer. <i>Revista Portuguesa De Pneumologia</i> , 2013, 19, 7-12. | 0.7 | 16 |
| 985 | p14ARF inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway. <i>Oncogene</i> , 2013, 32, 1050-1058. | 5.9 | 13 |
| 986 | Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). <i>Cancer Treatment Reviews</i> , 2013, 39, 252-260. | 7.7 | 68 |
| 987 | Detection of epidermal growth factor receptor mutations in formalin fixed paraffin embedded biopsies in Malaysian non-small cell lung cancer patients. <i>Journal of Biomedical Science</i> , 2013, 20, 22. | 7.0 | 7 |
| 988 | Identification of driver mutations in lung cancer: first step in personalized cancer. <i>Targeted Oncology</i> , 2013, 8, 3-14. | 3.6 | 26 |
| 989 | Erlotinib in the first-line treatment of non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 523-533. | 2.4 | 17 |
| 990 | The potential role of new targeted therapies in the treatment of advanced non-small-cell lung cancer. <i>Clinical Investigation</i> , 2013, 3, 369-383. | 0.0 | 3 |
| 991 | Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies. <i>Pharmacogenomics and Personalized Medicine</i> , 2013, 6, 25. | 0.7 | 30 |
| 992 | Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma. <i>Journal of Surgical Research</i> , 2013, 185, 217-224. | 1.6 | 35 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 993 | Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors. Journal of Molecular Diagnostics, 2013, 15, 415-453. | 2.8 | 397 |
| 994 | Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Archives of Pathology and Laboratory Medicine, 2013, 137, 828-860. | 2.5 | 415 |
| 995 | Molecular and Genetic Aspects of Lung Cancer. Biotechnology and Biotechnological Equipment, 2013, 27, 4051-4060. | 1.3 | 3 |
| 996 | Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. Lung Cancer, 2013, 82, 31-37. | 2.0 | 48 |
| 997 | Activating Germline R776H Mutation in the Epidermal Growth Factor Receptor Associated With Lung Cancer With Squamous Differentiation. Journal of Clinical Oncology, 2013, 31, e161-e164. | 1.6 | 44 |
| 998 | Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma. Head and Neck, 2013, 35, 1323-1330. | 2.0 | 23 |
| 999 | Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Journal of Thoracic Oncology, 2013, 8, 823-859. | 1.1 | 792 |
| 1000 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer. Current Pharmaceutical Design, 2013, 19, 818-832. | 1.9 | 24 |
| 1001 | Radiologic Implications of the 2011 Classification of Adenocarcinoma of the Lung. Radiology, 2013, 266, 62-71. | 7.3 | 201 |
| 1002 | Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers. Oncology Letters, 2013, 6, 1207-1212. | 1.8 | 23 |
| 1003 | Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation. Molecular and Clinical Oncology, 2013, 1, 575-581. | 1.0 | 42 |
| 1004 | Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinomas: Relationship with CT Characteristics and Histologic Subtypes. Radiology, 2013, 268, 254-264. | 7.3 | 156 |
| 1005 | Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study. Journal of Carcinogenesis, 2013, 12, 12. | 2.5 | 35 |
| 1006 | Gefitinib, Fluorouracil, Oxaliplatin, and Leucovorin (IFOX) Regimen for Colorectal Cancer. Hospital Pharmacy, 2013, 48, 905-911. | 1.0 | 1 |
| 1007 | Epidermal growth factor receptor mutation subtypes and geographical distribution among Indian non-small cell lung cancer patients. Indian Journal of Cancer, 2013, 50, 107. | 0.2 | 23 |
| 1008 | Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Annals of Oncology, 2013, 24, 2371-2376. | 1.2 | 510 |
| 1009 | Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A Review. Onkologie, 2013, 36, 5-5. | 0.8 | 77 |
| 1010 | The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non-Small Cell Lung Cancer Growth. Molecular Cancer Therapeutics, 2013, 12, 890-900. | 4.1 | 67 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1011 | Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue. <i>Journal of Clinical Pathology</i> , 2013, 66, 708-710. | 2.0 | 11 |
| 1012 | A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5523-5532. | 7.0 | 82 |
| 1013 | The Effectiveness of Erlotinib Against Brain Metastases in Non-Small Cell Lung Cancer Patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 110-115. | 1.3 | 32 |
| 1014 | Efficacy of tyrosine kinase inhibitors in routine clinical practice: Epidermal growth factor mutations and their implications. <i>Journal of Cancer Research and Therapeutics</i> , 2013, 9, 261. | 0.9 | 5 |
| 1015 | Association of epidermal growth factor receptor mutations with human papillomavirus 16/18 E6 oncoprotein expression in non-small cell lung cancer. <i>Cancer</i> , 2013, 119, 3367-3376. | 4.1 | 17 |
| 1016 | EGFR and TOPK expression in non-small cell lung cancer: its correlation and prognostic significance with KRAS and p53 expression. <i>Histopathology</i> , 2013, 63, 696-703. | 2.9 | 62 |
| 1017 | Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR tyrosine kinase inhibitors. <i>Cancer Science</i> , 2013, 104, 584-589. | 3.9 | 51 |
| 1018 | Mechanisms of resistance to EGFR targeted therapies. <i>Cancer Biology and Therapy</i> , 2013, 14, 304-314. | 3.4 | 56 |
| 1019 | Rare mutations in non-small-cell lung cancer. <i>Future Oncology</i> , 2013, 9, 699-711. | 2.4 | 23 |
| 1020 | Efficacy of third-generation chemotherapeutic agents combined with cisplatin or carboplatin in 3100 Chinese patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2013, 4, 117-122. | 1.9 | 2 |
| 1021 | Blocking NRG1 and Other Ligand-Mediated Her4 Signaling Enhances the Magnitude and Duration of the Chemotherapeutic Response of Non-Small Cell Lung Cancer. <i>Science Translational Medicine</i> , 2013, 5, 171ra18. | 12.4 | 63 |
| 1022 | Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma. <i>Modern Pathology</i> , 2013, 26, 1197-1203. | 5.5 | 22 |
| 1023 | Integration of targeted therapy in the management of locally advanced, unresectable non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2013, 2, 75-85. | 1.5 | 0 |
| 1024 | Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. <i>Oncology Reports</i> , 2013, 30, 2311-2315. | 2.6 | 20 |
| 1025 | Frequency and Type of Epidermal Growth Factor Receptor Mutations in Moroccan Patients with Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1212-1214. | 1.1 | 37 |
| 1026 | CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1378-1388. | 1.1 | 71 |
| 1027 | Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions. <i>Journal of Thoracic Oncology</i> , 2013, 8, 179-184. | 1.1 | 269 |
| 1028 | Ethnic differences in non-small-cell lung cancer treatment: the Asian perspective. <i>Lung Cancer Management</i> , 2013, 2, 309-315. | 1.5 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1029 | Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma in Malaysian Patients. Journal of Thoracic Oncology, 2013, 8, 766-772. | 1.1 | 35 |
| 1030 | Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients. Oncology Letters, 2013, 5, 271-276. | 1.8 | 31 |
| 1031 | Cytokeratin 19 Fragment Predicts the Efficacy of Epidermal Growth Factor Receptorâ€“Tyrosine Kinase Inhibitor in Nonâ€“Small-Cell Lung Cancer Harboring EGFR Mutation. Journal of Thoracic Oncology, 2013, 8, 892-898. | 1.1 | 44 |
| 1032 | Detection of EGFR gene mutations in non-small cell lung cancer: Lessons from a single-institution routine analysis of 1,403 tumor samples. International Journal of Oncology, 2013, 43, 1045-1051. | 3.3 | 32 |
| 1033 | Gefitinib: re-emerging from the shadows. Lung Cancer Management, 2013, 2, 423-437. | 1.5 | 0 |
| 1034 | Association of epidermal growth factor receptor and K-Ras mutations with smoking history in non-small cell lung cancer patients. Experimental and Therapeutic Medicine, 2013, 5, 495-498. | 1.8 | 13 |
| 1035 | ROS1-Rearranged Lung Cancer. American Journal of Surgical Pathology, 2013, 37, 554-562. | 3.7 | 155 |
| 1036 | How Sensitive Are Epidermal Growth Factor Receptorâ€“Tyrosine Kinase Inhibitors for Squamous Cell Carcinoma of the Lung Harboring EGFR Geneâ€“Sensitive Mutations?. Journal of Thoracic Oncology, 2013, 8, 89-95. | 1.1 | 68 |
| 1037 | -216G/T (rs712829), a functional variant of the EGFR promoter, is associated with the pleural metastasis of lung adenocarcinoma. Oncology Letters, 2013, 6, 693-698. | 1.8 | 15 |
| 1038 | Sex Disparities in the Association of Lung Adenocarcinoma with Colorectal Cancer. Journal of Cancer, 2013, 4, 691-696. | 2.5 | 1 |
| 1039 | A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Nonâ€“Small-Cell Lung Cancer. PLoS ONE, 2013, 8, e55917. | 2.5 | 46 |
| 1040 | Frequency of EGFR Mutations in 907 Lung Adenocarcinoma Patients of Indian Ethnicity. PLoS ONE, 2013, 8, e76164. | 2.5 | 94 |
| 1041 | An Integrated Inspection of the Somatic Mutations in a Lung Squamous Cell Carcinoma Using Next-Generation Sequencing. PLoS ONE, 2013, 8, e78823. | 2.5 | 5 |
| 1042 | Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma. PLoS ONE, 2013, 8, e81975. | 2.5 | 18 |
| 1043 | Expression of the Mismatch Repair Gene hMLH1 Is Enhanced in Non-Small Cell Lung Cancer with EGFR Mutations. PLoS ONE, 2013, 8, e78500. | 2.5 | 15 |
| 1045 | Adenocarcinoma of the lung., 2013, , 1043-1092. | | 1 |
| 1046 | Lung Cancer in Women. Southern Medical Journal, 2013, 106, 582-587. | 0.7 | 6 |
| 1047 | New modalities of cancer treatment for NSCLC: focus on immunotherapy. Cancer Management and Research, 2014, 6, 63. | 1.9 | 68 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1048 | Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Brazilian Journal of Medical and Biological Research, 2014, 47, 929-939. | 1.5 | 94 |
| 1049 | Opposing Functions of Akt Isoforms in Lung Tumor Initiation and Progression. PLoS ONE, 2014, 9, e94595. | 2.5 | 58 |
| 1050 | A Laboratory Prognostic Index Model for Patients with Advanced Non-Small Cell Lung Cancer. PLoS ONE, 2014, 9, e114471. | 2.5 | 41 |
| 1051 | EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. Drug Design, Development and Therapy, 2014, 8, 1595. | 4.3 | 36 |
| 1052 | In Vitro and In Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies. Current Medicinal Chemistry, 2014, 21, 1595-1606. | 2.4 | 52 |
| 1053 | Chronic Nicotine Exposure Mediates Resistance to Egfr-Tki in Egfr-Mutated Lung Cancer Via Egfr Signal. Annals of Oncology, 2014, 25, v73. | 1.2 | 0 |
| 1054 | Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors. Investigational New Drugs, 2014, 32, 1311-1315. | 2.6 | 28 |
| 1055 | Improving access to lung cancer treatment in northern Canada: the role of oral molecularly targeted agents. Cmaj, 2014, 186, 485-486. | 2.0 | 0 |
| 1056 | Somatic mutations of the HER2 in metastatic breast cancer. Tumor Biology, 2014, 35, 11851-11854. | 1.8 | 13 |
| 1057 | Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2014, 74, 1199-1206. | 2.3 | 14 |
| 1058 | TD-19, an Erlotinib Derivative, Induces Epidermal Growth Factor Receptor Wild-Type Nonsmall-Cell Lung Cancer Apoptosis through CIP2A-Mediated Pathway. Journal of Pharmacology and Experimental Therapeutics, 2014, 351, 352-358. | 2.5 | 27 |
| 1059 | Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer. British Journal of Cancer, 2014, 111, 2203-2204. | 6.4 | 37 |
| 1060 | Relationship of Thyroid Transcription Factor 1 to EGFR Status in Non-Small-Cell Lung Cancer. Current Oncology, 2014, 21, 305-308. | 2.2 | 8 |
| 1061 | Significance of the progesterone receptor and epidermal growth factor receptor, but not the estrogen receptor, in chemically induced lung carcinogenesis in female A/J mice. Oncology Letters, 2014, 8, 2379-2386. | 1.8 | 7 |
| 1062 | Protein expression, gene amplification, epidermal growth factor receptor mutations and lung carcinoma. Vojnosanitetski Pregled, 2014, 71, 679-684. | 0.2 | 1 |
| 1063 | Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2014, 4, 190. | 2.8 | 50 |
| 1064 | Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. Frontiers in Oncology, 2014, 4, 204. | 2.8 | 137 |
| 1065 | First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era. Future Oncology, 2014, 10, 1081-1093. | 2.4 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1066 | Identification of Recurrent <i>FGFR3</i> - <i>TACC3</i> Fusion Oncogenes from Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 6551-6558. | 7.0 | 85 |
| 1067 | Echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma. <i>Thoracic Cancer</i> , 2014, 5, 411-416. | 1.9 | 7 |
| 1068 | Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2014, 25, 1578-1584. | 1.2 | 10 |
| 1069 | Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2693-2708. | 1.8 | 20 |
| 1070 | Imaging EGFR and HER2 by PET and SPECT: A Review. <i>Medicinal Research Reviews</i> , 2014, 34, 596-643. | 10.5 | 55 |
| 1071 | Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitors. <i>Thoracic Cancer</i> , 2014, 5, 126-132. | 1.9 | 21 |
| 1072 | Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: Integrating with lung specific GPA score. <i>Lung Cancer</i> , 2014, 86, 363-368. | 2.0 | 17 |
| 1073 | Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1119-1125. | 2.8 | 28 |
| 1074 | Molecular alterations in non-small cell lung cancer: Perspective for targeted therapy and specimen management for the bronchoscopist. <i>Respirology</i> , 2014, 19, 1117-1125. | 2.3 | 15 |
| 1075 | Molecular alterations in non-small cell lung carcinomas of the young. <i>Human Pathology</i> , 2014, 45, 2379-2387. | 2.0 | 33 |
| 1076 | Resection for subcentimeter non-small cell lung cancer: Outcomes for a Chinese population with 70% adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2014, 110, 225-226. | 1.7 | 3 |
| 1077 | Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage. <i>Journal of Surgical Oncology</i> , 2014, 110, 245-251. | 1.7 | 32 |
| 1078 | The evolving genomic classification of lung cancer. <i>Journal of Pathology</i> , 2014, 232, 121-133. | 4.5 | 87 |
| 1079 | Human papillomavirus infections as a marker to predict overall survival in lung adenocarcinoma. <i>International Journal of Cancer</i> , 2014, 134, 65-71. | 5.1 | 23 |
| 1080 | Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC. <i>Journal of Cellular and Molecular Medicine</i> , 2014, 18, 1519-1539. | 3.6 | 33 |
| 1081 | p40 (p63) is more specific than p63 and cytokeratin 5 in identifying squamous cell carcinoma of bronchopulmonary origin: A review and comparative analysis. <i>Diagnostic Cytopathology</i> , 2014, 42, 453-458. | 1.0 | 17 |
| 1082 | Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. <i>Oncology</i> , 2014, 86, 86-93. | 1.9 | 19 |
| 1083 | New Aspects of the Clinicopathology and Genetic Profile of Metachronous Multiple Lung Cancers. <i>Annals of Surgery</i> , 2014, 259, 1018-1024. | 4.2 | 28 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1084 | Mutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA. BMC Gastroenterology, 2014, 14, 221. | 2.0 | 12 |
| 1085 | Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations. Journal of Thoracic Oncology, 2014, 9, 456-463. | 1.1 | 112 |
| 1086 | EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas. Journal of Thoracic Oncology, 2014, 9, 195-199. | 1.1 | 245 |
| 1087 | Impact of Non-“Small-Cell Lung Cancer-Not Otherwise Specified Immunophenotyping on Treatment Outcome. Journal of Thoracic Oncology, 2014, 9, 1540-1546. | 1.1 | 24 |
| 1088 | Aberrant transcriptional regulations in cancers: genome, transcriptome and epigenome analysis of lung adenocarcinoma cell lines. Nucleic Acids Research, 2014, 42, 13557-13572. | 14.5 | 102 |
| 1089 | EGFR Mutations in Lung Cancer: Different Frequencies for Different Folks. Journal of Thoracic Oncology, 2014, 9, 139-140. | 1.1 | 13 |
| 1090 | Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcome in Resected Non-“Small Cell Lung Cancer Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 343-349. | 1.3 | 20 |
| 1091 | Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non-“Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial. Journal of Thoracic Oncology, 2014, 9, 1523-1531. | 1.1 | 19 |
| 1092 | Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations. Clinical Cancer Research, 2014, 20, 3613-3622. | 7.0 | 39 |
| 1093 | Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients. Genetical Research, 2014, 96, e002. | 0.9 | 16 |
| 1094 | Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non-small-cell lung cancer. Molecular and Clinical Oncology, 2014, 2, 8-12. | 1.0 | 33 |
| 1095 | Histological subtype and smoking status, but not gender, are associated with epidermal growth factor receptor mutations in non-small-cell lung cancer. Molecular and Clinical Oncology, 2014, 2, 252-258. | 1.0 | 11 |
| 1096 | Whole-Genome Sequencing of Asian Lung Cancers: Second-Hand Smoke Unlikely to Be Responsible for Higher Incidence of Lung Cancer among Asian Never-Smokers. Cancer Research, 2014, 74, 6071-6081. | 0.9 | 40 |
| 1097 | A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-“Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER). Journal of Thoracic Oncology, 2014, 9, 154-162. | 1.1 | 1,131 |
| 1098 | Signal Transducer and Activator of Transcription 3 as Molecular Therapy for Non-“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 488-496. | 1.1 | 11 |
| 1099 | Clinical Significance of BIM Deletion Polymorphism in Non-“Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation. Journal of Thoracic Oncology, 2014, 9, 483-487. | 1.1 | 67 |
| 1100 | EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients. Journal of Thoracic Oncology, 2014, 9, e10-e11. | 1.1 | 5 |
| 1101 | Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma. American Journal of Surgical Pathology, 2014, 38, 1118-1127. | 3.7 | 131 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1102 | Targeting Epidermal Growth Factor Receptor in the Management of Lung Cancer. <i>Seminars in Oncology</i> , 2014, 41, 101-109. | 2.2 | 19 |
| 1103 | Detection of mutation-specific epidermal growth factor receptor (E746A750del) and lack of detection of human papillomavirus in oral squamous cell carcinoma. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2014, 43, 1199-1205. | 1.5 | 4 |
| 1104 | The mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance. <i>Surgery Today</i> , 2014, 44, 478-486. | 1.5 | 27 |
| 1105 | Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas. <i>Medical Oncology</i> , 2014, 31, 771. | 2.5 | 48 |
| 1106 | Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 385-392. | 2.5 | 54 |
| 1107 | The impact of germline mutations on targeted therapy. <i>Journal of Pathology</i> , 2014, 232, 230-243. | 4.5 | 7 |
| 1108 | Highly sensitive EGFR mutation detection by specific amplification of mutant alleles. <i>Experimental and Molecular Pathology</i> , 2014, 96, 85-91. | 2.1 | 2 |
| 1109 | EGFR mutation frequency and effectiveness of erlotinib: A prospective observational study in Danish patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 83, 224-230. | 2.0 | 41 |
| 1110 | RASSF3 downregulation increases malignant phenotypes of non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 83, 23-29. | 2.0 | 12 |
| 1111 | Establishment and characterization of a lung cancer cell line, SMC-L001, from a lung adenocarcinoma. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2014, 50, 519-526. | 1.5 | 3 |
| 1112 | Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents. <i>Journal of Biological Inorganic Chemistry</i> , 2014, 19, 259-270. | 2.6 | 21 |
| 1113 | Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2014, 120, 2289-2298. | 4.1 | 30 |
| 1114 | Pharmacogenomics and Personalized Medicines in Cancer Treatment. , 2014, , 55-90. | | 0 |
| 1115 | The impact of personalized medicine on survival: Comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers. <i>Cancer Treatment Reviews</i> , 2014, 40, 485-494. | 7.7 | 21 |
| 1116 | Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients. <i>Journal of Clinical Oncology</i> , 2014, 32, 121-128. | 1.6 | 176 |
| 1119 | Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ≤ 5 cm in maximal dimension. <i>Journal of Surgical Oncology</i> , 2014, 110, 99-106. | 1.7 | 32 |
| 1120 | A worldwide trend of increasing primary adenocarcinoma of the lung. <i>Surgery Today</i> , 2014, 44, 1004-1012. | 1.5 | 89 |
| 1121 | Epidermal growth factor receptor (EGFR) mutations as biomarker for head and neck squamous cell carcinomas (HNSCC). <i>Biomarkers</i> , 2014, 19, 198-206. | 1.9 | 18 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1122 | Serum 25-hydroxyvitamin D levels correlate with EGFR mutational status in pulmonary adenocarcinoma. <i>Endocrine-Related Cancer</i> , 2014, 21, 715-721. | 3.1 | 6 |
| 1123 | A microRNA gene signature for identification of lung cancer. <i>Surgical Oncology</i> , 2014, 23, 126-131. | 1.6 | 18 |
| 1124 | The prognostic impact of the amount of tobacco smoking in non-small cell lung cancer—Differences between adenocarcinoma and squamous cell carcinoma. <i>Lung Cancer</i> , 2014, 85, 125-130. | 2.0 | 29 |
| 1125 | First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial. <i>European Journal of Cancer</i> , 2014, 50, 2219-2230. | 2.8 | 44 |
| 1126 | Value of 18F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1889-1897. | 6.4 | 54 |
| 1127 | Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1063-1070. | 2.3 | 18 |
| 1128 | Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 543-551. | 3.3 | 49 |
| 1129 | Epidermal growth factor receptor mutations in lung adenocarcinoma. <i>Laboratory Investigation</i> , 2014, 94, 129-137. | 3.7 | 188 |
| 1130 | Evaluation of the new IASLC/ATS/ERS proposed classification of adenocarcinoma based on lepidic pattern in patients with pathological stage IA pulmonary adenocarcinoma. <i>General Thoracic and Cardiovascular Surgery</i> , 2014, 62, 671-677. | 0.9 | 26 |
| 1131 | A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib. <i>Medical Oncology</i> , 2014, 31, 36. | 2.5 | 7 |
| 1132 | SNP rs10248565 in HDAC9 as a novel genomic aberration biomarker of lung adenocarcinoma in non-smoking women. <i>Journal of Biomedical Science</i> , 2014, 21, 24. | 7.0 | 11 |
| 1133 | Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients. <i>BMC Cancer</i> , 2014, 14, 369. | 2.6 | 33 |
| 1134 | Customized Adjuvant Phase II Trial in Patients With Non-Small-Cell Lung Cancer: IFCT-0801 TASTE. <i>Journal of Clinical Oncology</i> , 2014, 32, 1256-1261. | 1.6 | 66 |
| 1135 | Treatment algorithm in 2014 for advanced non-small cell lung cancer: Therapy selection by tumour histology and molecular biology. <i>Advances in Medical Sciences</i> , 2014, 59, 308-313. | 2.1 | 21 |
| 1136 | Current concepts on the molecular pathology of non-small cell lung carcinoma. <i>Seminars in Diagnostic Pathology</i> , 2014, 31, 306-313. | 1.5 | 43 |
| 1137 | Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. <i>Lung Cancer</i> , 2014, 84, 161-167. | 2.0 | 81 |
| 1138 | Prospective screening for ALK: Clinical features and outcome according to ALK status. <i>European Journal of Cancer</i> , 2014, 50, 1239-1246. | 2.8 | 46 |
| 1139 | CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation. <i>Lung Cancer</i> , 2014, 85, 152-160. | 2.0 | 29 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1141 | Learning curve for endobronchial ultrasound-guided transbronchial needle aspiration: Experience of a community-based teaching hospital. <i>Molecular Medicine Reports</i> , 2014, 10, 2441-2446. | 2.4 | 2 |
| 1142 | Lung Carcinomas with EGFR Exon 19 Insertions Are Sensitive to Gefitinib Treatment. <i>Journal of Thoracic Oncology</i> , 2014, 9, e31-e33. | 1.1 | 12 |
| 1143 | Comprehensive Analysis of the Incidence and Survival Patterns of Lung Cancer by Histologies, Including Rare Subtypes, in the Era of Molecular Medicine and Targeted Therapy. <i>Medicine (United Tj ETQq0 0 0 rgB0/Overlook 10 Tf 50</i> | 0.0 | 0 |
| 1144 | Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, 738-746. | 1.1 | 70 |
| 1145 | Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced nonâ€‘small cell lung cancer. <i>Cancer</i> , 2015, 121, 3146-3156. | 4.1 | 11 |
| 1146 | Assessment of EGFR and KRAS mutation status from FNAs and coreâ€‘needle biopsies of nonâ€‘small cell lung cancer. <i>Cancer Cytopathology</i> , 2015, 123, 230-236. | 2.4 | 25 |
| 1147 | Risk of lung cancer and consumption of vegetables and fruit in Japanese: A pooled analysis of cohort studies in Japan. <i>Cancer Science</i> , 2015, 106, 1057-1065. | 3.9 | 13 |
| 1148 | Clinical features of lung adenocarcinomas with epidermal growth factor receptor mutations and miliary disseminated carcinomatosis. <i>Thoracic Cancer</i> , 2015, 6, 629-635. | 1.9 | 12 |
| 1149 | Elevated β -catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs. <i>Scientific Reports</i> , 2015, 5, 13076. | 3.3 | 40 |
| 1150 | A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: A case report and literature review. <i>Molecular Medicine Reports</i> , 2015, 12, 4370-4375. | 2.4 | 14 |
| 1151 | L858R-positive lung adenocarcinoma with KRAS G12V, EGFR T790M and EGFR L858R mutations: A case report. <i>Oncology Letters</i> , 2015, 10, 1293-1296. | 1.8 | 7 |
| 1152 | A new rapid method for detecting epidermal growth factor receptor mutations in non-small cell lung cancer. <i>Oncology Reports</i> , 2015, 33, 1040-1048. | 2.6 | 7 |
| 1153 | Feasibility of Rebiopsy in Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors. <i>Internal Medicine</i> , 2015, 54, 1977-1980. | 0.7 | 33 |
| 1154 | QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC. <i>Scientific Reports</i> , 2015, 5, 11934. | 3.3 | 9 |
| 1155 | Identification of Genetic Mutations in Human Lung Cancer by Targeted Sequencing. <i>Cancer Informatics</i> , 2015, 14, CIN.S22941. | 1.9 | 16 |
| 1156 | Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma. <i>Oncology Letters</i> , 2015, 10, 1775-1782. | 1.8 | 27 |
| 1157 | Reply. <i>Journal of Thoracic Oncology</i> , 2015, 10, e82-e83. | 1.1 | 0 |
| 1158 | Afatinib administration in a patient with non-small cell lung cancer harboring uncommon EGFR mutation G719A undergoing hemodialysis. <i>Cancer Treatment Communications</i> , 2015, 4, 169-171. | 0.4 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1159 | Structural investigations of T854A mutation in EGFR and identification of novel inhibitors using structure activity relationships. BMC Genomics, 2015, 16, S8. | 2.8 | 27 |
| 1160 | Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations. BMC Cancer, 2015, 15, 908. | 2.6 | 30 |
| 1161 | The ensemble of genetic factors and angiogenic signals via VEGF receptors in lung cancer progression. Cancer Biomarkers, 2015, 15, 619-633. | 1.7 | 2 |
| 1162 | Investigation of Prognostic Factors Affecting Efficacy in Carboplatin- and Paclitaxel-based First-line Chemotherapies for Advanced Non-small-cell Lung Cancer. Tumori, 2015, 101, 424-432. | 1.1 | 5 |
| 1163 | From Uniplex to Multiplex Molecular Profiling in Advanced Nonâ€“Small Cell Lung Carcinoma. Cancer Journal (Sudbury, Mass), 2015, 21, 413-424. | 2.0 | 3 |
| 1164 | Detection of EML4-ALK Fusion Gene in Chinese Nonâ€“Small Cell Lung Cancer by Using a Sensitive Quantitative Real-Time Reverse Transcriptase PCR Technique. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 245-254. | 1.2 | 12 |
| 1165 | Pulmonary Adenocarcinoma In Situ. American Journal of Surgical Pathology, 2015, 39, 912-921. | 3.7 | 12 |
| 1166 | Emerging Immunotherapies in the Treatment of Nonâ€“small Cell Lung Cancer (NSCLC). American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 422-430. | 1.3 | 64 |
| 1167 | Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma. Medicine (United States), 2015, 94, e1784. | 1.0 | 17 |
| 1168 | FDG Uptake in Nonâ€“Small Cell Lung Cancer Is Not an Independent Predictor of EGFR or KRAS Mutation Status. Clinical Nuclear Medicine, 2015, 40, 950-958. | 1.3 | 47 |
| 1169 | Implications of Evolving Medical Science for Proof of Lung Cancer Causation. Beitrage Zur Tabakforschung International/ Contributions To Tobacco Research, 2015, 26, 298-311. | 0.3 | 0 |
| 1170 | Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma. Molecular Medicine Reports, 2015, 12, 187-191. | 2.4 | 14 |
| 1171 | Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent. Drug Design, Development and Therapy, 2015, 9, 3837. | 4.3 | 7 |
| 1172 | Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer. OncoTargets and Therapy, 2015, 9, 13. | 2.0 | 3 |
| 1173 | Imaging Characteristics in <i>ALK</i> Fusion-Positive Lung Adenocarcinomas by Using HRCT. Annals of Thoracic and Cardiovascular Surgery, 2015, 21, 102-108. | 0.8 | 20 |
| 1174 | Afatinib for the treatment of metastatic non-small cell lung cancer. Cancer Management and Research, 2015, 7, 75. | 1.9 | 31 |
| 1175 | EGFR and KRAS mutations in pulmonary pleomorphic carcinoma and their correlation with clinicopathologic features. Wspolczesna Onkologia, 2015, 1, 22-27. | 1.4 | 4 |
| 1176 | The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget, 2015, 6, 14209-14219. | 1.8 | 209 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1177 | The Use of a Two-Tiered Testing Strategy for the Simultaneous Detection of Small EGFR Mutations and EGFR Amplification in Lung Cancer. PLoS ONE, 2015, 10, e0117983. | 2.5 | 16 |
| 1178 | TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells. PLoS ONE, 2015, 10, e0129838. | 2.5 | 9 |
| 1179 | Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations. PLoS ONE, 2015, 10, e0142306. | 2.5 | 28 |
| 1180 | Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation. OncoTargets and Therapy, 2015, 8, 905. | 2.0 | 14 |
| 1181 | Targeted Therapies for Non-Small Cell Lung Cancer: An Update on Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Inhibitors. Clinical Journal of Oncology Nursing, 2015, 19, 734-742. | 0.6 | 3 |
| 1182 | Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy. Critical Reviews in Oncogenesis, 2015, 20, 357-371. | 0.4 | 8 |
| 1183 | A Mutation-Sensitive Switch Assay to Detect Five Clinically Significant Epidermal Growth Factor Receptor Mutations. Genetic Testing and Molecular Biomarkers, 2015, 19, 316-323. | 0.7 | 3 |
| 1184 | Exploring Stage I non-small-cell lung cancer: development of a prognostic model predicting 5-year survival after surgical resection. European Journal of Cardio-thoracic Surgery, 2015, 47, 1037-1043. | 1.4 | 37 |
| 1185 | Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status. Revista Portuguesa De Pneumologia, 2015, 21, 113-125. | 0.7 | 3 |
| 1186 | Loss of MIC6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma. Cancer Discovery, 2015, 5, 534-549. | 9.4 | 57 |
| 1187 | Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. Lung Cancer, 2015, 88, 187-194. | 2.0 | 68 |
| 1188 | New strategies to develop new medications for lung cancer and metastasis. Cancer and Metastasis Reviews, 2015, 34, 265-275. | 5.9 | 10 |
| 1189 | Targeting EGFR in lung cancer: Lessons learned and future perspectives. Molecular Aspects of Medicine, 2015, 45, 67-73. | 6.4 | 42 |
| 1190 | Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. Future Oncology, 2015, 11, 2175-2191. | 2.4 | 5 |
| 1191 | Genetic Polymorphism, Telomere Biology and Non-Small Lung Cancer Risk. Journal of Genetics and Genomics, 2015, 42, 549-561. | 3.9 | 26 |
| 1192 | Therapeutic options in advanced squamous cell lung carcinoma. Lung Cancer Management, 2015, 4, 75-86. | 1.5 | 0 |
| 1193 | Advances in Molecular Biology of Lung Disease. Chest, 2015, 148, 1063-1072. | 0.8 | 18 |
| 1194 | Prospective Assessment of Pemetrexed or Pemetrexed Plus Platinum in Combination With Gefitinib or Erlotinib in Patients With Acquired Resistance to Gefitinib or Erlotinib: A Phase II Exploratory and Preliminary Study. Clinical Lung Cancer, 2015, 16, 121-127. | 2.6 | 12 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1195 | Impact of Smoking Status on EGFR-TKI Efficacy for Advanced Non-Small-Cell Lung Cancer in EGFR Mutants: A Meta-analysis. <i>Clinical Lung Cancer</i> , 2015, 16, 144-151.e1. | 2.6 | 60 |
| 1196 | Gefitinib: a review of its use in adults with advanced non-small cell lung cancer. <i>Targeted Oncology</i> , 2015, 10, 153-170. | 3.6 | 51 |
| 1197 | Somatic Diseases (Cancer)., 2015, , 343-360. | | 0 |
| 1198 | Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2014, 4, 6269. | 3.3 | 187 |
| 1199 | Current and Future Approaches in the Management of Non-Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs. <i>Clinical Lung Cancer</i> , 2015, 16, 252-261. | 2.6 | 27 |
| 1200 | Molecular Spectrum of Somatic EGFR and KRAS Gene Mutations in non Small Cell Lung Carcinoma: Determination of Frequency, Distribution Pattern and Identification of Novel Variations in Indian Patients. <i>Pathology and Oncology Research</i> , 2015, 21, 675-687. | 1.9 | 11 |
| 1201 | Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. <i>Future Oncology</i> , 2015, 11, 409-420. | 2.4 | 34 |
| 1202 | Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?. <i>Lung Cancer</i> , 2015, 87, 155-161. | 2.0 | 8 |
| 1203 | Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations. <i>International Journal of Clinical Oncology</i> , 2015, 20, 674-679. | 2.2 | 133 |
| 1204 | First Reported Case of Unexpected Response to an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the I744M Uncommon EGFR Mutation. <i>Clinical Lung Cancer</i> , 2015, 16, e259-e261. | 2.6 | 5 |
| 1205 | EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non-Small Cell Lung Cancer in Germany: An Observational Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1254-1261. | 2.5 | 38 |
| 1206 | TERT Polymorphism rs2736100-C Is Associated with EGFR Mutation-Positive Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5173-5180. | 7.0 | 47 |
| 1207 | First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. <i>Annals of Oncology</i> , 2015, 26, 1883-1889. | 1.2 | 616 |
| 1208 | Emerging treatment for advanced lung cancer with EGFR mutation. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 597-612. | 2.4 | 22 |
| 1209 | Kras, Egfr, and Tp53 Mutations in B6C3F1/N Mouse and F344/NTac Rat Alveolar/Bronchiolar Carcinomas Resulting from Chronic Inhalation Exposure to Cobalt Metal. <i>Toxicologic Pathology</i> , 2015, 43, 872-882. | 1.8 | 14 |
| 1210 | Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2015, 10, 910-923. | 1.1 | 534 |
| 1211 | Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). <i>Journal of Thoracic Oncology</i> , 2015, 10, 838-843. | 1.1 | 156 |
| 1212 | AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1689-1699. | 27.0 | 1,802 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1213 | Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma. <i>Thoracic Cancer</i> , 2015, 6, 224-226. | 1.9 | 1 |
| 1214 | Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States. <i>Gynecologic Oncology</i> , 2015, 136, 491-497. | 1.4 | 58 |
| 1215 | Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR -mutated lung cancer via an EGFR signal. <i>Lung Cancer</i> , 2015, 88, 16-23. | 2.0 | 31 |
| 1216 | Prospective cohort study of clinical characteristics and management patterns for patients with non-small-cell lung cancer in the Russian Federation: EPICLIN-Lung. <i>Current Medical Research and Opinion</i> , 2015, 31, 1117-1127. | 1.9 | 7 |
| 1217 | Impact of Specific Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in <i>EGFR</i>-Mutant Lung Cancer: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, 1958-1965. | 1.6 | 280 |
| 1218 | Immunohistochemistry with a novel mutation-specific monoclonal antibody as a screening tool for the EGFR L858R mutational status in primary lung adenocarcinoma. <i>Tumor Biology</i> , 2015, 36, 693-700. | 1.8 | 5 |
| 1219 | Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil. <i>Oncology</i> , 2015, 89, 175-186. | 1.9 | 21 |
| 1220 | Epidermal growth factor receptor gene mutations in patients with lung adenocarcinoma differ by frequency and type between Uighur and Han ethnic groups in Xinjiang Autonomous Region. <i>BMC Genetics</i> , 2015, 16, 20. | 2.7 | 4 |
| 1221 | Clinicopathological significance of nuclear factor (erythroid-2)-related factor 2 (Nrf2) expression in gastric cancer. <i>BMC Cancer</i> , 2015, 15, 5. | 2.6 | 54 |
| 1222 | The epidermal growth factor receptor (EGRF) in lung cancer. <i>Translational Respiratory Medicine</i> , 2015, 3, 1. | 3.8 | 34 |
| 1223 | Notch1 Mutations Are Drivers of Oral Tumorigenesis. <i>Cancer Prevention Research</i> , 2015, 8, 277-286. | 1.5 | 78 |
| 1225 | Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2015, 16, e25-e35. | 2.6 | 100 |
| 1226 | Patient-Derived Xenografts from Nonâ€“Small Cell Lung Cancer Brain Metastases Are Valuable Translational Platforms for the Development of Personalized Targeted Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 1172-1182. | 7.0 | 58 |
| 1227 | Application of clinical bioinformatics in lung cancer-specific biomarkers. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 209-216. | 5.9 | 32 |
| 1228 | An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. <i>Clinical Cancer Research</i> , 2015, 21, 3480-3491. | 7.0 | 48 |
| 1229 | Inhibition of β -Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Nonâ€“small-cell Lung Cancer with a T790M Mutation. <i>Journal of Thoracic Oncology</i> , 2015, 10, 93-101. | 1.1 | 44 |
| 1230 | New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer. <i>Anti-Cancer Drugs</i> , 2015, 26, 1-14. | 1.4 | 43 |
| 1231 | The Association Between Tumor Epidermal Growth Factor Receptor (EGFR) Mutation and Multiple Primary Malignancies in Patients With Adenocarcinoma of the Lungs. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 147-151. | 1.3 | 11 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1232 | Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (INFORM; C-TONG 0804). <i>Journal of Thoracic Oncology</i> , 2015, 10, 655-664. | 1.1 | 36 |
| 1233 | Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous non-small cell lung cancer. <i>Anti-Cancer Drugs</i> , 2015, 26, 456-463. | 1.4 | 6 |
| 1234 | Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (<sc>NSCLC</sc>). <i>Respirology</i> , 2015, 20, 370-378. | 2.3 | 119 |
| 1235 | Management of EGFR mutated nonsmall cell lung carcinoma patients. <i>European Respiratory Journal</i> , 2015, 45, 1132-1141. | 6.7 | 36 |
| 1236 | Novel use for an EGFR mutation-specific antibody in discriminating lung adenocarcinoma from reactive pneumocyte hyperplasia. <i>Histopathology</i> , 2015, 66, 816-823. | 2.9 | 4 |
| 1237 | MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer. <i>Pharmacological Research</i> , 2015, 102, 90-106. | 7.1 | 4 |
| 1238 | Overcoming Resistance to Targeted Therapies in Cancer. <i>Seminars in Oncology</i> , 2015, 42, 896-908. | 2.2 | 36 |
| 1239 | Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. <i>Journal of Structural Biology</i> , 2015, 192, 539-544. | 2.8 | 106 |
| 1240 | Divergent epidermal growth factor receptor mutation patterns between smokers and non-smokers with lung adenocarcinoma. <i>Lung Cancer</i> , 2015, 90, 472-476. | 2.0 | 14 |
| 1241 | Antitumoral Activity of Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations. <i>Molecular Diagnosis and Therapy</i> , 2015, 19, 267-272. | 3.8 | 7 |
| 1242 | Ligand-Independent EGFR Signaling. <i>Cancer Research</i> , 2015, 75, 3436-3441. | 0.9 | 166 |
| 1243 | Differential expression of bone morphogenetic protein 5 in human lung squamous cell carcinoma and adenocarcinoma. <i>Acta Biochimica Et Biophysica Sinica</i> , 2015, 47, 557-563. | 2.0 | 26 |
| 1244 | Genomic Alterations in the RB Pathway Indicate Prognostic Outcomes of Early-Stage Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 2613-2623. | 7.0 | 16 |
| 1245 | Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1553-1566. | 3.1 | 22 |
| 1246 | PTEN and PI3K/AKT in non-small-cell lung cancer. <i>Pharmacogenomics</i> , 2015, 16, 1843-1862. | 1.3 | 180 |
| 1248 | Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2015, 47, 550-555. | 1.4 | 29 |
| 1249 | Analysis of the EGFR gene mutation in patients with nonsmall cell lung cancer in a Chinese population. <i>Tropical Journal of Pharmaceutical Research</i> , 2016, 15, 1637. | 0.3 | 2 |
| 1250 | Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4301-4305. | 2.0 | 21 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1251 | Analysis of ultra-deep targeted sequencing reveals mutation burden is associated with gender and clinical outcome in lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 22857-22864. | 1.8 | 56 |
| 1252 | Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations. <i>OncoTargets and Therapy</i> , 2016, 9, 355. | 2.0 | 4 |
| 1253 | Plasma MiRNA alterations between NSCLC patients harboring Del19 and L858R EGFR mutations. <i>Oncotarget</i> , 2016, 7, 54965-54972. | 1.8 | 6 |
| 1254 | Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing. <i>Oncotarget</i> , 2016, 7, 61755-61763. | 1.8 | 29 |
| 1255 | Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma. <i>Tuberculosis and Respiratory Diseases</i> , 2016, 79, 248. | 1.8 | 41 |
| 1256 | Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 3884-3896. | 1.8 | 34 |
| 1257 | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. <i>Translational Lung Cancer Research</i> , 2016, 5, 563-578. | 2.8 | 30 |
| 1258 | Targeted Therapy in Brain Metastases: Ready for Primetime?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e123-e130. | 3.8 | 35 |
| 1259 | The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. <i>Journal of Thoracic Disease</i> , 2016, 8, 3175-3186. | 1.4 | 4 |
| 1260 | Are there any differences in genomic characterization of non-small cell lung cancer between African Americans and Whites?. <i>Journal of Thoracic Disease</i> , 2016, 8, E1517-E1519. | 1.4 | 1 |
| 1261 | Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer. <i>Mediators of Inflammation</i> , 2016, 2016, 1-11. | 3.0 | 29 |
| 1262 | The prevalence of <i>EGFR</i> mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. <i>Oncotarget</i> , 2016, 7, 78985-78993. | 1.8 | 500 |
| 1263 | Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma. <i>Current Drug Discovery Technologies</i> , 2016, 13, 68-76. | 1.2 | 15 |
| 1264 | Clinical and genetic features of lung squamous cell cancer in never-smokers. <i>Oncotarget</i> , 2016, 7, 35979-35988. | 1.8 | 22 |
| 1265 | Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis. <i>International Journal of Molecular Sciences</i> , 2016, 17, 524. | 4.1 | 28 |
| 1266 | The Clinical Significance of the Insulin-Like Growth Factor-1 Receptor Polymorphism in Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation. <i>International Journal of Molecular Sciences</i> , 2016, 17, 763. | 4.1 | 6 |
| 1267 | Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia. <i>Diagnostic Pathology</i> , 2016, 11, 90. | 2.0 | 9 |
| 1268 | Fragment Length of Circulating Tumor DNA. <i>PLoS Genetics</i> , 2016, 12, e1006162. | 3.5 | 502 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1269 | Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China. PLoS ONE, 2016, 11, e0151846. | 2.5 | 17 |
| 1270 | Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer. PLoS ONE, 2016, 11, e0152317. | 2.5 | 10 |
| 1271 | Comparative Analysis of Clinicopathologic Features of, Treatment in, and Survival of Americans with Lung or Bronchial Cancer. PLoS ONE, 2016, 11, e0156617. | 2.5 | 9 |
| 1272 | Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors. Anti-Cancer Drugs, 2016, 27, 353-363. | 1.4 | 5 |
| 1273 | Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations. Human Molecular Genetics, 2016, 26, ddw414. | 2.9 | 50 |
| 1274 | Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. Journal of Physical Education and Sports Management, 2016, 2, a001263. | 1.2 | 18 |
| 1275 | KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma. American Journal of Surgical Pathology, 2016, 40, 1579-1590. | 3.7 | 50 |
| 1276 | Regulatory mechanisms underlying sepsis progression in patients with tumor necrosis factor- α genetic variations. Experimental and Therapeutic Medicine, 2016, 12, 323-328. | 1.8 | 5 |
| 1277 | The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. Journal of Thoracic Oncology, 2016, 11, 946-963. | 1.1 | 173 |
| 1278 | 6-Oxoxazolidine-quinazolines as noncovalent inhibitors with the potential to target mutant forms of EGFR. Bioorganic and Medicinal Chemistry, 2016, 24, 3359-3370. | 3.0 | 17 |
| 1279 | Changes of serum amino acid profiles by an epidermal growth factor receptor mutation and benzo[a]pyrene in mouse lung tumorigenesis. Toxicology Research, 2016, 5, 1182-1192. | 2.1 | 0 |
| 1280 | Safety of gefitinib in non-small cell lung cancer treatment. Expert Opinion on Drug Safety, 2016, 15, 993-1000. | 2.4 | 14 |
| 1281 | CT Features of Epidermal Growth Factor Receptor-Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, 819-826. | 1.1 | 61 |
| 1282 | Cigarette Smoking, BPDE-DNA Adducts, and Aberrant Promoter Methylations of Tumor Suppressor Genes (TSGs) in NSCLC from Chinese Population. Cancer Investigation, 2016, 34, 173-180. | 1.3 | 17 |
| 1283 | First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial. Clinical Lung Cancer, 2016, 17, 150-160. | 2.6 | 16 |
| 1284 | Q787Q EGFR Polymorphism as a Prognostic Factor for Lung Squamous Cell Carcinoma. Oncology, 2016, 90, 289-298. | 1.9 | 9 |
| 1285 | EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature. Oncology Letters, 2016, 11, 3546-3550. | 1.8 | 14 |
| 1286 | Association between histopathological subtype, 18F-fluorodeoxyglucose uptake and epidermal growth factor receptor mutations in lung adenocarcinoma. Oncology Letters, 2016, 11, 1769-1777. | 1.8 | 10 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1287 | Early Events in the Molecular Pathogenesis of Lung Cancer. Cancer Prevention Research, 2016, 9, 518-527. | 1.5 | 82 |
| 1288 | KRAS-related proteins in pancreatic cancer. , 2016, 168, 29-42. | | 151 |
| 1289 | Clinical approach of intratumoral heterogeneity in lung adenocarcinoma. Two clinical cases with changing somatic driver mutations. Cancer Treatment and Research Communications, 2016, 9, 96-99. | 1.7 | 0 |
| 1290 | XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature, 2016, 538, 114-117. | 27.8 | 162 |
| 1291 | Synthetic lethality in lung cancer and translation to clinical therapies. Molecular Cancer, 2016, 15, 61. | 19.2 | 31 |
| 1292 | Similarities and differences between <sc>E</sc>ast and <sc>W</sc>est in COPD. Respiriology, 2016, 21, 1340-1341. | 2.3 | 8 |
| 1293 | Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. Journal of Clinical Oncology, 2016, 34, 3258-3266. | 1.6 | 153 |
| 1295 | The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope. Future Oncology, 2016, 12, 2713-2727. | 2.4 | 18 |
| 1296 | Gene aberrations for precision medicine against lung adenocarcinoma. Cancer Science, 2016, 107, 713-720. | 3.9 | 174 |
| 1297 | Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma. Annals of Thoracic Surgery, 2016, 102, 1821-1828. | 1.3 | 14 |
| 1298 | MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1381-1383. | 1.1 | 7 |
| 1299 | Study of efficacy and safety of pulsatile administration of highâ€“dose gefitinib or erlotinib for advanced nonâ€“small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial. Thoracic Cancer, 2016, 7, 663-669. | 1.9 | 19 |
| 1300 | Hot spot mutations in Finnish non-small cell lung cancers. Lung Cancer, 2016, 99, 102-110. | 2.0 | 21 |
| 1301 | The impact of epidermal growth factor receptor mutations on patterns of disease recurrence after chemoradiotherapy for locally advanced nonâ€“small cell lung cancer: a literature review and pooled analysis. Journal of Radiation Research, 2016, 57, 449-459. | 1.6 | 13 |
| 1302 | Resistance to Therapy. Cancer Treatment and Research, 2016, 170, 183-202. | 0.5 | 10 |
| 1303 | Trends in Lung Cancer Incidence Rates by Histological Type in 1975–2008: A Population-Based Study in Osaka, Japan. Journal of Epidemiology, 2016, 26, 579-586. | 2.4 | 37 |
| 1304 | Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. British Journal of Cancer, 2016, 115, 1504-1512. | 6.4 | 55 |
| 1305 | The safety of afatinib for the treatment of non-small cell lung cancer. Expert Opinion on Drug Safety, 2016, 15, 1563-1572. | 2.4 | 15 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1306 | Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients. Medical Oncology, 2016, 33, 117. | 2.5 | 13 |
| 1307 | Novel therapeutic targets on the horizon for lung cancer. Lancet Oncology, The, 2016, 17, e347-e362. | 10.7 | 156 |
| 1308 | Identification of potential therapeutic targets for lung cancer by bioinformatics analysis. Molecular Medicine Reports, 2016, 13, 1975-1982. | 2.4 | 15 |
| 1309 | Genetics of Pancreatic Cancer and Its Implications on Therapy. Surgical Clinics of North America, 2016, 96, 1207-1221. | 1.5 | 12 |
| 1310 | Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers. Lung Cancer, 2016, 102, 122-134. | 2.0 | 180 |
| 1311 | Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer. Scientific Reports, 2016, 6, 31636. | 3.3 | 10 |
| 1312 | Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer. Cancer Control, 2016, 23, 338-346. | 1.8 | 78 |
| 1313 | Association between human papillomavirus and EGFR mutations in advanced lung adenocarcinoma. Oncology Letters, 2016, 12, 1953-1958. | 1.8 | 9 |
| 1314 | Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment. Medicine (United States), 2016, 95, e3998. | 1.0 | 30 |
| 1315 | EGFR Exon 20 Insertion/Duplication Mutations Characterize Fibrous Hamartoma of Infancy. American Journal of Surgical Pathology, 2016, 40, 1713-1718. | 3.7 | 52 |
| 1316 | Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance. Oncology Letters, 2016, 11, 393-398. | 1.8 | 10 |
| 1317 | Spectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in Turkey. SpringerPlus, 2016, 5, 482. | 1.2 | 3 |
| 1318 | Epidermal growth factor receptor gene mutation as risk factor for recurrence in patients with surgically resected lung adenocarcinoma: a matched-pair analysis. Interactive Cardiovascular and Thoracic Surgery, 2016, 23, 216-222. | 1.1 | 13 |
| 1319 | Genetic alterations in lung adenocarcinoma with a micropapillary component. Molecular and Clinical Oncology, 2016, 4, 195-200. | 1.0 | 6 |
| 1320 | Gene mutation discovery research of non-smoking lung cancer patients due to indoor radon exposure. Annals of Occupational and Environmental Medicine, 2016, 28, 13. | 1.0 | 16 |
| 1321 | Differential Crizotinib Response Duration Among <i>ALK</i> Fusion Variants in <i>ALK</i> -Positive Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 3383-3389. | 1.6 | 236 |
| 1322 | Does chronic rhinosinusitis increase the risk of lung cancer? A population cohort study. Clinical Respiratory Journal, 2016, 10, 435-439. | 1.6 | 6 |
| 1323 | BioCircos.js: an interactive Circos JavaScript library for biological data visualization on web applications. Bioinformatics, 2016, 32, 1740-1742. | 4.1 | 119 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1324 | Improving Therapeutic Outcomes in Non-small Cell Lung Cancer not Suitable for Curative Intent Therapy – A Review of the Role of Radiation Therapy in an Era of Increasing Systemic Therapy Options. Clinical Oncology, 2016, 28, 327-333. | 1.4 | 4 |
| 1325 | Differential regulation and synthetic lethality of exclusive RB1 and CDKN2A mutations in lung cancer. International Journal of Oncology, 2016, 48, 367-375. | 3.3 | 19 |
| 1326 | Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. Journal of Clinical Oncology, 2016, 34, 91-101. | 1.6 | 146 |
| 1327 | Target Therapy in Lung Cancer. Advances in Experimental Medicine and Biology, 2016, 893, 127-136. | 1.6 | 18 |
| 1329 | Drug – diagnostic co-development: challenges and issues. Expert Review of Molecular Diagnostics, 2016, 16, 187-204. | 3.1 | 4 |
| 1330 | Epidermal growth factor receptor – tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 <scp>L858R</scp> mutation in non – small – cell lung cancer: Systematic review and meta analysis. Thoracic Cancer, 2016, 7, 406-414. | 1.9 | 22 |
| 1331 | Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials. Clinical Oncology, 2016, 28, 283-291. | 1.4 | 3 |
| 1332 | Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Lung Cancer, 2016, 93, 59-68. | 2.0 | 103 |
| 1333 | Skin problems and EGFR-tyrosine kinase inhibitor. Japanese Journal of Clinical Oncology, 2016, 46, 291-298. | 1.3 | 82 |
| 1334 | Personalized chemotherapy of lung cancer: What the radiologist should know. Diagnostic and Interventional Imaging, 2016, 97, 287-296. | 3.2 | 9 |
| 1335 | First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non – Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study. Journal of Thoracic Oncology, 2016, 11, 370-379. | 1.1 | 21 |
| 1336 | Compound <i>EGFR</i> mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. Cancer Biology and Therapy, 2016, 17, 237-245. | 3.4 | 92 |
| 1337 | Drug Resistance to EGFR Inhibitors in Lung Cancer. Chemotherapy, 2016, 61, 223-235. | 1.6 | 57 |
| 1338 | Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer. Molecular BioSystems, 2016, 12, 1552-1563. | 2.9 | 6 |
| 1339 | Wnt signaling as potential therapeutic target in lung cancer. Expert Opinion on Therapeutic Targets, 2016, 20, 999-1015. | 3.4 | 44 |
| 1340 | Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemotherapy and Pharmacology, 2016, 77, 767-776. | 2.3 | 118 |
| 1341 | Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non – Small Cell Lung Cancer: Results of a Phase I Study. Journal of Thoracic Oncology, 2016, 11, 737-747. | 1.1 | 54 |
| 1342 | Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: a preliminary study. Tumor Biology, 2016, 37, 10479-10486. | 1.8 | 13 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1343 | The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2016, 16, 383-390. | 2.4 | 58 |
| 1344 | Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. Journal of Thoracic Oncology, 2016, 11, 556-565. | 1.1 | 268 |
| 1345 | Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer. Expert Review of Respiratory Medicine, 2016, 10, 547-556. | 2.5 | 9 |
| 1346 | Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development. Advances in Experimental Medicine and Biology, 2016, 890, 1-23. | 1.6 | 7 |
| 1347 | Combination nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. Advanced Drug Delivery Reviews, 2016, 98, 3-18. | 13.7 | 399 |
| 1348 | EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET/CT scan. Medical Oncology, 2016, 33, 1. | 2.5 | 64 |
| 1349 | Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer. Critical Reviews in Oncology/Hematology, 2016, 97, 85-95. | 4.4 | 19 |
| 1350 | EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib. Journal of Thoracic Oncology, 2017, 12, 884-889. | 1.1 | 24 |
| 1351 | Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma. Clinical Lung Cancer, 2017, 18, e215-e217. | 2.6 | 5 |
| 1352 | Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures. , 2017, 174, 1-21. | | 123 |
| 1353 | Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White Populations. JAMA Oncology, 2017, 3, 801. | 7.1 | 78 |
| 1354 | Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. Future Oncology, 2017, 13, 1159-1171. | 2.4 | 17 |
| 1355 | Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France. Journal of Thoracic Oncology, 2017, 12, 963-973. | 1.1 | 56 |
| 1356 | Characterization of common and rare mutations in EGFR and associated clinicopathological features in a large population of Chinese patients with lung cancer. Pathology Research and Practice, 2017, 213, 749-758. | 2.3 | 9 |
| 1357 | Current status of research and treatment for non-small cell lung cancer in never-smoking females. Cancer Biology and Therapy, 2017, 18, 359-368. | 3.4 | 66 |
| 1358 | Correlation between epidermal growth factor receptor mutations and the expression of estrogen receptor- β in advanced non-small cell lung cancer. Oncology Letters, 2017, 13, 2359-2365. | 1.8 | 17 |
| 1359 | Dynamic Contrast-enhanced MR Imaging Parameters in Bone Metastases from Non-Small Cell Lung Cancer: Comparison between Lesions with and Lesions without Epidermal Growth Factor Receptor Mutation in Primary Lung Cancer. Radiology, 2017, 284, 815-823. | 7.3 | 14 |
| 1360 | Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations. Clinical Cancer Research, 2017, 23, 4753-4760. | 7.0 | 56 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1361 | Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions. Journal of the National Cancer Institute, 2017, 109, djw295. | 6.3 | 97 |
| 1362 | The Role of ErbB Receptors in Infection. Trends in Microbiology, 2017, 25, 942-952. | 7.7 | 58 |
| 1363 | EGFR, Growth Factors. , 2017, , 707-717. | | 0 |
| 1364 | EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of AŒsimertinib. Journal of Thoracic Oncology, 2017, 12, 1247-1256. | 1.1 | 48 |
| 1365 | Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1376-1387. | 1.1 | 39 |
| 1366 | A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R. Journal of Thoracic Oncology, 2017, 12, 1368-1375. | 1.1 | 79 |
| 1367 | Effects of polymorphisms identified in genome-wide association studies of never-smoking females on the prognosis of non-small cell lung cancer. Cancer Genetics, 2017, 212-213, 8-12. | 0.4 | 7 |
| 1368 | Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs, 2017, 77, 813-827. | 10.9 | 42 |
| 1369 | Clinicopathological and prognostic features of surgically resected pathological stage <sc>I</sc> lung adenocarcinoma harboring epidermal growth factor receptor and <sc>K</sc>-ras mutation. Thoracic Cancer, 2017, 8, 229-237. | 1.9 | 6 |
| 1370 | C-2-(E)-4-(Styryl)aniline substituted diphenylpyrimidine derivatives (Sty-DPPYs) as specific kinase inhibitors targeting clinical resistance related EGFR T790M mutant. Bioorganic and Medicinal Chemistry, 2017, 25, 2724-2729. | 3.0 | 12 |
| 1371 | Molecular biomarkers for lung adenocarcinoma. European Respiratory Journal, 2017, 49, 1601734. | 6.7 | 110 |
| 1372 | P3.02b-105 Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing. Journal of Thoracic Oncology, 2017, 12, S1256-S1257. | 1.1 | 0 |
| 1373 | Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 612-623. | 1.1 | 203 |
| 1374 | Understanding and targeting resistance mechanisms in NSCLC. Nature Reviews Cancer, 2017, 17, 637-658. | 28.4 | 679 |
| 1375 | Predictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in Poland. Oncology Letters, 2017, 14, 5611-5618. | 1.8 | 7 |
| 1376 | Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?. Cancer Treatment Reviews, 2017, 61, 70-81. | 7.7 | 62 |
| 1377 | Sex differences in lung cancer survival: long-term trends using population-based cancer registry data in Osaka, Japan. Japanese Journal of Clinical Oncology, 2017, 47, 863-869. | 1.3 | 28 |
| 1378 | Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 377, 849-861. | 27.0 | 578 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1379 | An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP). Lung Cancer, 2017, 113, 30-36. | 2.0 | 27 |
| 1380 | <i>De novo</i> activating epidermal growth factor mutations (<i>EGFR</i>) in small cell lung cancer. Internal Medicine Journal, 2017, 47, 1071-1074. | 0.8 | 3 |
| 1381 | MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact. Tumor Biology, 2017, 39, 101042831770643. | 1.8 | 16 |
| 1382 | Lung adenocarcinoma patients of young age have lower <i>EGFR</i> mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors. ERJ Open Research, 2017, 3, 00092-2016. | 2.6 | 33 |
| 1383 | Stable Property Clusters and Their Grounds. Philosophy of Science, 2017, 84, 944-955. | 1.0 | 5 |
| 1384 | Meta-analysis of first-line therapies with maintenance regimens for advanced non-small cell lung cancer (NSCLC) in molecularly and clinically selected populations. Cancer Medicine, 2017, 6, 1847-1860. | 2.8 | 23 |
| 1385 | Chimiothérapies personnalisées du cancer bronchique: ce que le radiologue doit connaître. Diagnostic and Interventional Imaging, 2017, 98, 146-156. | 0.0 | 0 |
| 1386 | Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer. Cancer Letters, 2017, 405, 100-110. | 7.2 | 90 |
| 1387 | Brain metastases in non-small cell lung cancer patients on epidermal growth factor receptor tyrosine kinase inhibitors: symptom and economic burden. Journal of Medical Economics, 2017, 20, 1136-1147. | 2.1 | 21 |
| 1388 | Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. Journal of Thoracic Oncology, 2017, 12, 1588-1594. | 1.1 | 21 |
| 1389 | Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?. Current Opinion in Oncology, 2017, 29, 89-96. | 2.4 | 13 |
| 1390 | Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1979-1986. | 2.3 | 10 |
| 1391 | Chemotherapeutics-resistance arms-race: An update on mechanisms involved in resistance limiting EGFR inhibitors in lung cancer. Life Sciences, 2017, 186, 25-32. | 4.3 | 17 |
| 1392 | Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma. Lung Cancer, 2017, 114, 23-30. | 2.0 | 12 |
| 1393 | <i>In vivo</i> imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs. Cancer Medicine, 2017, 6, 2972-2983. | 2.8 | 2 |
| 1394 | Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β -blockers. Science Translational Medicine, 2017, 9, . | 12.4 | 96 |
| 1395 | EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs. Cancer Letters, 2017, 403, 186-194. | 7.2 | 27 |
| 1396 | Application of Immunohistochemistry in the Diagnosis of Pulmonary and Pleural Neoplasms. Archives of Pathology and Laboratory Medicine, 2017, 141, 1195-1213. | 2.5 | 20 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1397 | The level of serum carcinoembryonic antigen is a surrogate marker for the efficacy of EGFR-TKIs but is not an indication of acquired resistance to EGFR-TKIs in NSCLC patients with EGFR mutationsm. Biomedical Reports, 2017, 7, 61-66. | 2.0 | 5 |
| 1398 | Sex-specific incidence of EGFR mutation and its association with age and obesity in lung adenocarcinomas: a retrospective analysis. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2283-2290. | 2.5 | 13 |
| 1399 | O6-methyl-guanine-DNA methyltransferase methylation and IDH1/2 mutation in small cell lung cancer. Experimental and Therapeutic Medicine, 2017, 14, 398-402. | 1.8 | 5 |
| 1400 | Comprehensive study of mutational and clinicopathologic characteristics of adenocarcinoma with lepidic pattern in surgical resected lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2017, 143, 181-186. | 2.5 | 4 |
| 1401 | Capilliposide from <i>Lysimachia capillipes</i> inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance. Acta Pharmacologica Sinica, 2017, 38, 100-109. | 6.1 | 14 |
| 1402 | In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma. Oncogene, 2017, 36, 2309-2318. | 5.9 | 27 |
| 1403 | Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages. Clinical Cancer Research, 2017, 23, 778-788. | 7.0 | 38 |
| 1404 | Lung cancer: current therapies and new targeted treatments. Lancet, The, 2017, 389, 299-311. | 13.7 | 2,267 |
| 1405 | Pathology and Molecular Pathology of Lung Cancer. , 2017, , 367-390. | | 1 |
| 1406 | Clinical Implications of the Autophagy Core Gene Variations in Advanced Lung Adenocarcinoma Treated with Gefitinib. Scientific Reports, 2017, 7, 17814. | 3.3 | 24 |
| 1407 | The Importance of EGFR Mutation Detection Method for the Correct Clinical Management of Patients with Non-Small Cell Lung Cancer: A Case Report. , 2017, 07, . | | 0 |
| 1408 | Comparison of clinical and radiological characteristics between anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in treatment naïve advanced lung adenocarcinoma. Journal of Thoracic Disease, 2017, 9, 3927-3937. | 1.4 | 11 |
| 1409 | Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. International Journal of Molecular Sciences, 2017, 18, 2420. | 4.1 | 102 |
| 1410 | Lipid-Based Nanoparticles for Targeted Drug Delivery of Anticancer Drug. , 2017, , 287-321. | | 2 |
| 1411 | Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers, 2017, 9, 52. | 3.7 | 1,153 |
| 1412 | Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2017, 7, 113. | 2.8 | 46 |
| 1413 | Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification. Frontiers in Oncology, 2017, 7, 193. | 2.8 | 343 |
| 1414 | Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Cancer, 2017, 8, 227-239. | 2.5 | 18 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1415 | Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291). <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1757-1766. | 2.0 | 18 |
| 1416 | Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma. <i>Oncology Letters</i> , 2017, 15, 3295-3304. | 1.8 | 9 |
| 1417 | Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4989-4995. | 2.0 | 19 |
| 1418 | Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists. <i>Korean Journal of Radiology</i> , 2017, 18, 6. | 3.4 | 12 |
| 1419 | Combining PET/CT with serum tumor markers to improve the evaluation of histological type of suspicious lung cancers. <i>PLoS ONE</i> , 2017, 12, e0184338. | 2.5 | 8 |
| 1420 | Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma. <i>PLoS ONE</i> , 2017, 12, e0175622. | 2.5 | 20 |
| 1421 | Genetic variation in the eicosanoid pathway is associated with non-small-cell lung cancer (NSCLC) survival. <i>PLoS ONE</i> , 2017, 12, e0180471. | 2.5 | 8 |
| 1422 | The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?. <i>Annals of Translational Medicine</i> , 2017, 5, 46-46. | 1.7 | 209 |
| 1423 | BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations. <i>Oncotarget</i> , 2017, 8, 39945-39962. | 1.8 | 29 |
| 1424 | Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed+carboplatin chemotherapy. <i>Ecancermedicalscience</i> , 2017, 11, 776. | 1.1 | 2 |
| 1425 | Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors. <i>Wspolczesna Onkologia</i> , 2017, 3, 254-258. | 1.4 | 8 |
| 1426 | Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. <i>Oncotarget</i> , 2017, 8, 11114-11126. | 1.8 | 22 |
| 1428 | Comment on prognostic value of epidermal growth factor receptor mutation subtypes in surgically resected non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, E499-E502. | 1.4 | 0 |
| 1429 | Overview of current systemic management of EGFR-mutant NSCLC. <i>Annals of Oncology</i> , 2018, 29, i3-i9. | 1.2 | 229 |
| 1430 | Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 2138-2147. | 7.0 | 21 |
| 1431 | Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2018, 105, 1648-1654. | 1.3 | 18 |
| 1432 | Clinicopathological analysis of Large Cell Lung Carcinomas definitely diagnosed according to the New World Health Organization Criteria. <i>Pathology Research and Practice</i> , 2018, 214, 555-559. | 2.3 | 4 |
| 1433 | Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 3097-3107. | 7.0 | 357 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1434 | First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance. <i>Journal of Thoracic Oncology</i> , 2018, 13, 968-977. | 1.1 | 50 |
| 1435 | Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients. <i>Journal of Immunotherapy</i> , 2018, 41, 292-299. | 2.4 | 30 |
| 1436 | OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer. <i>BMJ Open</i> , 2018, 8, e020128. | 1.9 | 11 |
| 1437 | Transformation to small-cell lung cancer following treatment with icotinib in a patient with lung adenocarcinoma. <i>Oncology Letters</i> , 2018, 15, 5799-5802. | 1.8 | 7 |
| 1438 | Concomitance of EGFR mutations and ALK rearrangement in patients with Lung Cancer. <i>Gene Reports</i> , 2018, 11, 196-204. | 0.8 | 2 |
| 1439 | Characterization of two splice variants of EGFR and their effects on the growth of the razor clam. <i>Aquaculture and Fisheries</i> , 2018, 3, 62-71. | 2.2 | 5 |
| 1440 | Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 323-358. | 1.1 | 408 |
| 1441 | Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 321-346. | 2.5 | 586 |
| 1442 | EFEMP2. , 2018, , 1502-1502. | | 0 |
| 1443 | Epidermal Surface Antigen (ESA). , 2018, , 1603-1603. | | 0 |
| 1444 | Sequencing of circulating tumor DNA for dynamic monitoring of gene mutations in advanced non-small cell lung cancer. <i>Oncology Letters</i> , 2018, 15, 3726-3734. | 1.8 | 6 |
| 1445 | Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing. <i>Nature Communications</i> , 2018, 9, 216. | 12.8 | 136 |
| 1446 | ETA Type Endothelin Receptor. , 2018, , 1653-1653. | | 0 |
| 1447 | Validation of the digital PCR system in tyrosine kinase inhibitor-resistant <i>EGFR</i> mutant non-small-cell lung cancer. <i>Pathology International</i> , 2018, 68, 167-173. | 1.3 | 6 |
| 1448 | Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer. <i>Targeted Oncology</i> , 2018, 13, 141-156. | 3.6 | 17 |
| 1449 | Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 129-159. | 2.8 | 241 |
| 1450 | Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 211-220. | 2.8 | 24 |
| 1451 | Personalized Lung Cancer Treatment: A Teamwork. , 2018, , 333-348. | | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1452 | PD-L1 expression according to the EGFR status in primary lung adenocarcinoma. Lung Cancer, 2018, 116, 1-6. | 2.0 | 51 |
| 1453 | Population-based differences in the outcome and presentation of lung cancer patients based upon racial, histologic, and economic factors in all lung patients and those with metastatic disease. Cancer Medicine, 2018, 7, 1211-1220. | 2.8 | 22 |
| 1454 | EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China. Thoracic Cancer, 2018, 9, 814-819. | 1.9 | 42 |
| 1455 | Influence of wellness education on first-line icotinib hydrochloride patients with stage IV non-small cell lung cancer and their family caregivers. Current Problems in Cancer, 2018, 42, 358-366. | 2.0 | 8 |
| 1456 | Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea. Lung Cancer, 2018, 119, 36-41. | 2.0 | 7 |
| 1457 | A Decade of Never-smokers Among Lung Cancer Patients: Increasing Trend and Improved Survival. Clinical Lung Cancer, 2018, 19, e539-e550. | 2.6 | 21 |
| 1458 | Assessment of EGFR mutation status in Tunisian patients with pulmonary adenocarcinoma. Current Research in Translational Medicine, 2018, 66, 65-70. | 1.8 | 12 |
| 1459 | Fluorometric detection of EGFR exon 19 deletion mutation in lung cancer cells using graphene oxide. Analyst, The, 2018, 143, 1797-1804. | 3.5 | 13 |
| 1460 | Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib. Clinical Lung Cancer, 2018, 19, e431-e438. | 2.6 | 14 |
| 1461 | Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors. Clinical and Translational Oncology, 2018, 20, 140-149. | 2.4 | 3 |
| 1462 | A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2018, 19, 27-34. | 2.6 | 21 |
| 1463 | Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations. Molecular Cancer Therapeutics, 2018, 17, 17-25. | 4.1 | 37 |
| 1464 | Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?. Journal of Cancer Research and Clinical Oncology, 2018, 144, 165-171. | 2.5 | 6 |
| 1465 | Lung Cancer in Never-Smokers. , 2018, , 23-29.e3. | | 5 |
| 1466 | Clinical Presentation and Prognostic Factors in Lung Cancer. , 2018, , 186-198.e6. | | 0 |
| 1467 | Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer. Journal of Medical Economics, 2018, 21, 113-121. | 2.1 | 30 |
| 1468 | Comparison of genome-wide analysis techniques to DNA methylation analysis in human cancer. Journal of Cellular Physiology, 2018, 233, 3968-3981. | 4.1 | 32 |
| 1469 | Molecular Diagnosis and Targeting for Lung Cancer. Current Human Cell Research and Applications, 2018, , 1-32. | 0.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1471 | Associations between clinical data and computed tomography features in patients with epidermal growth factor receptor mutations in lung adenocarcinoma. International Journal of Clinical Oncology, 2018, 23, 249-257. | 2.2 | 7 |
| 1472 | NSCLC Patients Harboring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy. Respiration, 2018, 95, 169-176. | 2.6 | 14 |
| 1473 | Phosphorylation of Mig6 negatively regulates the ubiquitination and degradation of EGFR mutants in lung adenocarcinoma cell lines. Cellular Signalling, 2018, 43, 21-31. | 3.6 | 14 |
| 1474 | Discovery of anilino-furo[2,3- d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity. European Journal of Medicinal Chemistry, 2018, 144, 330-348. | 5.5 | 30 |
| 1475 | EGFR Mutation Detection and Its Association With Clinicopathological Characters of Lung Cancer Patients. World Journal of Oncology, 2018, 9, 151-155. | 1.5 | 12 |
| 1476 | Integrative Bioinformatics Analysis Reveals Potential Long Non-Coding RNA Biomarkers and Analysis of Function in Non-Smoking Females with Lung Cancer. Medical Science Monitor, 2018, 24, 5771-5778. | 1.1 | 34 |
| 1477 | Inherited lung cancer syndromes targeting never smokers. Translational Lung Cancer Research, 2018, 7, 498-504. | 2.8 | 31 |
| 1478 | Therapeutic bronchoscopy in the era of genotype directed lung cancer management. Journal of Thoracic Disease, 2018, 10, 6298-6309. | 1.4 | 16 |
| 1479 | Value of combining serum carcinoembryonic antigen and PET/CT in predicting EGFR mutation in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 723-731. | 1.4 | 20 |
| 1480 | A combined subtype of small cell lung cancer and adenocarcinoma with epidermal growth factor receptor (EGFR) mutation responds to EGFR tyrosine kinase inhibitors. Journal of Thoracic Disease, 2018, 10, E739-E743. | 1.4 | 1 |
| 1481 | Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. JCO Precision Oncology, 2018, 2, 1-11. | 3.0 | 2 |
| 1482 | CT-pathologic correlation in lung adenocarcinoma and squamous cell carcinoma. Medicine (United States), 2018, 97, e13809. | 1.0 | 13 |
| 1483 | Essential roles of mitochondrial and heme function in lung cancer bioenergetics and tumorigenesis. Cell and Bioscience, 2018, 8, 56. | 4.8 | 31 |
| 1484 | Clinical factors associated with mortality within three months after radiosurgery of asymptomatic brain metastases from non-small cell lung cancer. Journal of Neuro-Oncology, 2018, 140, 705-715. | 2.9 | 5 |
| 1485 | Nonsmall cell lung cancer with rare exon 7 p.A289V mutation in the EGFR gene responds to Icotinib treatment. Medicine (United States), 2018, 97, e13809. | 1.0 | 12 |
| 1486 | Nile Tilapia Derived TP4 Shows Broad Cytotoxicity Toward to Non-Small-Cell Lung Cancer Cells. Marine Drugs, 2018, 16, 506. | 4.6 | 17 |
| 1487 | Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors. Oncotarget, 2018, 9, 1641-1655. | 1.8 | 25 |
| 1488 | Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation. Analytical Cellular Pathology, 2018, 2018, 1-9. | 1.4 | 35 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1489 | Real-world EGFR testing in patients with stage IIIB/IV non-small cell lung cancer in North China: A multicenter, non-interventional study. <i>Thoracic Cancer</i> , 2018, 9, 1461-1469. | 1.9 | 28 |
| 1490 | Analysis of Racial/Ethnic Representation in Select Basic and Applied Cancer Research Studies. <i>Scientific Reports</i> , 2018, 8, 13978. | 3.3 | 105 |
| 1491 | Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment. <i>DNA and Cell Biology</i> , 2018, 37, 903-908. | 1.9 | 2 |
| 1492 | Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas. <i>Advances in Anatomic Pathology</i> , 2018, 25, 374-386. | 4.3 | 15 |
| 1493 | Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures. <i>Pathology Research and Practice</i> , 2018, 214, 2103-2105. | 2.3 | 7 |
| 1494 | Significance of the epidermal growth factor receptor mutation status and differences among molecular subgroups in surgically resected lung microinvasive adenocarcinoma. <i>Oncology Letters</i> , 2018, 16, 7057-7067. | 1.8 | 3 |
| 1495 | Identification of genes and analysis of prognostic values in nonsmoking females with non-small cell lung carcinoma by bioinformatics analyses. <i>Cancer Management and Research</i> , 2018, Volume 10, 4287-4295. | 1.9 | 20 |
| 1496 | EGFR-TKI-sensitive mutations in lung carcinomas: are they related to clinical features and CT findings?. <i>Cancer Management and Research</i> , 2018, Volume 10, 4019-4027. | 1.9 | 6 |
| 1497 | The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 226. | 8.6 | 107 |
| 1498 | Multiple treatment modalities for brain metastasis in patients with EGFR-mutant non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2149-2155. | 2.0 | 10 |
| 1499 | Detection of Rare Mutations in EGFR-ARMS-PCR-Negative Lung Adenocarcinoma by Sanger Sequencing. <i>Yonsei Medical Journal</i> , 2018, 59, 13. | 2.2 | 10 |
| 1500 | Clinicopathological and genetic characteristics associated with brain metastases from lung adenocarcinoma and utility as prognostic factors. <i>Oncology Letters</i> , 2018, 16, 4243-4252. | 1.8 | 6 |
| 1501 | A curated target gene pool assisting disease prediction and patient-specific biomarker selection for lung squamous cell carcinoma. <i>Oncology Letters</i> , 2018, 16, 5140-5146. | 1.8 | 16 |
| 1502 | Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1601-1611. | 2.5 | 8 |
| 1503 | Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer. <i>Targeted Oncology</i> , 2018, 13, 389-398. | 3.6 | 2 |
| 1504 | An Observational Study Evaluating the Performance of LENT Score in the Selected Population of Malignant Pleural Effusion from Lung Adenocarcinoma in Singapore. <i>Respiration</i> , 2018, 96, 308-313. | 2.6 | 17 |
| 1505 | Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2018, 69, 143-151. | 7.7 | 23 |
| 1506 | Exosome-mediated transfer of lncRNA RP11-838N2.4 promotes erlotinib resistance in non-small cell lung cancer. <i>International Journal of Oncology</i> , 2018, 53, 527-538. | 3.3 | 74 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1507 | The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2345-2353. | 2.0 | 9 |
| 1508 | Small Molecules in Oncology. <i>Recent Results in Cancer Research</i> , 2018, , . | 1.8 | 5 |
| 1509 | Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients. <i>Frontiers in Pharmacology</i> , 2018, 9, 360. | 3.5 | 9 |
| 1510 | Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, T790M, and Clinical Trials. <i>Current Oncology</i> , 2018, 25, 28-37. | 2.2 | 23 |
| 1511 | Gefitinib. <i>Recent Results in Cancer Research</i> , 2018, 211, 235-246. | 1.8 | 68 |
| 1512 | Update on Immunohistochemistry for the Diagnosis of Lung Cancer. <i>Cancers</i> , 2018, 10, 72. | 3.7 | 94 |
| 1513 | Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506). <i>Lung Cancer</i> , 2018, 123, 7-13. | 2.0 | 2 |
| 1514 | Outcome of advanced lung cancer with central airway obstruction <i>versus</i> without central airway obstruction. <i>ERJ Open Research</i> , 2018, 4, 00173-2017. | 2.6 | 12 |
| 1515 | Clinicopathological Characteristics and Mutations Driving Development of Early Lung Adenocarcinoma: Tumor Initiation and Progression. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1259. | 4.1 | 98 |
| 1516 | TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1648-1658. | 4.1 | 64 |
| 1517 | Kinase-targeted cancer therapies: progress, challenges and future directions. <i>Molecular Cancer</i> , 2018, 17, 48. | 19.2 | 796 |
| 1518 | Xenograft tumors derived from malignant pleural effusion of the patients with nonâ€smallâ€cell lung cancer as models to explore drug resistance. <i>Cancer Communications</i> , 2018, 38, 1-12. | 9.2 | 14 |
| 1519 | Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). <i>Annals of Translational Medicine</i> , 2018, 6, 144-144. | 1.7 | 19 |
| 1520 | Notch3-dependent β -catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. <i>Nature Communications</i> , 2018, 9, 3198. | 12.8 | 61 |
| 1521 | A Nexus model of cellular transition in cancer. <i>Biological Research</i> , 2018, 51, 23. | 3.4 | 1 |
| 1522 | Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 513-521. | 2.8 | 12 |
| 1523 | EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry. <i>BMC Pulmonary Medicine</i> , 2018, 18, 132. | 2.0 | 8 |
| 1524 | LncRNAs and β -catenin sequestered in TEPs enable blood-based NSCLC diagnosis. <i>Cancer Management and Research</i> , 2018, Volume 10, 1449-1459. | 1.9 | 38 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1525 | Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 529-538. | 2.0 | 13 |
| 1526 | Molecular Basis of Pulmonary Disease. , 2018, , 347-386. | | 0 |
| 1527 | The prognostic effect of the epidermal growth factor receptor gene mutation on recurrence dynamics of lung adenocarcinoma. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 54, 1022-1027. | 1.4 | 6 |
| 1528 | Pulmonary Adenocarcinoma, Harboring Both an <i>EGFR</i> Mutation and <i>ALK</i> Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib. <i>Internal Medicine</i> , 2018, 57, 2377-2382. | 0.7 | 5 |
| 1529 | Molecular designing, virtual screening and docking study of novel curcumin analogue as mutation (S769L and K846R) selective inhibitor for EGFR. <i>Saudi Journal of Biological Sciences</i> , 2019, 26, 439-448. | 3.8 | 20 |
| 1530 | Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib. <i>Supportive Care in Cancer</i> , 2019, 27, 1029-1039. | 2.2 | 4 |
| 1531 | AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 756-767. | 2.6 | 29 |
| 1532 | Prognostic implication of EGFR mutation status and subtype in resected lung adenocarcinoma patients irrespective of therapy. <i>Clinical and Translational Oncology</i> , 2019, 21, 298-303. | 2.4 | 9 |
| 1533 | TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer. <i>PLoS ONE</i> , 2019, 14, e0220173. | 2.5 | 6 |
| 1534 | Permutation-based simultaneous confidence bounds for the false discovery proportion. <i>Biometrika</i> , 2019, 106, 635-649. | 2.4 | 24 |
| 1535 | Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines. <i>Cells</i> , 2019, 8, 878. | 4.1 | 17 |
| 1536 | Role of tumor gene mutations in treatment response to immune checkpoint blockades. <i>Precision Clinical Medicine</i> , 2019, 2, 100-109. | 3.3 | 11 |
| 1537 | Deep targeted sequencing analysis of hot spot mutations in non-small cell lung cancer patients from the Middle Eastern population. <i>Journal of Thoracic Disease</i> , 2019, 11, 2383-2391. | 1.4 | 3 |
| 1538 | Association of <i>EGFR</i> mutations and <i>HMGB1</i> genetic polymorphisms in lung adenocarcinoma patients. <i>Journal of Cancer</i> , 2019, 10, 2907-2914. | 2.5 | 14 |
| 1539 | Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. <i>Lung Cancer</i> , 2019, 135, 66-72. | 2.0 | 22 |
| 1540 | Effect of Wellness Education on Quality of Life of Patients With Nonâ€“Small Cell Lung Cancer Treated With First-Line Icotinib and on Their Family Caregivers. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541984237. | 2.0 | 12 |
| 1541 | Increased EGFR mRNA Expression Levels in Non-Small Cell Lung Cancer. <i>Eurasian Journal of Medicine</i> , 2019, 51, 176-184. | 0.6 | 6 |
| 1542 | EGFR Targeted Therapy. <i>Current Cancer Research</i> , 2019, , 1-30. | 0.2 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1543 | Lung genotoxicity of benzo(a)pyrene in vivo involves reactivation of LINE-1 retrotransposon and early reprogramming of oncogenic regulatory networks. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L816-L822. | 2.9 | 3 |
| 1544 | A multiple signal amplification electrochemical biosensors based on target DNA recycling for detection of the EGFR mutation status in lung cancer patients. Journal of Electroanalytical Chemistry, 2019, 853, 113555. | 3.8 | 6 |
| 1545 | The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706). Cancer Communications, 2019, 39, 69. | 9.2 | 19 |
| 1546 | Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review. BMC Cancer, 2019, 19, 1068. | 2.6 | 31 |
| 1547 | <p></p>Landscape on CT screening for lung cancer in Asia</p>. Lung Cancer: Targets and Therapy, 2019, Volume 10, 107-124. | 2.7 | 20 |
| 1548 | Prognostic value of adjuvant therapy in T4 non-small cell lung cancer: An inverse probability of treatment weighting analysis. Thoracic Cancer, 2019, 10, 472-482. | 1.9 | 3 |
| 1549 | Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors. European Journal of Cancer, 2019, 119, 77-86. | 2.8 | 23 |
| 1550 | Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma. Clinical Cancer Research, 2019, 25, 5866-5877. | 7.0 | 24 |
| 1551 | Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. BMC Cancer, 2019, 19, 896. | 2.6 | 33 |
| 1552 | Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor. Journal of Thoracic Oncology, 2019, 14, 1766-1783. | 1.1 | 30 |
| 1553 | Mechanism of Resistance to Third-Generation Inhibitors. , 2019, , 163-171. | | 1 |
| 1554 | Conclusion and Future Perspectives. , 2019, , 179-181. | | 0 |
| 1555 | Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer. Future Oncology, 2019, 15, 805-816. | 2.4 | 32 |
| 1556 | <p></p>Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial</p>. Cancer Management and Research, 2019, Volume 11, 4449-4459. | 1.9 | 5 |
| 1557 | Potential Influence on Clinical Trials of Long-Term Survivors of Stage IV Non-small cell Lung Cancer. JNCI Cancer Spectrum, 2019, 3, pkz010. | 2.9 | 8 |
| 1558 | A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the third-generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers. Basic and Clinical Pharmacology and Toxicology, 2019, 125, 370-381. | 2.5 | 9 |
| 1559 | Prognostic significance of GAD1 overexpression in patients with resected lung adenocarcinoma. Cancer Medicine, 2019, 8, 4189-4199. | 2.8 | 16 |
| 1560 | The p53/miR-193a/EGFR feedback loop function as a driving force for non-small cell lung carcinoma tumorigenesis. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985066. | 3.2 | 17 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1561 | MET in glioma: signaling pathways and targeted therapies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 270. | 8.6 | 99 |
| 1562 | The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies. <i>Diagnostic Pathology</i> , 2019, 14, 59. | 2.0 | 17 |
| 1564 | Molecular profile of non-small cell lung cancer in northeastern Brazil. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20180181. | 0.7 | 12 |
| 1565 | Frequency and significance of epidermal growth factor receptor mutations detected by PCR methods in patients with non-small cell lung cancer. <i>Oncology Letters</i> , 2019, 17, 5125-5131. | 1.8 | 6 |
| 1566 | An endothelial growth factor receptor compound mutation of T790M substitution with exon 19 deletion in a previously untreated patient: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 144. | 0.8 | 0 |
| 1567 | Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. <i>Cancer Discovery</i> , 2019, 9, 926-943. | 9.4 | 220 |
| 1568 | Targeted methods for molecular characterization of EGFR mutational profile in lung cancer Moroccan cohort. <i>Gene</i> , 2019, 705, 36-43. | 2.2 | 5 |
| 1569 | Implementation planning for lung cancer screening in China. <i>Precision Clinical Medicine</i> , 2019, 2, 13-44. | 3.3 | 28 |
| 1570 | Re-biopsy and liquid biopsy for patients with non-small cell lung cancer after EGFR tyrosine kinase inhibitor failure. <i>Thoracic Cancer</i> , 2019, 10, 957-965. | 1.9 | 25 |
| 1571 | Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma. <i>BMC Cancer</i> , 2019, 19, 175. | 2.6 | 1 |
| 1572 | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 547-559. | 2.4 | 22 |
| 1573 | Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 5. | 17.1 | 231 |
| 1574 | Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 1767-1775. | 1.1 | 10 |
| 1575 | Tobacco Smoking Modifies the Association between Hormonal Factors and Lung Cancer Occurrence among Post-Menopausal Chinese Women. <i>Translational Oncology</i> , 2019, 12, 819-827. | 3.7 | 11 |
| 1576 | The Diagnostic Value of Quantitative CT Analysis of Ground-Glass Volume Percentage in Differentiating Epidermal Growth Factor Receptor Mutation and Subtypes in Lung Adenocarcinoma. <i>BioMed Research International</i> , 2019, 2019, 1-8. | 1.9 | 4 |
| 1577 | Osimertinib Did Not Respond to a Pulmonary Adenocarcinoma with Triple Mutations of Epidermal Growth Factor Receptor, G719S, T790M and S768I. <i>Case Reports in Oncology</i> , 2019, 12, 178-182. | 0.7 | 1 |
| 1578 | Clinical development of targeted and immune based anti-cancer therapies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 156. | 8.6 | 170 |
| 1579 | Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 671-675. | 1.3 | 17 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1580 | Clinical features and treatment of patients with lung adenocarcinoma with bone marrow metastasis. <i>Tumori</i> , 2019, 105, 388-393. | 1.1 | 15 |
| 1581 | Discovery Stories of RET Fusions in Lung Cancer: A Mini-Review. <i>Frontiers in Physiology</i> , 2019, 10, 216. | 2.8 | 33 |
| 1582 | Genetic and Immunohistochemical Studies Investigating the Histogenesis of Neuroendocrine and Carcinomatous Components of Combined Neuroendocrine Carcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 1744-1750. | 1.5 | 4 |
| 1583 | Novel mechanism of resistance to targeted therapies in lung cancer. <i>Molecular and Cellular Oncology</i> , 2019, 6, 1551015. | 0.7 | 1 |
| 1584 | Disparities and Trends in Genetic Testing and Erlotinib Treatment among Metastatic Non-Small Cell Lung Cancer Patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 926-934. | 2.5 | 27 |
| 1585 | Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations. <i>Investigational New Drugs</i> , 2019, 37, 1207-1217. | 2.6 | 6 |
| 1586 | First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease. <i>Journal of Cancer</i> , 2019, 10, 522-529. | 2.5 | 43 |
| 1587 | Genetic and epigenetic alterations of the EGFR and mutually independent association with BRCA1, MGMT, and RASSF1A methylations in Vietnamese lung adenocarcinomas. <i>Pathology Research and Practice</i> , 2019, 215, 885-892. | 2.3 | 10 |
| 1588 | The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2019, 19, 145. | 2.6 | 47 |
| 1589 | Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 867-875. | 1.1 | 260 |
| 1590 | Genotyping and cytomorphological subtyping of lung adenocarcinoma based on liquid-based cytology. <i>Diagnostic Cytopathology</i> , 2019, 47, 564-570. | 1.0 | 9 |
| 1591 | Significant differences in T cell receptor repertoires in lung adenocarcinomas with and without epidermal growth factor receptor mutations. <i>Cancer Science</i> , 2019, 110, 867-874. | 3.9 | 17 |
| 1592 | Non-Smoking-Associated Lung Cancer: A distinct Entity in Terms of Tumor Biology, Patient Characteristics and Impact of Hereditary Cancer Predisposition. <i>Cancers</i> , 2019, 11, 204. | 3.7 | 48 |
| 1593 | Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations. <i>Scientific Reports</i> , 2019, 9, 3209. | 3.3 | 38 |
| 1594 | Mechanisms of resistance to pemetrexed in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 1107-1118. | 2.8 | 34 |
| 1595 | Radiographic appearance of leptomeningeal disease in patients with EGFR-mutated non-small-cell lung carcinoma treated with tyrosine kinase inhibitors: a case series. <i>CNS Oncology</i> , 2019, 8, CNS42. | 3.0 | 3 |
| 1596 | High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. , 2019, 7, 351. | | 39 |
| 1597 | Assessing EGFR gene mutation status in non-small cell lung cancer with imaging features from PET/CT. <i>Nuclear Medicine Communications</i> , 2019, 40, 842-849. | 1.1 | 30 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1598 | Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib. <i>Medicine (United States)</i> , 2019, 98, e13890. | 1.0 | 14 |
| 1599 | Epidermal growth factor receptor first generation tyrosine-kinase inhibitors. <i>Translational Lung Cancer Research</i> , 2019, 8, S235-S246. | 2.8 | 8 |
| 1600 | The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 61. | 17.1 | 436 |
| 1601 | Comparison of next-generation sequencing and immunohistochemistry analysis for targeted therapy-related genomic status in lung cancer patients. <i>Journal of Thoracic Disease</i> , 2019, 11, 4992-5003. | 1.4 | 14 |
| 1602 | Knowledge base toward understanding actionable alterations and realizing precision oncology. <i>International Journal of Clinical Oncology</i> , 2019, 24, 123-130. | 2.2 | 9 |
| 1603 | Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 174-182. | 2.5 | 15 |
| 1604 | Emerging drugs for EGFR-mutated non-small cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 5-16. | 2.4 | 10 |
| 1605 | Prediction of EGFR mutations by conventional CT-features in advanced pulmonary adenocarcinoma. <i>European Journal of Radiology</i> , 2019, 112, 44-51. | 2.6 | 11 |
| 1606 | Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients. <i>Lung Cancer</i> , 2019, 127, 25-33. | 2.0 | 13 |
| 1607 | Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications. <i>Seminars in Cancer Biology</i> , 2019, 54, 14-28. | 9.6 | 51 |
| 1608 | Survival Disparities in Black Patients With EGFR-mutated Nonâ€‘small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 177-185. | 2.6 | 10 |
| 1609 | Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Nonâ€‘small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. <i>Clinical Lung Cancer</i> , 2020, 21, 1-14.e3. | 2.6 | 19 |
| 1610 | Cancer of the Lung. , 2020, , 1108-1158.e16. | | 11 |
| 1612 | Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis. <i>European Journal of Cancer</i> , 2020, 124, 1-14. | 2.8 | 32 |
| 1613 | Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision. <i>Lung Cancer</i> , 2020, 139, 35-40. | 2.0 | 35 |
| 1614 | Brain malignancies: Glioblastoma and brain metastases. <i>Seminars in Cancer Biology</i> , 2020, 60, 262-273. | 9.6 | 208 |
| 1615 | Precision medicine at the academic-industry interface. , 2020, , 545-560. | | 1 |
| 1616 | From clinical specimens to human cancer preclinical modelsâ€‘a journey the NCIâ€‘cell line databaseâ€‘25 years later. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 3986-3999. | 2.6 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1617 | Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e191-e204. | 2.6 | 26 |
| 1618 | mPR1± mediates P4/Org OD02 to improve the sensitivity of lung adenocarcinoma to EGFR-TKIs via the EGFR-SRC-ERK1/2 pathway. <i>Molecular Carcinogenesis</i> , 2020, 59, 179-192. | 2.7 | 10 |
| 1619 | Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. <i>Lung Cancer</i> , 2020, 139, 207-215. | 2.0 | 79 |
| 1620 | Reproductive factors and lung cancer risk: a comprehensive systematic review and meta-analysis. <i>BMC Public Health</i> , 2020, 20, 1458. | 2.9 | 14 |
| 1621 | Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 T</i> | 1.6 | 1 |
| 1622 | Frequency and types of EGFR mutations in Moroccan patients with non-small cell lung cancer. <i>Tumori</i> , 2021, 107, 335-340. | 1.1 | 7 |
| 1623 | Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis. <i>Lung Cancer</i> , 2020, 150, 83-89. | 2.0 | 9 |
| 1624 | Magnetic Iron Nanocubes Effectively Capture Epithelial and Mesenchymal Cancer Cells. <i>ACS Omega</i> , 2020, 5, 23724-23735. | 3.5 | 2 |
| 1625 | Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation. <i>Clinical Lung Cancer</i> , 2020, 21, 273-280.e4. | 2.6 | 21 |
| 1626 | Predictors of Acquired EGFR T790M Mutation in Patients Failing First- or Second-Generation EGFR-TKIs: A Retrospective Cohort Study. <i>Cancer Management and Research</i> , 2020, Volume 12, 5439-5450. | 1.9 | 8 |
| 1627 | Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2020, 150, 178-185. | 2.0 | 18 |
| 1628 | How should molecular findings be integrated in the classification for lung cancer?. <i>Translational Lung Cancer Research</i> , 2020, 9, 2245-2254. | 2.8 | 5 |
| 1629 | Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way. <i>Annals of Translational Medicine</i> , 2020, 8, 1111-1111. | 1.7 | 2 |
| 1630 | Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2020, 13, 374. | 3.8 | 11 |
| 1631 | A New Bioassay Platform Design for the Discovery of Small Molecules with Anticancer Immunotherapeutic Activity. <i>Marine Drugs</i> , 2020, 18, 604. | 4.6 | 10 |
| 1632 | SOX4 Mediates BRAF Inhibitor Resistance in Melanoma through Regulation of IGF-1R Signaling: In Vitro Study. <i>International Journal of Dermatology and Venereology</i> , 2020, 3, 156-165. | 0.3 | 1 |
| 1633 | High frequency of exon 20 EGFR S768I mutation detected in malignant pleural effusions: A poor prognosticator of NSCLC. <i>Cancer Reports</i> , 2020, 3, e1262. | 1.4 | 4 |
| 1634 | Molecular profiling of non-small cell lung cancer. <i>PLoS ONE</i> , 2020, 15, e0236580. | 2.5 | 17 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1635 | Identification of a Microsatellite Stable, EGFR-Mutant Lung Adenocarcinoma Developing in a Patient With Lynch Syndrome. <i>JCO Precision Oncology</i> , 2020, 4, 818-822. | 3.0 | 2 |
| 1636 | Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, 664-674.e7. | 0.8 | 34 |
| 1637 | The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models. <i>BMC Cancer</i> , 2020, 20, 738. | 2.6 | 9 |
| 1638 | Multiomics Reveals Ectopic ATP Synthase Blockade Induces Cancer Cell Death via a lncRNA-mediated Phospho-signaling Network. <i>Molecular and Cellular Proteomics</i> , 2020, 19, 1805-1825. | 3.8 | 11 |
| 1639 | Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types. <i>Annals of Translational Medicine</i> , 2020, 8, 860-860. | 1.7 | 9 |
| 1640 | Associations of TIMP-3 Genetic Polymorphisms with EGFR Statuses and Cancer Clinicopathologic Development in Lung Adenocarcinoma Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8023. | 4.1 | 11 |
| 1641 | An examination of two dichotomies: Women with lung cancer and living with lung cancer as a chronic disease. <i>Respirology</i> , 2020, 25, 24-36. | 2.3 | 10 |
| 1642 | Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 517-525. | 2.3 | 3 |
| 1643 | Can smoking duration alone replace pack-years to predict the risk of smoking-related oncogenic mutations in non-small cell lung cancer? A cross-sectional study in Japan. <i>BMJ Open</i> , 2020, 10, e035615. | 1.9 | 4 |
| 1644 | Expression, intracellular localization, and mutation of EGFR in conjunctival squamous cell carcinoma and the association with prognosis and treatment. <i>PLoS ONE</i> , 2020, 15, e0238120. | 2.5 | 6 |
| 1645 | An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan. <i>Frontiers in Oncology</i> , 2020, 10, 1481. | 2.8 | 25 |
| 1646 | Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment. <i>Crystals</i> , 2020, 10, 725. | 2.2 | 4 |
| 1647 | Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 602762. | 2.8 | 59 |
| 1648 | Genotyping Squamous Cell Lung Carcinoma in Colombia (Geno1.1-CLICaP). <i>Frontiers in Oncology</i> , 2020, 10, 588932. | 2.8 | 4 |
| 1649 | Cancer of unknown primary with EGFR mutation successfully treated with targeted therapy directed by clinical next-generation sequencing: a case report. <i>BMC Cancer</i> , 2020, 20, 1177. | 2.6 | 3 |
| 1650 | Proteomic signatures of 16 major types of human cancer reveal universal and cancer-type-specific proteins for the identification of potential therapeutic targets. <i>Journal of Hematology and Oncology</i> , 2020, 13, 170. | 17.0 | 25 |
| 1651 | Sparse superlayered neural network-based multi-omics cancer subtype classification. <i>International Journal of Data Mining and Bioinformatics</i> , 2020, 24, 58. | 0.1 | 2 |
| 1652 | Bridging the Gap: The Impact of Genetic Ancestry on Routes to Tumorigenesis. <i>Cancer Cell</i> , 2020, 37, 619-621. | 16.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1653 | Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial. <i>Investigational New Drugs</i> , 2020, 38, 1854-1861. | 2.6 | 18 |
| 1654 | Epidermal growth factor receptor mutations in non-small cell lung cancer undetected by high-sensitivity allele-specific real-time polymerase chain reaction-based assays. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 345-349. | 1.4 | 2 |
| 1655 | Combination effects of ellagic acid with erlotinib in a Ba/ F3 cell line expressing EGFR H773_V774 insH mutation. <i>Thoracic Cancer</i> , 2020, 11, 2101-2111. | 1.9 | 5 |
| 1656 | Multi-omics analysis reveals the functional transcription and potential translation of enhancers. <i>International Journal of Cancer</i> , 2020, 147, 2210-2224. | 5.1 | 11 |
| 1657 | Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non-Small Cell Lung Cancer and Response to EGFR TKIs. <i>Translational Oncology</i> , 2020, 13, 100791. | 3.7 | 17 |
| 1658 | Real-world disease burden and outcomes of brain metastases in EGFR mutation-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2020, 16, 1575-1584. | 2.4 | 9 |
| 1659 | Targeted Therapy for Non-Small Cell Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 409-434. | 2.1 | 11 |
| 1660 | Molecular Diagnostics in Non-Small Cell Lung Carcinoma. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 386-399. | 2.1 | 3 |
| 1661 | Lung cancer histology-driven strategic therapeutic approaches. <i>Shanghai Chest</i> , 0, 4, 29-29. | 0.3 | 4 |
| 1662 | Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment. <i>Cancers</i> , 2020, 12, 1587. | 3.7 | 24 |
| 1663 | Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, e33. | 4.0 | 13 |
| 1664 | The top 100 cited articles in lung cancer – a bibliometric analysis. <i>Wspolczesna Onkologia</i> , 2020, 24, 17-28. | 1.4 | 7 |
| 1665 | Combining Allosteric and Orthosteric Drugs to Overcome Drug Resistance. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 336-348. | 8.7 | 60 |
| 1666 | Integrative Analysis of Methylation and Gene Expression in Lung Adenocarcinoma and Squamous Cell Lung Carcinoma. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 3. | 4.1 | 11 |
| 1667 | Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 904. | 2.8 | 34 |
| 1668 | <p>Icotinib as Adjuvant Treatment for Stage II-IIIa Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 4633-4643. | 1.9 | 8 |
| 1669 | Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. <i>Advances in Cancer Research</i> , 2020, 147, 1-57. | 5.0 | 32 |
| 1670 | Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature. <i>World Journal of Surgical Oncology</i> , 2020, 18, 153. | 1.9 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1671 | Validating a targeted next-generation sequencing assay and profiling somatic variants in Chinese non-small cell lung cancer patients. <i>Scientific Reports</i> , 2020, 10, 2070. | 3.3 | 13 |
| 1672 | Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation-Positive Lung Adenocarcinoma. <i>Tuberculosis and Respiratory Diseases</i> , 2020, 83, 51. | 1.8 | 13 |
| 1673 | Diagnostic Molecular Pathology. , 2020, , 2145-2159. | | 0 |
| 1674 | Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 148, 102906. | 4.4 | 43 |
| 1675 | Investigation of Potential Mechanisms Associated with Non-small Cell Lung Cancer. <i>Journal of Computational Biology</i> , 2020, 27, 1433-1442. | 1.6 | 5 |
| 1676 | Front-line Therapy in Advanced Non-Small Cell Lung Cancer With Sensitive Epidermal Growth Factor Receptor Mutations: A Network Meta-analysis. <i>Clinical Therapeutics</i> , 2020, 42, 338-350.e4. | 2.5 | 13 |
| 1677 | Imaging-Based Surrogate Markers of Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinoma: A Local Perspective. <i>Canadian Association of Radiologists Journal</i> , 2020, 71, 208-216. | 2.0 | 2 |
| 1678 | Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors. <i>Advances in Therapy</i> , 2020, 37, 946-954. | 2.9 | 15 |
| 1679 | Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer. <i>BMC Cancer</i> , 2020, 20, 76. | 2.6 | 14 |
| 1680 | Racial disparities in bone metastasis patterns and targeted screening and treatment strategies in newly diagnosed lung cancer patients. <i>Ethnicity and Health</i> , 2022, 27, 329-342. | 2.5 | 8 |
| 1681 | Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. <i>Molecular Oncology</i> , 2021, 15, 27-42. | 4.6 | 15 |
| 1682 | Comparison of Detection of Epidermal Growth Factor Receptor (EGFR) Gene Mutation in Peripheral Blood Plasma (Liquid Biopsy) with Cytological Specimens in Lung Adenocarcinoma Patients. <i>Indian Journal of Surgical Oncology</i> , 2021, 12, 65-71. | 0.7 | 6 |
| 1683 | Development, internal validation and calibration of a risk score to predict survival in patients with EGFR-mutant non-small cell lung cancer. <i>Journal of Clinical Pathology</i> , 2021, 74, 116-122. | 2.0 | 5 |
| 1684 | Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2021, 16, 113-126. | 1.1 | 13 |
| 1685 | Hormonal factors in association with lung cancer among Asian women: A pooled analysis from the International Lung Cancer Consortium. <i>International Journal of Cancer</i> , 2021, 148, 2241-2254. | 5.1 | 9 |
| 1686 | Clinical Characteristics, Treatments, and Concurrent Mutations in Non-Small Cell Lung Cancer Patients With NF1 Mutations. <i>Clinical Lung Cancer</i> , 2021, 22, 32-41.e1. | 2.6 | 6 |
| 1687 | Germline EGFR variants are over-represented in adolescents and young adults (AYA) with adrenocortical carcinoma. <i>Human Molecular Genetics</i> , 2021, 29, 3679-3690. | 2.9 | 6 |
| 1688 | Clinical and radiological predictors of epidermal growth factor receptor mutation in nonsmall cell lung cancer. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 271-280. | 1.9 | 13 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1689 | Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study. Thoracic Cancer, 2021, 12, 90-96. | 1.9 | 5 |
| 1690 | Cancer health disparities in racial/ethnic minorities in the United States. British Journal of Cancer, 2021, 124, 315-332. | 6.4 | 447 |
| 1691 | Deciphering the T790M/L858R-Selective Inhibition Mechanism of an Allosteric Inhibitor of EGFR: Insights from Molecular Simulations. ACS Chemical Neuroscience, 2021, 12, 462-472. | 3.5 | 7 |
| 1692 | Development and external validation of a composite immune-clinical prognostic model associated with EGFR mutation in East-Asian patients with lung adenocarcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110069. | 3.2 | 4 |
| 1693 | Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib. Journal of Cancer, 2021, 12, 644-651. | 2.5 | 8 |
| 1694 | Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 612. | 4.1 | 79 |
| 1695 | Advances in anti-BRAF therapies for lung cancer. Investigational New Drugs, 2021, 39, 879-890. | 2.6 | 22 |
| 1696 | Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US. Journal of Medical Economics, 2021, 24, 328-338. | 2.1 | 0 |
| 1698 | The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Reports Medicine, 2021, 2, 100186. | 6.5 | 90 |
| 1699 | Genomic Profiling and Prognostic Value Analysis of Genetic Alterations in Chinese Resected Lung Cancer With Invasive Mucinous Adenocarcinoma. Frontiers in Oncology, 2020, 10, 603671. | 2.8 | 8 |
| 1700 | Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study. Lung Cancer, 2021, 152, 127-134. | 2.0 | 17 |
| 1701 | Use tumor suppressor genes as biomarkers for diagnosis of non-small cell lung cancer. Scientific Reports, 2021, 11, 3596. | 3.3 | 10 |
| 1702 | Extensive functional evaluation of exon 20 insertion mutations of EGFR. Lung Cancer, 2021, 152, 135-142. | 2.0 | 15 |
| 1703 | Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. Cancers, 2021, 13, 804. | 3.7 | 76 |
| 1704 | Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review. PLoS ONE, 2021, 16, e0247620. | 2.5 | 43 |
| 1705 | Synthesis and evaluation of azalamellarin N and its A-ring-modified analogues as non-covalent inhibitors of the EGFR T790M/L858R mutant. Bioorganic and Medicinal Chemistry, 2021, 34, 116039. | 3.0 | 6 |
| 1706 | Molecular characterization of advanced non-small cell lung cancer patients by cfDNA analysis: experience from routine laboratory practice. Journal of Thoracic Disease, 2021, 13, 1658-1670. | 1.4 | 4 |
| 1707 | Potential Impacts of Interleukin-17A Promoter Polymorphisms on the EGFR Mutation Status and Progression of Non-Small Cell Lung Cancer in Taiwan. Genes, 2021, 12, 427. | 2.4 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1708 | Genomic landscape of ground glass opacities (GGOs) in East Asians. <i>Journal of Thoracic Disease</i> , 2021, 13, 2393-2403. | 1.4 | 2 |
| 1709 | Targeted exome sequencing identifies mutational landscape in a cohort of 1500 Chinese patients with non-small cell lung carcinoma (NSCLC). <i>Human Genomics</i> , 2021, 15, 21. | 2.9 | 8 |
| 1710 | Non-Small-Cell Lung Cancer: New Rare Targetsâ€”New Targeted Therapiesâ€”State of The Art and Future Directions. <i>Cancers</i> , 2021, 13, 1829. | 3.7 | 14 |
| 1711 | Lung Cancer and Processing the Unknown: The Shoes of Damocles and 8 Coping Strategies. <i>Clinical Therapeutics</i> , 2021, 43, 1432-1434. | 2.5 | 1 |
| 1712 | Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103300. | 4.4 | 6 |
| 1713 | Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review. <i>Molecular Biology Reports</i> , 2021, 48, 3593-3604. | 2.3 | 12 |
| 1714 | Comparison and Fusion of Machine Learning Algorithms for Prospective Validation of PET/CT Radiomic Features Prognostic Value in Stage II-III Non-Small Cell Lung Cancer. <i>Diagnostics</i> , 2021, 11, 675. | 2.6 | 17 |
| 1715 | Evaluation of the Idylla ctEGFR mutation assay to detect EGFR mutations in plasma from patients with non-small cell lung cancers. <i>Scientific Reports</i> , 2021, 11, 10470. | 3.3 | 7 |
| 1717 | Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation. <i>Lung Cancer</i> , 2021, 155, 127-135. | 2.0 | 6 |
| 1718 | The status of WIF1 methylation in cell-free DNA is associated with the insusceptibility for gefitinib in the treatment of lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2239-2248. | 2.5 | 1 |
| 1719 | EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP). <i>JCO Precision Oncology</i> , 2021, 5, 839-848. | 3.0 | 3 |
| 1720 | Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?. <i>Translational Oncology</i> , 2021, 14, 101056. | 3.7 | 17 |
| 1721 | Impact of EGFR mutation on outcomes following SRS for brain metastases in non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 155, 34-39. | 2.0 | 6 |
| 1722 | Quantitative analysis of cell-free DNA by droplet digital PCR reveals the presence of EGFR mutations in non-malignant lung pathologies. <i>Monaldi Archives for Chest Disease</i> , 2021, 91, . | 0.6 | 1 |
| 1723 | Kinase drug discovery 20 years after imatinib: progress and future directions. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 551-569. | 46.4 | 497 |
| 1725 | The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 1091-1103. | 5.0 | 6 |
| 1726 | Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. <i>Cancer Research</i> , 2021, 81, 3916-3929. | 0.9 | 13 |
| 1727 | Somatic mutation subtypes of lung adenocarcinoma in East Asian reveal divergent biological characteristics and therapeutic vulnerabilities. <i>IScience</i> , 2021, 24, 102522. | 4.1 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1728 | Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas. Scientific Reports, 2021, 11, 14999. | 3.3 | 5 |
| 1729 | Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. Future Oncology, 2021, 17, 2513-2527. | 2.4 | 7 |
| 1730 | Paradigm shift in the management of metastatic nonsmall cell lung cancer. International Journal of Clinical Practice, 2021, 75, e14533. | 1.7 | 0 |
| 1731 | Massage therapy as a complementary and alternative approach for people with multiple sclerosis: a systematic review. Disability and Rehabilitation, 2022, 44, 5758-5769. | 1.8 | 5 |
| 1732 | Amivantamab in EGFR Exon 20 Insertionâ€“Mutated Nonâ€“Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. Journal of Clinical Oncology, 2021, 39, 3391-3402. | 1.6 | 320 |
| 1733 | Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Nonâ€“Squamous Nonâ€“Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy. Clinical Lung Cancer, 2021, 22, 587-595. | 2.6 | 7 |
| 1734 | Long-term survival in a patient with advanced lung adenocarcinoma harboring synchronous EGFR exon 18 G719A and BRAF V600E mutations and treated with afatinib. Anti-Cancer Drugs, 2021, Publish Ahead of Print, . | 1.4 | 0 |
| 1735 | Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC. Life, 2021, 11, 843. | 2.4 | 5 |
| 1736 | Cytoplasmic P120ctn Promotes Gefitinib Resistance in Lung Cancer Cells by Activating PAK1 and ERK Pathway. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 750-758. | 1.2 | 8 |
| 1737 | Survival of gefitinib treated advanced non-small cell lung cancer patients harbouring EGFR mutations. Pharmacy & Pharmacology International Journal, 2021, 9, 171-174. | 0.2 | 0 |
| 1738 | Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Chest, 2021, 160, 1095-1107. | 0.8 | 23 |
| 1739 | Updates in the molecular pathology of non-small cell lung cancer. Seminars in Diagnostic Pathology, 2021, 38, 54-61. | 1.5 | 10 |
| 1740 | A Novel Tool for the Risk Assessment and Personalized Chemo-/Immunotherapy Response Prediction of Adenocarcinoma and Squamous Cell Carcinoma Lung Cancer. International Journal of General Medicine, 2021, Volume 14, 5771-5785. | 1.8 | 2 |
| 1741 | Clinicopathologic features and prognostic value of epidermal growth factor receptor mutation in patients with pT1a and pT1b invasive lung adenocarcinoma after surgical resection. Journal of Thoracic Disease, 2021, 13, 5496-5507. | 1.4 | 2 |
| 1742 | Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 128-142. | 2.8 | 13 |
| 1743 | Clinical Effects of T790M Mutation in EGFR Tyrosine Kinase Inhibitor Resistant NSCLC Patients. Kocaeli Medical Journal, 2021, 10, 51-56. | 0.1 | 0 |
| 1744 | Supplements for Smoking-Related Lung Diseases. Encyclopedia, 2021, 1, 76-86. | 4.5 | 5 |
| 1746 | Molecular Biology of Preneoplastic Lesions of the Lung. , 0, , 84-98. | | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1747 | Antibodies as Cancer Immunotherapy. , 2013, , 335-376. | | 2 |
| 1748 | Epidermal Growth Factor Receptor. , 2016, , 1-11. | | 1 |
| 1749 | Molecular Basis of Lung Carcinogenesis. , 2017, , 447-496. | | 4 |
| 1750 | Clinical Implications of Epigenetic Alterations in Human Thoracic Malignancies: Epigenetic Alterations in Lung Cancer. Methods in Molecular Biology, 2012, 863, 221-239. | 0.9 | 7 |
| 1751 | The Metabolic Remodelling in Lung Cancer and Its Putative Consequence in Therapy Response. Advances in Experimental Medicine and Biology, 2020, 1219, 311-333. | 1.6 | 6 |
| 1752 | Cancer of the Lung: Non-Small Cell Lung Cancer and Small Cell Lung Cancer. , 2008, , 1307-1366. | | 7 |
| 1753 | DEFINITIVE MANAGEMENT OF INOPERABLE NONâ€“SMALL CELL LUNG CANCER. , 2008, , 804-821. | | 1 |
| 1754 | Cancer of the Lung. , 2014, , 1143-1192.e13. | | 5 |
| 1755 | Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. Cancer Cell, 2020, 37, 639-654.e6. | 16.8 | 151 |
| 1756 | Next-Generation Sequencing. Journal of Molecular Diagnostics, 2017, 19, 870-880. | 2.8 | 43 |
| 1757 | Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2012, 58, 263-268. | 0.7 | 4 |
| 1758 | Genomic landscape of lung adenocarcinoma in East Asians. Nature Genetics, 2020, 52, 177-186. | 21.4 | 281 |
| 1761 | An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer. Expert Review of Molecular Diagnostics, 2018, 18, 35-45. | 3.1 | 42 |
| 1762 | An overview of cancer health disparities: new approaches and insights and why they matter. Carcinogenesis, 2021, 42, 2-13. | 2.8 | 39 |
| 1763 | E12-01: NCI Director's challenge gene profiling of lung adenocarcinomas: impact on histologic classification. Journal of Thoracic Oncology, 2007, 2, S254-S256. | 1.1 | 1 |
| 1764 | Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non???Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. Journal of Thoracic Oncology, 2006, 1, 52-60. | 1.1 | 13 |
| 1765 | Clinico-Pathological and Biological Significance of Tyrosine Kinase Domain Gene Mutations and Overexpression of Epidermal Growth Factor Receptor for Lung Adenocarcinoma. Journal of Thoracic Oncology, 2006, 1, 787-795. | 1.1 | 34 |
| 1766 | Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 22-28. | 1.1 | 134 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1767 | The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 171-178. | 1.1 | 79 |
| 1769 | Abstract 275: Burkitt lymphoma cells express GLI1 but are not responsive to Hedgehog signaling. <i>Cancer Research</i> , 2011, 71, 275-275. | 0.9 | 91 |
| 1770 | New molecularly targeted therapies for lung cancer. <i>Journal of Clinical Investigation</i> , 2007, 117, 2740-2750. | 8.2 | 180 |
| 1771 | ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion. <i>Journal of Clinical Investigation</i> , 2012, 122, 1869-1880. | 8.2 | 109 |
| 1772 | Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. <i>Tumor Biology</i> , 2017, 39, 101042831770534. | 1.8 | 4 |
| 1773 | Novel visualized quantitative epigenetic imprinted gene biomarkers diagnose the malignancy of ten cancer types. <i>Clinical Epigenetics</i> , 2020, 12, 71. | 4.1 | 13 |
| 1774 | Correlation Between Nuclear Factor E2-Related Factor 2 Expression and Gastric Cancer Progression. <i>Medical Science Monitor</i> , 2015, 21, 2893-2899. | 1.1 | 21 |
| 1775 | Absence of Epidermal Growth Factor Receptor Gene Mutations in Lung and Liver Tumors in Rats. <i>Journal of Toxicologic Pathology</i> , 2007, 20, 65-69. | 0.7 | 1 |
| 1776 | Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells. <i>PLoS ONE</i> , 2009, 4, e7464. | 2.5 | 205 |
| 1777 | Curcumin Induces EGFR Degradation in Lung Adenocarcinoma and Modulates p38 Activation in Intestine: The Versatile Adjuvant for Gefitinib Therapy. <i>PLoS ONE</i> , 2011, 6, e23756. | 2.5 | 95 |
| 1778 | Cigarette Smoking and p16INK4a Gene Promoter Hypermethylation in Non-Small Cell Lung Carcinoma Patients: A Meta-Analysis. <i>PLoS ONE</i> , 2011, 6, e28882. | 2.5 | 24 |
| 1779 | Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e64816. | 2.5 | 71 |
| 1780 | Identification and Characterization of Cancer Mutations in Japanese Lung Adenocarcinoma without Sequencing of Normal Tissue Counterparts. <i>PLoS ONE</i> , 2013, 8, e73484. | 2.5 | 41 |
| 1781 | Colorectal Cancers from Distinct Ancestral Populations Show Variations in BRAF Mutation Frequency. <i>PLoS ONE</i> , 2013, 8, e74950. | 2.5 | 34 |
| 1782 | Anti-Cancer Effects of REIC/Dkk-3-encoding Adenoviral Vector for the Treatment of Non-small Cell Lung Cancer. <i>PLoS ONE</i> , 2014, 9, e87900. | 2.5 | 23 |
| 1783 | The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients. <i>PLoS ONE</i> , 2015, 10, e0124354. | 2.5 | 17 |
| 1784 | Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib. <i>PLoS ONE</i> , 2015, 10, e0125232. | 2.5 | 27 |
| 1785 | Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations. <i>PLoS ONE</i> , 2015, 10, e0135393. | 2.5 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1786 | Clinical Features and Gene Mutations of Lung Cancer Patients 30 Years of Age or Younger. PLoS ONE, 2015, 10, e0136659. | 2.5 | 13 |
| 1787 | MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells. PLoS ONE, 2015, 10, e0143333. | 2.5 | 21 |
| 1788 | Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients. PLoS ONE, 2016, 11, e0150623. | 2.5 | 4 |
| 1789 | Identification of Gene Expression Differences between Lymphangiogenic and Non-Lymphangiogenic Non-Small Cell Lung Cancer Cell Lines. PLoS ONE, 2016, 11, e0150963. | 2.5 | 12 |
| 1790 | A Histopathological Feature of EGFR-Mutated Lung Adenocarcinomas with Highly Malignant Potential "An Implication of Micropapillary Element". PLoS ONE, 2016, 11, e0166795. | 2.5 | 13 |
| 1791 | Identifying EGFR Mutations from SCLC Patient Plasma by Mutant-Enriched Liquidchip Technology. Advances in Clinical and Experimental Medicine, 2014, 23, 191-195. | 1.4 | 1 |
| 1792 | Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients. Oncotarget, 2016, 7, 53299-53308. | 1.8 | 9 |
| 1793 | A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?. Oncotarget, 2016, 7, 56998-57010. | 1.8 | 51 |
| 1794 | Predictive and prognostic value of preoperative serum tumor markers in resectable adenosquamous lung carcinoma. Oncotarget, 2016, 7, 64798-64809. | 1.8 | 10 |
| 1795 | BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations. Oncotarget, 2016, 7, 68933-68942. | 1.8 | 26 |
| 1796 | Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR. Oncotarget, 2017, 8, 5861-5873. | 1.8 | 41 |
| 1797 | Impact of country of birth on genetic testing of metastatic lung adenocarcinomas in France: African women exhibit a mutational spectrum more similar to Asians than to Caucasians. Oncotarget, 2017, 8, 50792-50803. | 1.8 | 2 |
| 1798 | A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. Oncotarget, 2017, 8, 41474-41486. | 1.8 | 13 |
| 1799 | Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer. Oncotarget, 2017, 8, 100801-100818. | 1.8 | 35 |
| 1800 | EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget, 2017, 8, 98384-98393. | 1.8 | 58 |
| 1801 | Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations. Oncotarget, 2017, 8, 105479-105491. | 1.8 | 41 |
| 1802 | Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget, 2014, 5, 8937-8946. | 1.8 | 6 |
| 1803 | Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget, 2018, 9, 14268-14284. | 1.8 | 12 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1804 | Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 33258-33270. | 1.8 | 9 |
| 1805 | The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy. <i>Oncotarget</i> , 2020, 11, 1953-1960. | 1.8 | 19 |
| 1806 | Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A. <i>Oncotarget</i> , 2015, 6, 2164-2179. | 1.8 | 43 |
| 1807 | Molecular landscape of pancreatic cancer: implications for current clinical trials. <i>Oncotarget</i> , 2015, 6, 4553-4561. | 1.8 | 85 |
| 1808 | Nuclear estrogen receptor- β expression is an independent predictor of recurrence in male patients with pT1aNO lung adenocarcinomas, and correlates with regulatory T-cell infiltration. <i>Oncotarget</i> , 2015, 6, 27505-27518. | 1.8 | 21 |
| 1809 | <i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer. <i>Oncotarget</i> , 2015, 6, 38789-38803. | 1.8 | 137 |
| 1810 | The status of epidermal growth factor receptor in borderline ovarian tumours. <i>Oncotarget</i> , 2016, 7, 10568-10577. | 1.8 | 5 |
| 1811 | Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status. <i>Oncotarget</i> , 2016, 7, 46628-46635. | 1.8 | 36 |
| 1812 | Drug resistance to EGFR tyrosine kinase inhibitors for non-small cell lung cancer. <i>Acta Medica Okayama</i> , 2014, 68, 191-200. | 0.2 | 15 |
| 1813 | The impact of epidermal growth factor receptor mutations on the prognosis of resected non-small cell lung cancer: a meta-analysis of literatures. <i>Translational Lung Cancer Research</i> , 2019, 8, 124-134. | 2.8 | 30 |
| 1814 | Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2017, 29, 543-552. | 2.2 | 27 |
| 1815 | Biomarkers for the targeted therapies of non-small cell lung cancer. <i>Current Biomarker Findings</i> , 0, , 7. | 0.4 | 3 |
| 1816 | IMPMD: An Integrated Method for Predicting Potential Associations Between miRNAs and Diseases. <i>Current Genomics</i> , 2020, 20, 581-591. | 1.6 | 2 |
| 1817 | From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 18, 1235-1240. | 1.7 | 9 |
| 1818 | Lung Adenocarcinoma in Never Smokers: Problems of Primary Prevention from Aspects of Susceptible Genes and Carcinogens. <i>Anticancer Research</i> , 2016, 36, 6207-6224. | 1.1 | 30 |
| 1819 | Frequency of Epidermal Growth Factor Receptor Mutation in Smokers with Lung Cancer Without Pulmonary Emphysema. <i>Anticancer Research</i> , 2017, 37, 765-772. | 1.1 | 6 |
| 1820 | The frequency of EGFR And KRAS mutations in the Turkish population with non-small cell lung cancer and their response to erlotinib therapy. <i>Balkan Journal of Medical Genetics</i> , 2018, 21, 21-26. | 0.5 | 11 |
| 1821 | A Case of Small-cell Lung Carcinoma with EGFR Gene Mutation. <i>Japanese Journal of Lung Cancer</i> , 2011, 51, 798-802. | 0.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1822 | Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC. Asian Pacific Journal of Cancer Prevention, 2019, 20, 3581-3589. | 1.2 | 6 |
| 1823 | Identifying the Causes of Cancer Health Disparities. Californian Journal of Health Promotion, 2010, 8, 101-111. | 0.3 | 2 |
| 1824 | Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy. Frontiers in Oncology, 2019, 9, 263. | 2.8 | 62 |
| 1825 | Comprehensive Perspective for Lung Cancer Characterisation Based on AI Solutions Using CT Images. Journal of Clinical Medicine, 2021, 10, 118. | 2.4 | 14 |
| 1826 | Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). Pharmaceuticals, 2020, 13, 273. | 3.8 | 28 |
| 1829 | EGFR mutation status in a series of Turkish non-small cell lung cancer patients. Biomedical Reports, 2020, 13, 2. | 2.0 | 5 |
| 1830 | Placenta-specific protein 8 promotes the proliferation of lung adenocarcinoma PC9 cells and their tolerance to an epidermal growth factor receptor tyrosine kinase inhibitor by activating the ERK signaling pathway. Oncology Letters, 2019, 18, 5621-5627. | 1.8 | 7 |
| 1831 | A Comparison of Patient Acceptance and Preferences Between CT Colonography and Conventional Colonoscopy in Colorectal Cancer Screening. Korean Journal of Internal Medicine, 2009, 24, 43. | 1.7 | 41 |
| 1832 | EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung. Korean Journal of Internal Medicine, 2009, 24, 48. | 1.7 | 60 |
| 1833 | A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC. Mathematical Biosciences and Engineering, 2019, 16, 5687-5696. | 1.9 | 1 |
| 1834 | The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer. Journal of Thoracic Disease, 2010, 2, 144-53. | 1.4 | 10 |
| 1835 | Treatment of advanced non small cell lung cancer. Journal of Thoracic Disease, 2011, 3, 122-33. | 1.4 | 99 |
| 1836 | Molecular biology of lung cancer. Journal of Thoracic Disease, 2013, 5 Suppl 5, S479-90. | 1.4 | 173 |
| 1837 | The pivotal role of pathology in the management of lung cancer. Journal of Thoracic Disease, 2013, 5 Suppl 5, S463-78. | 1.4 | 99 |
| 1838 | Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer. Journal of Thoracic Disease, 2014, 6, 387-98. | 1.4 | 23 |
| 1839 | Immunotherapy in lung cancer. Translational Lung Cancer Research, 2014, 3, 53-63. | 2.8 | 50 |
| 1840 | Epidermal growth factor receptor in non-small cell lung cancer. Translational Lung Cancer Research, 2015, 4, 110-8. | 2.8 | 56 |
| 1841 | Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer. Translational Lung Cancer Research, 2015, 4, 165-76. | 2.8 | 103 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1842 | Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer. Translational Lung Cancer Research, 2015, 4, 584-97. | 2.8 | 52 |
| 1843 | Predictive molecular markers for EGFR-TKI in non-small cell lung cancer patients: new insights and critical aspects. Journal of Nucleic Acids Investigation, 2010, 1, 10. | 0.8 | 2 |
| 1844 | Association between thyroid cancer and epidermal growth factor receptor mutation in female with nonsmall cell lung cancer. Annals of Thoracic Medicine, 2017, 12, 36. | 1.8 | 1 |
| 1845 | Team Management of Skin Rash Associated with Use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors. Asia-Pacific Journal of Oncology Nursing, 2018, 5, 430-434. | 1.6 | 4 |
| 1846 | Prevalence of the epidermal growth factor receptor mutations in lung adenocarcinoma patients from the Middle East region. Annals of Thoracic Medicine, 2019, 14, 173. | 1.8 | 8 |
| 1847 | Saudi lung cancer management guidelines 2017. Annals of Thoracic Medicine, 2017, 12, 221. | 1.8 | 16 |
| 1848 | Targeted therapy in nonsmall cell lung cancer. Indian Journal of Cancer, 2017, 54, 83. | 0.2 | 6 |
| 1849 | Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?. Lung India, 2018, 35, 27. | 0.7 | 3 |
| 1850 | Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey. Journal of Pathology and Translational Medicine, 2015, 49, 481-488. | 1.1 | 24 |
| 1851 | Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial. Cancer Research and Treatment, 2015, 47, 616-629. | 3.0 | 10 |
| 1852 | Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study. Cancer Research and Treatment, 2017, 49, 937-946. | 3.0 | 7 |
| 1853 | Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer. Cancer Research and Treatment, 2018, 50, 95-102. | 3.0 | 22 |
| 1854 | Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014. Cancer Research and Treatment, 2019, 51, 1400-1410. | 3.0 | 49 |
| 1855 | Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. Cancer Research and Treatment, 2020, 52, 284-291. | 3.0 | 4 |
| 1856 | Overexpression of Nrf2 promotes colon cancer progression via ERK and AKT signaling pathways. Annals of Surgical Treatment and Research, 2020, 98, 159. | 1.0 | 19 |
| 1857 | Better Selection Model for EML4-ALK Fusion Gene Test in Patients with Non-Small-Cell Lung Cancer. Journal of Cancer Therapy, 2013, 04, 54-58. | 0.4 | 3 |
| 1858 | Prevalence of Epidermal Growth Factor Receptor Mutations in Patients with Non-Small Cell Lung Cancer in Turkish Population. Balkan Medical Journal, 2017, 34, 567-571. | 0.8 | 7 |
| 1859 | Lessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures. Pharmacy Practice, 2006, 4, 168-78. | 1.5 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1860 | Treatment After First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non- Small-Cell Lung Cancer. Turkish Thoracic Journal, 2017, 18, 66-71. | 0.6 | 7 |
| 1861 | Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges. International Journal of Biological Markers, 2007, 22, 10-23. | 1.8 | 5 |
| 1862 | Tunable structure priors for Bayesian rule learning for knowledge integrated biomarker discovery. World Journal of Clinical Oncology, 2018, 9, 98-109. | 2.3 | 2 |
| 1863 | Correlation of genes associated with drug response to prognosis of large cell lung carcinoma. Chinese Journal of Cancer, 2011, 30, 497-504. | 4.9 | 5 |
| 1864 | Bronchioloalveolar Carcinoma: A Review of Current Concepts and Evolving Issues. Archives of Pathology and Laboratory Medicine, 2007, 131, 1027-1032. | 2.5 | 53 |
| 1865 | Is the Epidermal Growth Factor Receptor Status in Lung Cancers Reflected in Clinicopathologic Features?. Archives of Pathology and Laboratory Medicine, 2010, 134, 66-72. | 2.5 | 86 |
| 1866 | Molecular Testing of Solid Tumors. Archives of Pathology and Laboratory Medicine, 2011, 135, 67-82. | 2.5 | 35 |
| 1867 | The Abu Dhabi Declaration: Why the Hustle?. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, S-2-S-4. | 4.9 | 3 |
| 1868 | Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients. Clinics, 2012, 67, 419-424. | 1.5 | 41 |
| 1869 | EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation. International Journal of Medical Sciences, 2013, 10, 320-330. | 2.5 | 106 |
| 1870 | A study of incidence of EGFR mutations in non-smoker adenocarcinoma of the lung: disparity between north and south indian patients. Journal of Cancer Therapeutics & Research, 2014, 3, 4. | 1.2 | 5 |
| 1871 | High Resolution Melting Analysis for Epidermal Growth Factor Receptor Mutations in Formalin-fixed Paraffin-embedded Tissue and Plasma Free DNA from Non-small Cell Lung Cancer Patients. Asian Pacific Journal of Cancer Prevention, 2013, 14, 6619-6623. | 1.2 | 39 |
| 1872 | Differences in Epidermal Growth Factor Receptor Gene Mutations and Relationship with Clinicopathological Features in NSCLC Between Uyghur and Han Ethnic Groups. Asian Pacific Journal of Cancer Prevention, 2013, 14, 2879-2883. | 1.2 | 6 |
| 1873 | Concomitant EGFR Inhibitors Combined with Radiation for Treatment of Non-small Cell Lung Carcinoma. Asian Pacific Journal of Cancer Prevention, 2013, 14, 4485-4494. | 1.2 | 16 |
| 1874 | Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancers in a Multiethnic Malaysian Patient Population. Asian Pacific Journal of Cancer Prevention, 2014, 15, 321-326. | 1.2 | 15 |
| 1875 | Epidermal Growth Factor Receptor Mutations in Japanese Men with Lung Adenocarcinomas. Asian Pacific Journal of Cancer Prevention, 2015, 15, 10627-10630. | 1.2 | 8 |
| 1876 | Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study. Asian Pacific Journal of Cancer Prevention, 2015, 16, 7071-7076. | 1.2 | 8 |
| 1877 | Correlation of EGFR G873R mutation with prognosis of docetaxel in non-small cell lung cancer. Journal of Thoracic Disease, 2021, 13, 5964-5972. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1878 | Predictive value of EGFR mutation in non-small cell lung cancer patients treated with platinum doublet postoperative chemotherapy. <i>Cancer Science</i> , 2022, 113, 287-296. | 3.9 | 10 |
| 1879 | A Sensitive PCR-Based Method for Somatic Mutations Enrichment and Screening. <i>Cancer Management and Research</i> , 2021, Volume 13, 8099-8107. | 1.9 | 0 |
| 1880 | Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 163-176. | 2.5 | 4 |
| 1882 | Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. <i>Yearbook of Oncology</i> , 2006, 2006, 253-254. | 0.1 | 0 |
| 1883 | Clinical Characteristics of Primary Lung Cancer Patients in a Tertiary Hospital. <i>Tuberculosis and Respiratory Diseases</i> , 2006, 60, 321. | 1.8 | 4 |
| 1884 | Epidermal Growth Factor Receptor Targeted Therapy—Markers of Sensitivity and Response. <i>Translational Medicine Series</i> , 2007, , 97-122. | 0.0 | 0 |
| 1885 | Signal Transduction Inhibitors, HER Family, EGFR Inhibition and Clinical Achievements. , 2007, , 19-44. | | 2 |
| 1886 | EGFR 5'UTR Uracil-Tegafur 3'UTR. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 285-292. | | 0 |
| 1887 | EGFR 5'UTR Uracil-Tegafur 3'UTR. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 285-292. | 0.0 | 0 |
| 1888 | Molecular Genetics of Lung and Pleural Neoplasms. , 2008, , 47-157. | | 2 |
| 1889 | Response to Conventional Therapy and Targeted Molecular Therapy. <i>Molecular Pathology Library</i> , 2008, , 226-232. | 0.1 | 0 |
| 1890 | Molecular Pathology of Squamous Cell Carcinoma and Its Precursors. <i>Molecular Pathology Library</i> , 2008, , 270-278. | 0.1 | 0 |
| 1891 | Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. , 2008, , 317-365. | | 0 |
| 1892 | EGFR K-ras 5'UTR Uracil-Tegafur 3'UTR. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 285-292. | | 0 |
| 1893 | The intersection of EGFR and the Ras signaling pathway. , 2008, , 84-90. | | 1 |
| 1894 | Adenocarcinoma and Its Precursor Lesions. <i>Molecular Pathology Library</i> , 2008, , 251-269. | 0.1 | 0 |
| 1895 | EGFR Mutations, Other Molecular Alterations Related To Sensitivity to EGFR Inhibitors, and Molecular Testing for EGFR-Targeted Therapies in Non-Small Cell Lung Cancer. , 2008, , 281-324. | | 0 |
| 1896 | Genomics of Lung Cancer. , 2009, , 856-868. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1897 | EGFR Mutation, But Not Sex and Smoking, Is Independently Associated with Favorable Prognosis of Gefitinib-treated Patients with Lung Adenocarcinoma. Japanese Journal of Lung Cancer, 2009, 49, 409-415. | 0.1 | 0 |
| 1898 | Targeted Approaches to Drug Development. , 2009, , 57-98. | | 3 |
| 1899 | Intron 1 Polymorphism, Mutation and the Protein Expression of Epidermal Growth Factor Receptor in Relation to the Gefitinib Sensitivity of Korean Lung Cancer Patients. Korean Journal of Pathology, 2009, 43, 509. | 1.3 | 0 |
| 1900 | Morphologic Features of Adenocarcinoma of the Lung Predictive of Response to the Epidermal Growth Factor Receptor Kinase Inhibitors Erlotinib and Gefitinib. Archives of Pathology and Laboratory Medicine, 2009, 133, 470-477. | 2.5 | 42 |
| 1901 | Inhibitory Effect of Epidermal Growth Factor on the Proliferation of Lung Cancer Cell Lines. Journal of Lung Cancer, 2010, 9, 64. | 0.2 | 0 |
| 1902 | Molecular Pathology of Lung Cancer. , 2010, , 1-25. | | 1 |
| 1903 | Pharmacogenetics in Lung Cancer. , 2010, , 87-99. | | 0 |
| 1904 | Targeting EGFR in HPV-Associated Cancer. , 2010, , 211-234. | | 0 |
| 1905 | Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer. , 2010, , 205-226. | | 2 |
| 1907 | Genotyping non-small cell lung cancer (NSCLC) in Latin America (LATAM).. Journal of Clinical Oncology, 2011, 29, e21155-e21155. | 1.6 | 0 |
| 1908 | Pharmacogenomics in Developing Asian Countries. Advances in Microbial Ecology, 2012, , 183-214. | 0.1 | 0 |
| 1909 | Predictive Markers in Lung Cancer. , 2013, , 43-68. | | 0 |
| 1910 | Molecular Pathology of Lung Cancers. , 2013, , 83-94. | | 1 |
| 1911 | EGFR, Growth Factors. , 2013, , 1-11. | | 0 |
| 1912 | Epidemiology of Lung Cancer in Women. , 2013, , 1191-1208. | | 0 |
| 1913 | The Biology of K-Ras Signaling Pathways in Pancreatic Cancer. , 2013, , 83-115. | | 0 |
| 1914 | Molecular Pathology and Diagnostics of Non-small Cell Lung Carcinoma. , 2014, , 75-118. | | 0 |
| 1915 | Signal Transduction Inhibitors of the HER Family. , 2013, , 17-50. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1917 | Gender Does Not Have a Potential Predictive Value for the Presence of Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinoma. <i>Advances in Lung Cancer</i> (Irvine), 2014, 03, 82-87. | 0.2 | 0 |
| 1918 | Frequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung. <i>Journal of Cancer Therapy</i> , 2014, 05, 1012-1020. | 0.4 | 1 |
| 1919 | The 2013 Incentive Award of the Okayama Medical Association in General Medical Science (2013 Yuuki) Tj ETQq0 0.0 rgBT /Overlock 10 | 0.0 | 0 |
| 1920 | Lung Cancer Among Asian Americans. , 2016, , 107-136. | | 0 |
| 1921 | - Gene Body Methylation and Transcriptional Regulation: Statistical Modelling and More. , 2016, , 225-243. | | 0 |
| 1922 | Epidermal growth factor receptor mutation in adenocarcinoma lung in a North Indian population: Prevalence and relation with different clinical variables. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2016, 37, 189-195. | 0.2 | 6 |
| 1923 | Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Nonâ€“Small Cell Lung Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 514-524. | 0.4 | 1 |
| 1924 | Mutations in the tyrosine kinase domain of the EGFR gene are rare in the Korean Oral Squamous Cell Carcinoma. <i>Journal of the Korea Society of Computer and Information</i> , 2016, 21, 101-106. | 0.0 | 0 |
| 1925 | QUANTITATIVE ASSESSMENT OF BETA-III TUBULIN EXPRESSION IN LUNG ADENOCARCINOMA AND SQUAMOUS CELL CARCINOMA. , 2016, 15, 95-98. | 0.3 | 0 |
| 1926 | Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation. <i>Bosnian Journal of Basic Medical Sciences</i> , 2016, 16, 280-285. | 1.0 | 2 |
| 1927 | Management Strategies for Adverse Events Associated With EGFR TKIs in Nonâ€“Small Cell Lung Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, . | 0.4 | 6 |
| 1928 | Companion Diagnostics. , 2017, , 117-136. | | 0 |
| 1929 | Overview of Malignant Epithelial Neoplasms of Lung. , 2017, , 74-75. | | 0 |
| 1930 | Comparison of Thoracic Radiotherapy Efficacy Between Patients With and Without EGFR-mutated Lung Adenocarcinoma. <i>In Vivo</i> , 2018, 32, 203-209. | 1.3 | 1 |
| 1931 | Epidermal Growth Factor Receptor. , 2018, , 1593-1603. | | 0 |
| 1932 | Cross-Sectional Study of Gene Expression Analysis Identifies Critical Biological Pathways and Key Genes Implicated in Non-Small Cell Lung Cancer. <i>Iranian Red Crescent Medical Journal</i> , 2018, 20, . | 0.5 | 0 |
| 1933 | Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma. <i>Anti-Cancer Drugs</i> , 2018, 29, 281-285. | 1.4 | 1 |
| 1934 | KÃ¼Ã¼k HÃ¼creli DÃ¼ÅŸ AkciÃ¶er Kanseri HastalarÃ±nda Onkogen MutasyonlarÃ±n AraÃŸtÃ¼rÃ¼lmesi, SÃ¼leyman Demirel Ãœniversitesi TÃ±p FakÃ¼ltesi Dergisi, 0, , . | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1935 | EGFR Tyrosine kinase inhibitors in the treatment of metastases of non-small cell lung cancer in the brain. , 2018, 17, 22-30. | 0.3 | 0 |
| 1936 | Non-small Cell Lung Cancer. , 2019, , 143-192. | | 0 |
| 1937 | Proteomics for Cancer: Approaches and Challenges. , 2019, , 343-368. | | 0 |
| 1938 | Possibilities of consistent targeted therapy for EGFR-positive NSCLC. Clinical case. Onkologiya Zhurnal Imeni P A Gertsena, 2019, 8, 289. | 0.2 | 0 |
| 1939 | Correlative analysis of gene mutation and clinical features in patients with non-small cell lung cancer. Translational Cancer Research, 2019, 8, 736-751. | 1.0 | 0 |
| 1940 | Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation. Meditsinskiy Sovet, 2019, , 64-71. | 0.5 | 2 |
| 1941 | Application of International association for the study of lung cancer/American Thoracic Society/European Respiratory Society criteria for the diagnosis of lung carcinomas on small biopsies: A tertiary care center experience. South Asian Journal of Cancer, 2019, 08, 191-194. | 0.6 | 0 |
| 1942 | Lung and Respiratory Tract Cytology. , 2020, , 95-117. | | 0 |
| 1943 | Epidermal growth factor receptor mutation subtype has differential effects on adjuvant chemotherapy for resected adenocarcinoma pathological stages I-III. Oncology Letters, 2019, 18, 6451-6458. | 1.8 | 0 |
| 1946 | Next Generation of Advanced Non-Small Cell Lung Cancer Therapy: Targeted and Immuno-Therapies. International Journal of Medical Students, 2020, 8, 26-32. | 0.5 | 0 |
| 1947 | Greater specificity of p40 compared with p63 in distinguishing squamous cell carcinoma from adenocarcinoma in effusion cellblocks. CytoJournal, 2020, 17, 13. | 1.7 | 2 |
| 1948 | Characteristics of female lung cancer in Korea: analysis of Korean National Lung Cancer Registry. Journal of Thoracic Disease, 2020, 12, 4612-4622. | 1.4 | 4 |
| 1949 | Molecular typing of lung adenocarcinoma with computed tomography and CT image-based radiomics: a narrative review of research progress and prospects. Translational Cancer Research, 2021, 10, 4217-4231. | 1.0 | 2 |
| 1950 | Tumor Mutations Across Racial Groups in a Real-World Data Registry. JCO Precision Oncology, 2021, 5, 1654-1658. | 3.0 | 16 |
| 1951 | Platelet/lymphocyte ratio is a significant prognostic factor for targeted therapy in patients with EGFR-mutated non-small-cell lung cancer. Journal of International Medical Research, 2020, 48, 030006052098020. | 1.0 | 4 |
| 1952 | Association of <i>hOGG1</i> variants with occurrence of <i>p53</i> and <i>EGFR</i> deletion mutations in non-small cell lung cancer. Thoracic Cancer, 2021, 12, 534-538. | 1.9 | 3 |
| 1954 | Precision Medicine in Lung Cancer. European Medical Journal Oncology, 0, , . | 0.0 | 0 |
| 1955 | Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR tyrosine kinase inhibitor treatment in patients with non-small cell lung cancer from different ethnic groups. Experimental and Therapeutic Medicine, 2020, 19, 3513-3520. | 1.8 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1956 | The Impact of EGFR Tyrosine Kinase Inhibitor on the Natural Course of Concurrent Subsolid Nodules in Patients with Non-Small Cell Lung Cancer. Cancer Research and Treatment, 2021, , . | 3.0 | 3 |
| 1957 | Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies. JAMA Network Open, 2021, 4, e2133205. | 5.9 | 70 |
| 1960 | Advanced Non-Small Cell Lung Carcinoma: Acquired Resistance to Gefitinib. , 2008, , 307-316. | | 1 |
| 1961 | Non-Small Cell Lung Cancer with Brain Metastasis: Role of Epidermal Growth Factor Receptor Gene Mutation. , 2008, , 371-387. | | 0 |
| 1962 | The Molecular Genetics of Lung Cancer. , 0, , 61-83. | | 24 |
| 1963 | Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature. Tumori, 2013, 99, e241-4. | 1.1 | 10 |
| 1965 | Epidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung. American Journal of Translational Research (discontinued), 2010, 2, 309-15. | 0.0 | 4 |
| 1966 | A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells. Annals of Thoracic and Cardiovascular Surgery, 2009, 15, 213-20. | 0.8 | 9 |
| 1967 | Mutations in epidermal growth factor receptor gene in esophageal squamous cell carcinoma patients in kashmir- a high incidence area of India. International Journal of Health Sciences, 2008, 2, 17-25. | 0.4 | 3 |
| 1968 | Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors. International Journal of Clinical and Experimental Pathology, 2011, 4, 403-9. | 0.5 | 3 |
| 1969 | Claudins 10 and 18 are predominantly expressed in lung adenocarcinomas and in tumors of nonsmokers. International Journal of Clinical and Experimental Pathology, 2011, 4, 667-73. | 0.5 | 11 |
| 1970 | Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. Journal of Thoracic Disease, 2010, 2, 48-51. | 1.4 | 223 |
| 1971 | RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib. International Journal of Clinical and Experimental Pathology, 2013, 6, 1493-504. | 0.5 | 20 |
| 1974 | Predictive factors associated with gefitinib response in patients with advanced non-small-cell lung cancer (NSCLC). Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 466-70. | 2.2 | 6 |
| 1976 | EGFR mutations in patients with non-small cell lung cancer from mainland China and their relationships with clinicopathological features: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2014, 7, 1967-78. | 1.3 | 16 |
| 1977 | EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. American Journal of Cancer Research, 2014, 4, 411-35. | 1.4 | 102 |
| 1978 | Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts. Journal of Thoracic Disease, 2014, 6, S568-80. | 1.4 | 10 |
| 1979 | Does the order of factors affect the product? Lessons learned from the TORCH trial. Translational Lung Cancer Research, 2013, 2, 50-4. | 2.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1980 | Disparate survival trends in histologic subtypes of metastatic non-small cell lung cancer: a population-based analysis. American Journal of Cancer Research, 2015, 5, 2229-40. | 1.4 | 9 |
| 1981 | Correlation between expression of NF-E2-related factor 2 and progression of gastric cancer. International Journal of Clinical and Experimental Medicine, 2015, 8, 13235-42. | 1.3 | 5 |
| 1982 | EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). American Journal of Cancer Research, 2015, 5, 2892-911. | 1.4 | 272 |
| 1983 | Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Thoracic Disease, 2016, 8, 68-78. | 1.4 | 6 |
| 1984 | Role of epidermal growth factor receptor in lung cancer and targeted therapies. American Journal of Cancer Research, 2017, 7, 187-202. | 1.4 | 43 |
| 1986 | Prognostic significance of EGFR and KRAS mutations in NSCLC patients with brain metastases treated with radiosurgery. Journal of Radiosurgery and SBRT, 2015, 3, 171-178. | 0.2 | 2 |
| 1987 | Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer. Journal of the Advanced Practitioner in Oncology, 2016, 7, 723-735. | 0.4 | 4 |
| 1988 | Identifying the Causes of Cancer Health Disparities: Biologic and Non Biologic Determinants. Californian Journal of Health Promotion, 2010, 8, 101-111. | 0.3 | 1 |
| 1997 | Frequency of ALK Rearrangement by FISH Testing and its Correlation with ALK-IHC in Adenocarcinoma of Primary Lung Origin. Asian Pacific Journal of Cancer Prevention, 2018, 19, 1735-1738. | 1.2 | 1 |
| 2001 | Comparison of clinicopathological and molecular features between young and old patients with lung cancer. International Journal of Clinical and Experimental Pathology, 2018, 11, 1031-1035. | 0.5 | 2 |
| 2002 | Impact of age on EGFR mutations in never-smoking female lung adenocarcinoma patients with malignant pleural effusion. International Journal of Clinical and Experimental Pathology, 2018, 11, 2811-2815. | 0.5 | 0 |
| 2003 | Comparison of clinicopathologic characteristics between patients with EGFR exon 19 deletion and EGFR L858R mutation in lung cancer. International Journal of Clinical and Experimental Pathology, 2018, 11, 4644-4649. | 0.5 | 0 |
| 2004 | Accuracy and clinical influence of plasma EGFR mutation detection in management of advanced lung adenocarcinoma. International Journal of Clinical and Experimental Pathology, 2017, 10, 9559-9566. | 0.5 | 0 |
| 2005 | Cell-Free Circulating Tumour DNA Blood Testing to Detect T790M Mutation in People With Advanced Non-Small Cell Lung Cancer: A Health Technology Assessment. Ontario Health Technology Assessment Series, 2020, 20, 1-176. | 1.8 | 7 |
| 2006 | Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis. Molecular Diagnosis and Therapy, 2022, 26, 7-18. | 3.8 | 57 |
| 2007 | Frequency of Epidermal Growth Factor Receptor and T790M Mutations Among Patients With Non-Small Cell Lung Carcinoma: A Hospital-Based Study in the King Khalid University Hospital (KKUH) Since 2009-2017. Cureus, 2021, 13, e19816. | 0.5 | 0 |
| 2008 | First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study. Investigational New Drugs, 2022, 40, 430-437. | 2.6 | 8 |
| 2009 | Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study. JTO Clinical and Research Reports, 2022, 3, 100257. | 1.1 | 11 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2010 | Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer. Lung Cancer: Targets and Therapy, 2021, Volume 12, 133-138. | 2.7 | 11 |
| 2011 | Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials. Oncologist, 2022, 27, e286-e293. | 3.7 | 4 |
| 2012 | EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States. JTO Clinical and Research Reports, 2022, 3, 100285. | 1.1 | 7 |
| 2013 | Evaluation of molecular methods for plasma detection of EGFR mutations in non-small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 2022, , . | 1.1 | 1 |
| 2014 | Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors. Molecules, 2022, 27, 819. | 3.8 | 32 |
| 2015 | Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study. BMC Pulmonary Medicine, 2022, 22, 32. | 2.0 | 5 |
| 2016 | PTP-PEST Regulated Membranous/Cytoplasmic Translocation of p120ctn in the Lung Cancer Resistance to Tyrosine Kinase Inhibitor. Applied Immunohistochemistry and Molecular Morphology, 2022, Publish Ahead of Print, . | 1.2 | 0 |
| 2017 | Mutation patterns of epidermal growth factor receptor gene in non-small cell lung cancer among Egyptian patients. Egyptian Journal of Basic and Applied Sciences, 2022, 9, 77-90. | 0.6 | 2 |
| 2018 | Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. Journal of Clinical Oncology, 2022, 40, 611-625. | 1.6 | 242 |
| 2019 | Three-Dimensional Convolutional Neural Network-Based Prediction of Epidermal Growth Factor Receptor Expression Status in Patients With Non-Small Cell Lung Cancer. Frontiers in Oncology, 2022, 12, 772770. | 2.8 | 8 |
| 2020 | Extracellular domain of semaphorin 5A serves a tumor-suppressing role by activating interferon signaling pathways in lung adenocarcinoma cells. International Journal of Oncology, 2022, 60, . | 3.3 | 0 |
| 2021 | Insights into the negative regulation of EGFR upon the binding of an allosteric inhibitor. Chemical Biology and Drug Design, 2022, 99, 650-661. | 3.2 | 3 |
| 2022 | A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors. Lung Cancer, 2022, 166, 98-106. | 2.0 | 1 |
| 2023 | Evaluating Prognostic Factors for Sex Differences in Lung Cancer Survival: Findings From a Large Australian Cohort. Journal of Thoracic Oncology, 2022, 17, 688-699. | 1.1 | 24 |
| 2024 | The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors. Frontiers in Oncology, 2022, 12, 843299. | 2.8 | 6 |
| 2026 | Research progress in immunotherapy of NSCLC with EGFR sensitive mutations. Oncology Research, 2022, , . | 1.5 | 0 |
| 2027 | Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis. Targeted Oncology, 2022, 17, 153-166. | 3.6 | 15 |
| 2028 | Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis. Future Oncology, 2022, 18, 2007-2028. | 2.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2029 | Case Report: Benefits of a NSCLC Patient With EGFR A289G/F287_G288insHA cis Mutations From Immunotherapy in Combination With Antiangiogenesis and Chemotherapy and Sequential Treatment of EGFR-TKI. <i>Frontiers in Oncology</i> , 2022, 12, 826938. | 2.8 | 1 |
| 2030 | Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 869672. | 2.8 | 30 |
| 2031 | Pretreatment <scp>HDL</scp> and <scp>ApoA1</scp> are predictive biomarkers of progression-free survival in patients with EGFR mutated advanced non-small cell lung cancer treated with <scp>TKI</scp>. <i>Thoracic Cancer</i> , 2022, 13, 1126-1135. | 1.9 | 4 |
| 2032 | <scp>PD-L1</scp> expressed from tumor cells promotes tumor growth and invasion in lung cancer via modulating <scp>TGF- β 1</scp>/<scp>SMAD4</scp> expression. <i>Thoracic Cancer</i> , 2022, 13, 1322-1332. | 1.9 | 5 |
| 2033 | RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100303. | 1.1 | 1 |
| 2034 | Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 111-126. | 2.4 | 2 |
| 2035 | Harnessing Reversed Allosteric Communication: A Novel Strategy for Allosteric Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 17728-17743. | 6.4 | 29 |
| 2036 | Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. <i>MedComm</i> , 2021, 2, 692-729. | 7.2 | 38 |
| 2037 | The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management. <i>Cancer Cell International</i> , 2021, 21, 675. | 4.1 | 9 |
| 2038 | Emerging Role of EGFR Mutations in Creating an Immune Suppressive Tumour Microenvironment. <i>Biomedicines</i> , 2022, 10, 52. | 3.2 | 4 |
| 2039 | EGFR signaling pathway as therapeutic target in human cancers. <i>Seminars in Cancer Biology</i> , 2022, 85, 253-275. | 9.6 | 61 |
| 2040 | A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status and 18F-FDG Metabolic Activity in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 780186. | 2.8 | 8 |
| 2041 | Analysis of Molecular Biomarkers in Resected Early-Stage Non-Small Cells Lung Cancer: A Narrative Review. <i>Cancers</i> , 2022, 14, 1949. | 3.7 | 2 |
| 2047 | Epidermal Growth Factor Receptor Inhibitors. , 0, , 352-368. | | 0 |
| 2048 | The Pathology and Pathogenesis of Peripheral Lung Adenocarcinoma Including Bronchioloalveolar Carcinoma. , 0, , 121-143. | | 0 |
| 2049 | Analysis of the molecular expression profile of non small cell lung carcinoma associated to chronic obstructive pulmonary disease. <i>Histology and Histopathology</i> , 2009, 24, 417-23. | 0.7 | 0 |
| 2072 | Utility of Select Gene Mutation Detection in Tumors by the Idylla Rapid Multiplex PCR Platform in Comparison to Next-Generation Sequencing. <i>Genes</i> , 2022, 13, 799. | 2.4 | 4 |
| 2073 | Respiratory Tract and Mediastinum. , 2014, , 59-104. | | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2074 | Amivantamab: A New Hope in Targeting Non-small Cell Lung Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2023, 23, 124-141. | 1.7 | 1 |
| 2075 | Distinct mutational features across preinvasive and invasive subtypes identified through comprehensive profiling of surgically resected lung adenocarcinoma. <i>Modern Pathology</i> , 2022, 35, 1181-1192. | 5.5 | 11 |
| 2076 | Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study. <i>Respiratory Research</i> , 2022, 23, . | 3.6 | 7 |
| 2078 | Uncovering the Molecular Basis for the Better Gefitinib Sensitivity of EGFR with Complex Mutations over Single Rare Mutation: Insights from Molecular Simulations. <i>Molecules</i> , 2022, 27, 3844. | 3.8 | 4 |
| 2079 | MERTK activation drives osimertinib resistance in EGFR-mutant nonâ€‘small cell lung cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, . | 8.2 | 12 |
| 2080 | Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. <i>Journal of Clinical Oncology</i> , 2022, 40, 3709-3718. | 1.6 | 9 |
| 2081 | The High Proportion of Discordant EGFR Mutations among Multiple Lung Tumors. <i>Cancers</i> , 2022, 14, 3011. | 3.7 | 1 |
| 2082 | Leptomeningeal Metastatic L858R EGFR-mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib. <i>OncoTargets and Therapy</i> , 0, Volume 15, 659-667. | 2.0 | 2 |
| 2083 | DUSP3 regulates phosphorylation-mediated degradation of occludin and is required for maintaining epithelial tight junction. <i>Journal of Biomedical Science</i> , 2022, 29, . | 7.0 | 3 |
| 2084 | Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Nonâ€‘Small Cell Lung Cancer. <i>Frontiers in Pharmacology</i> , 0, 13, . | 3.5 | 3 |
| 2085 | Realâ€‘world treatment patterns of metastatic nonâ€‘small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors. <i>Cancer Medicine</i> , 2023, 12, 159-169. | 2.8 | 8 |
| 2087 | The Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Predicting Treatment Response Before EGFR TKI Treatment in Patients with Advanced Lung Adenocarcinoma. <i>Molecular Imaging and Radionuclide Therapy</i> , 2022, 31, 104-113. | 0.7 | 1 |
| 2088 | Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer. <i>BMC Pulmonary Medicine</i> , 2022, 22, . | 2.0 | 0 |
| 2090 | Two Distinct Primary EGFR-Mutated Lung Adenocarcinoma Within the Same Patient: A Case Report. <i>International Journal of Cancer Care and Delivery</i> , 2022, 2, . | 0.0 | 0 |
| 2092 | Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor. <i>Cellular Oncology (Dordrecht)</i> , 2022, 45, 709-728. | 4.4 | 12 |
| 2093 | Non-small-cell lung cancer: how to manage EGFR-mutated disease. <i>Drugs in Context</i> , 0, 11, 1-17. | 2.2 | 3 |
| 2094 | Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report. <i>Medicine (United States)</i> , 2022, 101, e30080. | 1.0 | 3 |
| 2095 | Prognostic evaluation of preoperative serum tumor markerâ€‘negative cases in nonâ€‘small cell lung cancer: A retrospective study. <i>Cancer Reports</i> , 0, , . | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 2096 | Predominance of the Rare EGFR Mutation p.L861Q in Tunisian Patients with Non-Small Cell Lung Carcinoma. <i>Genes</i> , 2022, 13, 1499. | 2.4 | 1 |
| 2097 | P21-activated kinase 2-mediated β -catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer. <i>Oncogene</i> , 0, , . | 5.9 | 5 |
| 2098 | The Clinical Significance of Deglycosylated PD-L1 Level Detection Using 28-8 Monoclonal Antibody in Lung Adenocarcinoma. <i>International Journal of General Medicine</i> , 0, Volume 15, 7383-7393. | 1.8 | 1 |
| 2099 | EGFR Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil. <i>Oncologist</i> , 0, , . | 3.7 | 1 |
| 2100 | Understanding the Molecular Kinetics in NSCLC Through Computational Method. , 2022, , 129-163. | | 0 |
| 2101 | Translational Research in Lung Cancer. <i>Medical Radiology</i> , 2022, , . | 0.1 | 0 |
| 2102 | Targeted Therapies in Non-small Cell Lung Cancer. <i>Medical Radiology</i> , 2022, , . | 0.1 | 1 |
| 2103 | Temporal Pattern of Cardiac Adverse Events Associated with EGFR-TKIs in Lung Cancer Patients: A Pharmacovigilance Analysis. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |
| 2104 | The comparison of cancer gene mutation frequencies in Chinese and U.S. patient populations. <i>Nature Communications</i> , 2022, 13, . | 12.8 | 7 |
| 2105 | Can EGFR be a therapeutic target in breast cancer?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188789. | 7.4 | 14 |
| 2107 | Identification of Activating Mutations in the Transmembrane and Extracellular Domains of EGFR. <i>Biochemistry</i> , 2022, 61, 2049-2062. | 2.5 | 1 |
| 2108 | Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer. <i>Journal of Radiation Research</i> , 2023, 64, 142-153. | 1.6 | 8 |
| 2109 | Genomic landscape of lung adenocarcinomas in different races. <i>Frontiers in Oncology</i> , 0, 12, . | 2.8 | 6 |
| 2111 | Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort. <i>Cancer Discovery</i> , 2022, 12, 2552-2565. | 9.4 | 21 |
| 2112 | Clinicopathologic characteristics and prognostic impact of atypical EGFR mutations in completely resected lung adenocarcinoma. <i>European Journal of Cancer</i> , 2022, 177, 53-62. | 2.8 | 3 |
| 2113 | Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations. <i>Thoracic Cancer</i> , 2022, 13, 3217-3224. | 1.9 | 6 |
| 2114 | Nanoencapsulation of tyrosine kinase inhibitors for oncological therapeutics. , 2022, , 251-267. | | 0 |
| 2115 | Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue. , 2022, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 2116 | <scp><i>ERBB2</i></scp> exon 20 insertions are rare in Brazilian nonâ€small cell lung cancer. Thoracic Cancer, 2022, 13, 3402-3407. | 1.9 | 3 |
| 2117 | Integrated Tissue and Blood miRNA Expression Profiles Identify Novel Biomarkers for Accurate Non-Invasive Diagnosis of Breast Cancer: Preliminary Results and Future Clinical Implications. Genes, 2022, 13, 1931. | 2.4 | 1 |
| 2118 | <scp>TAS2940</scp>, a novel <scp>brainâ€penetrable panâ€ERBB</scp> inhibitor, for tumors with <i>HER2</i> and <i>EGFR</i> aberrations. Cancer Science, 2023, 114, 654-664. | 3.9 | 3 |
| 2119 | Immunotherapeutic progress and application of bispecific antibody in cancer. Frontiers in Immunology, 0, 13, . | 4.8 | 9 |
| 2120 | Prognostic Impact of EBUS TBNA for Lung Adenocarcinoma Patients with Postoperative Recurrences. Diagnostics, 2022, 12, 2547. | 2.6 | 1 |
| 2121 | Association of smoking status with non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor mutation. Frontiers in Immunology, 0, 13, . | 4.8 | 3 |
| 2122 | Prediction of the Presence of Targetable Molecular Alteration(s) with Clinico-Metabolic 18 F-FDG PET Radiomics in Non-Asian Lung Adenocarcinoma Patients. Diagnostics, 2022, 12, 2448. | 2.6 | 2 |
| 2123 | Multiple mutations in the EGFR gene in lung cancer: a systematic review. Translational Lung Cancer Research, 2022, 11, 2148-2163. | 2.8 | 6 |
| 2125 | Exploring the Next Frontier in Nonâ€Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor. Journal of Clinical Oncology, 0, , . | 1.6 | 0 |
| 2126 | Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors. European Journal of Medicinal Chemistry, 2022, 244, 114856. | 5.5 | 5 |
| 2127 | Targeting the epidermal growth factor receptor (EGFR) - a new therapeutic option in oncology?. Swiss Medical Weekly, 0, , . | 1.6 | 6 |
| 2128 | Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases. Frontiers in Oncology, 0, 12, . | 2.8 | 3 |
| 2129 | Changes in survival of patients with nonâ€small cell lung cancer in Japan: An interrupted time series study. Cancer Science, 2023, 114, 1154-1164. | 3.9 | 3 |
| 2130 | Targeting exon 20 insertion mutations in lung cancer. Current Opinion in Oncology, 0, Publish Ahead of Print, . | 2.4 | 1 |
| 2131 | Nuclear factor erythroid-2-related factor 2 (Nrf2) is a potential prognostic factor in patients with gastric adenocarcinoma. Arab Journal of Gastroenterology, 2022, , . | 0.9 | 0 |
| 2132 | Economic Burden of Recurrence in Completely Resected Stage IB-IIIa Non-Small Cell Lung Cancer: A Retrospective Study Using Nationwide Claims Data of South Korea. Advances in Therapy, 0, , . | 2.9 | 0 |
| 2133 | Therapeutic targets and signaling mechanisms of dasatinib activity against radiation skin ulcer. Frontiers in Public Health, 0, 10, . | 2.7 | 1 |
| 2134 | The coming decade in precision oncology: six riddles. Nature Reviews Cancer, 2023, 23, 43-54. | 28.4 | 52 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 2136 | Immunoregulatory framework and the role of miRNA in the pathogenesis of NSCLC – A systematic review. <i>Frontiers in Oncology</i> , 0, 12, . | 2.8 | 2 |
| 2137 | Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. <i>Molecular Biomedicine</i> , 2022, 3, . | 4.4 | 8 |
| 2138 | Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study. <i>Current Oncology</i> , 2023, 30, 145-156. | 2.2 | 0 |
| 2139 | Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100459. | 1.1 | 4 |
| 2140 | Inter-Ethnic Differences – How Important is it in Cancer Treatment?. <i>Annals of the Academy of Medicine, Singapore</i> , 2011, 40, 356-361. | 0.4 | 20 |
| 2141 | Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis. <i>BMC Pulmonary Medicine</i> , 2022, 22, . | 2.0 | 0 |
| 2142 | Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology. <i>Cancers</i> , 2023, 15, 1433. | 3.7 | 3 |
| 2143 | Chronic Inhalation Exposure to Antimony Trioxide Exacerbates the MAPK Signaling in Alveolar Bronchiolar Carcinomas in B6C3F1/N Mice. <i>Toxicologic Pathology</i> , 2023, 51, 39-55. | 1.8 | 1 |
| 2144 | Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2023, 161, 114452. | 5.6 | 5 |
| 2145 | Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non – Small Cell Lung Cancer. <i>Biomolecules</i> , 2023, 13, 210. | 4.0 | 2 |
| 2146 | The complexity of EGFR exon 19 deletion and L858R mutant cells as assessed by proteomics, transcriptomics, and metabolomics. <i>Experimental Cell Research</i> , 2023, 424, 113503. | 2.6 | 2 |
| 2147 | CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. <i>Cancer Cell</i> , 2023, 41, 340-355.e6. | 16.8 | 23 |
| 2148 | Advances in the Study of Hyperprogression of Different Tumors Treated with PD-1/PD-L1 Antibody and the Mechanisms of Its Occurrence. <i>Cancers</i> , 2023, 15, 1314. | 3.7 | 2 |
| 2149 | A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine. <i>Journal of Clinical Medicine</i> , 2023, 12, 1936. | 2.4 | 3 |
| 2150 | TRIP13 overexpression promotes gefitinib resistance in non – small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway. <i>Oncology Reports</i> , 2023, 49, . | 2.6 | 4 |
| 2151 | Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation. <i>Current Issues in Molecular Biology</i> , 2023, 45, 2505-2520. | 2.4 | 2 |
| 2152 | Molecular Pathology of Lung Cancer. , 0, , . | | 0 |
| 2153 | Polygenic risk scores for the prediction of common cancers in East Asians: A population-based prospective cohort study. <i>ELife</i> , 0, 12, . | 6.0 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2154 | Global burden and trends of lung cancer incidence and mortality. Chinese Medical Journal, 2023, 136, 1583-1590. | 2.3 | 11 |
| 2155 | Correlation between gene mutation status and clinicopathologic features in early multiple primary lung cancer. Frontiers in Oncology, 0, 13, . | 2.8 | 0 |
| 2156 | Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation. Cancer Discovery, 2023, 13, 1572-1591. | 9.4 | 13 |
| 2157 | Diagnostic performance of RASSF1A and SHOX2 methylation combined with EGFR mutations for differentiation between small pulmonary nodules. Journal of Cancer Research and Clinical Oncology, 2023, 149, 8557-8571. | 2.5 | 3 |
| 2158 | Clinical outcomes of chemotherapy in cancer patients with different ethnicities. Cancer Reports, 0, , . | 1.4 | 1 |
| 2159 | Case report: Neuroendocrine breast carcinoma with a germline EGFR T790M mutation. Frontiers in Oncology, 0, 13, . | 2.8 | 1 |
| 2160 | Is EGFR gene mutation testing necessary in smokers with non-small cell lung cancer?. , 2017, 3, 156-159. | | 0 |
| 2161 | Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study. Targeted Oncology, 0, , . | 3.6 | 0 |
| 2162 | Identifying druggable targets from active constituents of <sc><i>Azadirachta indica</i></sc> A. Juss. for non-small cell lung cancer using network pharmacology and validation through molecular docking. Phytochemical Analysis, 2023, 34, 855-868. | 2.4 | 2 |
| 2163 | Evaluating the efficacy and cardiotoxicity of EGFR-TKI AC0010 with a novel multifunctional biosensor. Microsystems and Nanoengineering, 2023, 9, . | 7.0 | 1 |
| 2164 | Outcome benefits of bevacizumab biosimilar (SIBP04) combined with carboplatin and paclitaxel in advanced non-squamous non-small-cell lung cancer patients with EGFR mutation: subgroup analysis of a prospective, randomized phase III clinical trial. Journal of Cancer Research and Clinical Oncology, 0, , . | 2.5 | 0 |
| 2165 | Smart Sensors and Microtechnologies in the Precision Medicine Approach against Lung Cancer. Pharmaceuticals, 2023, 16, 1042. | 3.8 | 1 |
| 2166 | EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies. Cancer Treatment Reviews, 2023, 120, 102605. | 7.7 | 1 |
| 2167 | A Functional Genomics Review of Non-Small-Cell Lung Cancer in Never Smokers. International Journal of Molecular Sciences, 2023, 24, 13314. | 4.1 | 0 |
| 2168 | Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer. Therapeutic Advances in Medical Oncology, 2023, 15, . | 3.2 | 0 |
| 2169 | EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)â€”A Podcast Discussion Between Patients and Oncologists. Oncology and Therapy, 0, , . | 2.6 | 0 |
| 2170 | Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs. International Journal of Molecular Sciences, 2023, 24, 13618. | 4.1 | 7 |
| 2171 | Exploring the molecular features and genetic prognostic factors of pulmonary high-grade neuroendocrine carcinomas. Human Pathology, 2023, , . | 2.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2172 | Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations. Journal of Medicinal Chemistry, 2023, 66, 11656-11671. | 6.4 | 0 |
| 2173 | Different gene alterations in patients with non-small-cell lung cancer between the eastern and southern China. Heliyon, 2023, 9, e20171. | 3.2 | 0 |
| 2175 | Bispecific Antibodies in Lung Cancer: A State-of-the-Art Review. Pharmaceuticals, 2023, 16, 1461. | 3.8 | 1 |
| 2176 | CRISPR/dCas9-Mediated Specific Molecular Assembly Facilitates Genotyping of Mutant Circulating Tumor DNA. Analytical Chemistry, 2023, 95, 16305-16314. | 6.5 | 1 |
| 2177 | Use of pyridazinediones for tuneable and reversible covalent cysteine modification applied to peptides, proteins and hydrogels. Chemical Science, 2023, 14, 13743-13754. | 7.4 | 0 |
| 2178 | Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients. Biomedicines, 2023, 11, 2916. | 3.2 | 0 |
| 2179 | Molecular pathology of non-small cell carcinoma. Histopathology, 2024, 84, 50-66. | 2.9 | 2 |
| 2180 | Clinical practice guidelines for molecular tumor markers, 2nd edition review part 1. International Journal of Clinical Oncology, 0, , . | 2.2 | 1 |
| 2181 | RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants. JTO Clinical and Research Reports, 2024, 5, 100624. | 1.1 | 0 |
| 2182 | Primary versus acquired epidermal growth factor receptor Thr790Met mutant non-small cell lung cancer: clinical features and prognoses. Clinical and Translational Oncology, 0, , . | 2.4 | 0 |
| 2183 | Dual-energy CT-based radiomics in predicting EGFR mutation status non-invasively in lung adenocarcinoma. Heliyon, 2024, 10, e24372. | 3.2 | 0 |
| 2184 | Computational insights into the stereo-selectivity of catechins for the inhibition of the cancer therapeutic target EGFR kinase. Frontiers in Pharmacology, 0, 14, . | 3.5 | 0 |
| 2185 | Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions. Scientific Reports, 2024, 14, . | 3.3 | 0 |
| 2186 | The Roles and Regulatory Mechanisms of Tight Junction Protein Cingulin and Transcription Factor Forkhead Box Protein O1 in Human Lung Adenocarcinoma A549 Cells and Normal Lung Epithelial Cells. International Journal of Molecular Sciences, 2024, 25, 1411. | 4.1 | 0 |
| 2187 | Social and Biological Determinants in Lung Cancer Disparity. Cancers, 2024, 16, 612. | 3.7 | 0 |
| 2188 | Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma. Cell Reports, 2024, 43, 113771. | 6.4 | 0 |
| 2189 | Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study. Journal of Cancer Research and Clinical Oncology, 2024, 150, . | 2.5 | 0 |
| 2190 | Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer. Pathology Research and Practice, 2024, 256, 155222. | 2.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2191 | Management of Treatment Resistance in Patients With Advanced Epidermal Growth Factor Receptor–Mutated Lung Cancer: Personalization, Parsimony, and Partnership. Journal of Clinical Oncology, 2024, 42, 1215-1221. | 1.6 | 0 |
| 2192 | Detection of a co-mutation in the epidermal growth factor receptor gene exon 20 H773L/V774M by FoundationOne test and treatment with osimertinib: A case report. Current Problems in Cancer Case Reports, 2024, 14, 100286. | 0.1 | 0 |
| 2193 | Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability. BMC Proceedings, 2024, 18, . | 1.6 | 0 |
| 2194 | A narrative review of the role of common EGFR mutations in pathogenesis and treatment of non-small-cell lung carcinoma. Cancer Research Statistics and Treatment, 2022, 5, 507. | 0.6 | 0 |